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Introduction
Cervical cancer is the second most common female cancer in the world, with approxi-
mately 490 000 new cases of cancer of the cervix diagnosed yearly, and over 230 000 
deaths, of whom 80% occur in developing countries.1 Since Zur Hausen initiated the 
concept of viral oncogenesis in the development of cervical cancer, many studies have 
confirmed that a persistent genital human papillomavirus (HPV) infection is a necessary 
factor in cervical carcinogenesis.2-6
The human papillomavirus
The HPV genome consists of about 8000 basepairs, double stranded, circular DNA. HPV 
is part of the Papillomaviridae family. Over 120 different HPV genotypes have been iden-
tified and more than 40 of them can infect the epithelial and mucosal lining of the ano-
genital tract.7;8 According to their carcinogenicity, these anogenital HPV types have been 
subdivided into low-risk and high-risk HPV genotypes. In condylomata and a subset of 
cervical intraepithelial neoplasia grade 1 and 2 (CIN1 and CIN2) low-risk types may be 
present. High-risk types are found in almost all CIN3 lesions and cervical cancers.9 On 
the basis of epidemiological criteria HPV types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and 
CP6108 are classified as low-risk. HPV types 6 and 11 are the most frequently detected 
HPV types in genital warts. There are 15 mucosal HPV types classified as high-risk. These 
types are HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82. In addition 
three other HPV types (i.e. HPV 26, 53, and 66) are considered as probably carcinogenic. 
The high-risk genital HPV types belong to the genus alpha-papillomaviruses. 
Phylogenetically related oncogenic types HPV 18, 39, 45, 59 and 68 belong to species 7 
and HPV types 16, 31, 33, 35, 52 and 58 to species 9.9-11 Infections with HPV 16 and 18 
account for about 70% of all squamous cervical cancers.11
Papillomaviruses are perfectly adapted to their natural host tissue, the differentiating epi-
thelial cells of skin or mucosa. The life cycle of the virus is initiated when infectious par-
ticles reach the basal layer of the epithelium, where they bind and enter into the cells. 
The completion of their life cycle depends on epithelial differentiation. The HPV genome 
can be subdivided in three regions: a non-coding long control region (LCR), an early 
encoding region (E), containing 6 early genes and a late encoding region (L), containing 
2 late genes (Figure 1). These eight genes are responsible for the translation of a series of 
functional proteins necessary for the viral life cycle. In the normal viral life cycle the viral 
proteins E1 and E2 are essential for the basal DNA replication and transcription. Other 
critical proteins in the process of virus replication are the viral proteins E6 and E7. These 
proteins enable the virus to replicate by activating DNA synthesis and blocking important 
apoptotic routes in differentiated non-dividing host cells.7;10;12-14
12
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Human papillomavirus detection
Estimates of single point prevalence of genital HPV infection among women worldwide 
vary from 2% up to 44%.3;16 In women with normal cervical scrapes, the point prevalence 
of any-type HPV is influenced by the specific population studied, as they differ in geogra-
phy and risk factors for development of cervical carcinoma. The prevalence of HPV also 
differs between age groups, varying from 20% in women aged between 20-25 years, to 
6% in women ≥30 years, and some studies show a second peak in HPV prevalence in 
women above the age of 55 years.4;17;18 Furthermore the sensitivity of the DNA assay used 
for the detection of HPV influences the results of these studies.
Several methods for the detection and typing of HPV DNA in cervico-vaginal smears 
have been developed. The most widely used HPV DNA tests are Hybrid Capture 2 (HC2, 
Digene Corp., USA) and polymerase chain reaction (PCR) methods: PGMY09/11, 
GP5+/6+, SPF10 consensus primers, and Roche Linear Array HPV genotyping assay.
19-27
HC2 is a signal amplification method based on hybridization of the target HPV DNA 
to labeled RNA probes in solution.28;29 HC2 uses two different probe cocktails one with 
five low-risk genotypes: 6, 11, 42, 43 and 44, and the other containing 13 high-risk 
genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. With these probes HC2 
distinguishes between the high-risk and low-risk groups, but it does not permit identifica-
tion of specific HPV genotypes.25
The consensus or general PCR primers are based on PCR amplification of the target 
sequences in the HPV L1 gene, as the L1 region is the most conserved part of the viral 
genome.10;21 Reverse hybridization permits detection of type specific infections and de-
tection of multiple HPV types from the PCR product in a single step. The most frequently 
used reverse hybridization technologies are, line probe assay (LiPA), line blot assay (LBA) 
or linear array (LA).25
Figure 1: The HPV genome and its expression within the 
epithelium (adapted from Schiffman et all.15)
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The threshold of the viral load that is still detectable determines the sensitivity of the 
HPV test used. HPV tests using PCR techniques have been generally proven to be more 
sensitive in detecting high-risk HPV genotypes than hybridization tests like the HC2.27 
Although the GP5+/6+ PCR test has a clinical sensitivity like the HC2. Additionally, 
the Greiner Bio-One PapilloCheck assay has proven to be clinically compatible to the 
GP5+/6+ PCR assay.30 The relative sensitivity of the HC2 assay is equivalent to 1 pico-
gram of HPV DNA, whereas the sensitivity of many PCR assays is at the sub-picogram 
level.31 The PCR test SPF10LiPA appeared to have the highest sensitivity to detect HPV 
DNA.22;31;32 However, detection of very low viral copy numbers in cervical scrapings may 
overestimate the risk of high-grade cervical disease.31;33 Thus, when HPV testing is used 
to identify women at risk for developing cervical cancer, a highly sensitive HPV detection 
assay may overestimate the proportion of women who have cervical abnormalities.25;31;34 
On the other hand, accurately studying both the epidemiology of HPV and the global 
impact of HPV infections, requires a test with the highest analytical sensitivity possible.31 
The choice of an HPV DNA test will therefore depend on its application, whether a high 
analytical or a high clinical sensitivity is required.
Incidence of the human papillomavirus
Acquisition of genital HPV is very common, particularly among sexually active young 
adults, and several studies have clearly shown that HPV is predominantly transmitted 
through sexual intercourse.35-38 About 50% of the women becoming sexually active con-
tract a genital HPV infection within 2 years, and the lifetime risk of a genital HPV infec-
tion is estimated to be 80%.39 Because HPV is basically sexually transmitted, risk factors 
associated with acquiring HPV infections are clearly related with the individuals sexual 
behavior.40 Most importantly: early age at start of sexual relationships, high number of 
sexual partners throughout life, and having a recent new sexual partner. The use of con-
doms is reported to reduce, although not completely prevent, the risk of transmission of 
HPV between sexual partners.36;41-47
Clearance and persistence of the human papillomavirus
In a large prospective study, only 1.73% of the women with a positive HPV test at base-
line developed a CIN3 lesion or cervical cancer within 45 months, and 6.92% within 
122 months.48 Therefore it is important to realize that, although a high-risk HPV infection 
represents the first step of cervical cancer carcinogenesis, most of these infections are 
transient, while a persistent HPV infection is necessary for the progression to cervical 
cancer.6;14 Most infections become undetectable within 1-2 years.35;49-51 Infections lasting 
more than 1 year appear to be associated with a lower clearance rate, and therefore pose 
a greater risk to the infected women.35;51 Whether infections clear completely, or whether 
the virus remains latent in the basal cells at undetectable levels, remains unclear.16 Figure 
2 displays the average clearance, persistence, and progression of a high-risk HPV infec-
tion in time.
14
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Although there is no consensus on its definition, most investigators define a persistent 
HPV infection as detection of the same HPV type or group of types on two consecutive 
visits, but these visits could be from 2 months up to 72 months apart.52;53 Therefore it is 
difficult to point out when an HPV infection is truly persistent or may still be transient. 
Furthermore, within this definition it is also impossible to distinguish a persistent infec-
tion from one that represents a cleared infection with subsequent reacquisition of the 
same HPV type before the next screening round.16 It would be useful to come to one 
definition of persistence. This new definition should be based on the duration of infection 
rather than a positive HPV test on two consecutive screening moments. This definition of 
persistence should preferably be based on the average duration of an HPV infection pre-
dicting oncogenicity, rather than the average duration to clear an infection. Furthermore, 
consensus should be reached whether this definition should be based on persistence of 
high-risk HPV as a group or genotype-specific. Finally, this new definition on HPV persis-
tency should also address whether or not there may be a single negative test in between 
two positive tests, in other words, are two negative test necessary to declare an infection 
cleared? When there is one definition of persistence, results from epidemiologic studies 
will be more uniform and stronger conclusions may be drawn in meta analysis on co-
factors influencing HPV persistence and cervical carcinogenesis.
Co-factors in the development of cervical intraepithelial neoplasia and cancer
It is not clearly understood why HPV infections resolve in certain individuals and result 
in CIN lesions in others, but several factors are thought to play a role.10 Three groups of 
potential co-factors are; (1) environmental or exogenous co-factors; long-term use of 
hormonal contraceptives, tobacco smoking, parity, condom use, number of sex partners 
Figure 2: Average clearance, persistence, and progression of 
carcinogenic HPV infections (adapted from Schiffman et al.15)
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and co-infection with (other than HPV) sexually transmitted agents; 35;54;55 (2) viral co-
factors; type specific infections, co-infection with another HPV type(s), viral load, and 
viral integration; 35;56;57 and (3) host co-factors; endogenous hormones (fluctuations dur-
ing menstrual cycle), genetic factors, human histocompatibility leukocyte antigen (HLA) 
expression and other factors related to immune response.10;58
The International Agency for Research on Cancer (IARC) multicentre study found three 
main factors to have a causal relationship with development of cervical cancer; (1) oral 
contraceptive pill (OCP), (2) parity, and (3) smoking. 59-61 Among current users of OCPs 
the risk of cervical cancer increased with increasing duration of use, with a relative risk 
for 5 years or more versus never use of 1.90 (95% CI: 1.69-2.13). This risk declined after 
use ceased, and by 10 or more years had returned to that of never users.62 HPV positive 
women who reported seven or more full term pregnancies had a fourfold increased risk 
of cervical cancer compared with similar HPV positive nulliparous women.60 The effect 
of parity on cervical cancer risk was less visible in low parity populations.11 After con-
trolling for other co-factors, the IARC multicentre study found that ever smoking gave a 
twofold increased risk for cervical carcinoma, with a higher risk for squamous cell car-
cinoma compared to adenocarcinoma.61 Generally, these risk factors are only found in 
studies restricted to HPV DNA positive women and study results about these risk factors 
and their influence on HPV persistency remain inconsistent.11
Despite the increased risk of CIN and cervical cancer ascribed to these co-factors among 
women with high-risk HPV, the risk of cervical cancer is still mainly a result of a persis-
tent high-risk HPV infection and lack of effective screening.15
Cervical cancer prevention
Cervical cancer is a preventable disease. The possibility to detect abnormal cells in 
cytology and the ability to treat pre-malignancies, prevents progression of lesions towards 
invasive cervical cancer (especially squamous cell carcinoma).63;64 The Dutch population 
based cervical screening aims at women aged 30-60 years, with an interval of 5 years 
between screening rounds.65 The sensitivity of conventional cytology for detecting high-
grade CIN (CIN2 and 3) is estimated to be about 60%.66;67 Approximately 70% of the 
invited women actually participate in the Dutch screening program, this all leads to a 
mortality reduction of maximal 56%.68 (Figure 3)
The close association between high-risk HPV and cervical cancer has resulted in the idea 
to use high-risk HPV testing on cervical scrapes for the detection of ≥CIN2 lesions and 
cervical cancer. Several studies have clearly shown that application of high-risk HPV test-
ing in cervical screening improves the sensitivity and negative predictive value for ≥CIN2 
lesions, compared to cytology alone. This leads to a markedly earlier detection of these 
lesions.6;70-73 However, the positive predictive value for ≥CIN2 lesions of even a clinically 
validated test (i.e. HC2 and GP5+/6+ PCR) is lower than that of cytology because still 
a substantial number of test positive women do not have high-grade CIN lesions.71;74;75
16
In the Dutch national cervical cancer screening program, HPV testing is currently used 
as an additional test to repeat cytology after a primary borderline or mildly abnormal 
cytology test. However, in literature it is suggested to implement HPV DNA testing as 
the sole primary screening test. This is based on the principle that the more sensitive test 
should be applied first (i.e. HPV DNA testing) and the more specific test (i.e. cytology) 
should then be used only for HPV-positive women to determine management (i.e. 
follow-up or treatment).74 Previous studies show that HPV-positive women with negative 
cytology can be safely managed by repeating the testing with both cytology and HPV 
after one year.72;73;76;77
Together with preventing the development of precancerous lesions via screening, vac-
cination has become today’s main prevention front against cervical cancer.67 The two 
vaccines Gardasil® and Cervarix®, containing immunogens for the HPV genotypes 16 and 
18 that cause 70% of all cervical cancers, are highly effective to prevent pre-cancerous 
disease. Additionally, there is some cross-protection for HPV type 45, 31, 33, 35, 52, 58 
infections.78 Longitudinal studies on the natural behavior of HPV type-specific infections 
before the implementation of the HPV vaccine provide valuable baseline information for 
future epidemiologic studies analyzing the impact of HPV vaccination on the dynamics 
of HPV.
Self-sampling for HPV detection
The introduction of HPV detection in primary screening creates the possibility of the 
use of self-sampling for HPV detection. However, more studies within general screening 
populations are necessary before implementation of self-sampling in national cervical 
cancer screening program is possible. Self-sampling is generally easy to use and is an 
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Figure 3: Reduction in cervical cancer 
mortality in relation to the sensitivity of the 
screening and the coverage of the target 
population in the Netherlands. Model based 
on M. van Ballegooijen.69 Black line: ideal 
screening method (100% sensitivity of the 
combination: screening tool, screening 
interval, and the cohort to be screened); 
grey line: ideal line in the Netherlands with 
5-yearly screening of women between 30 
and 60 years of age; dotted line, actual 
situation with a 70% coverage rate. (Adapted 
from Bekkers et al.68)
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inexpensive method, that is highly accepted by women.79;80 Studies already showed that 
self-sampling increases participation of non responders in current screening programs.80-85 
In 2005 and 2007, two meta-analyses showed a high level of concordance for HPV DNA 
detection between self-collected samples and physician-collected samples.86;87 Because 
it is easy to use, highly accepted by women, and has a good performance on HPV DNA 
collection, self-sampling seems to be the ideal method to collect HPV DNA in a prospec-
tive epidemiologic study on the dynamics of HPV.
Outline of this thesis
The present thesis is based on the longitudinal data of a large prospective epidemiologic 
study in young women in the pre-vaccine era. The main objective is to focus on the in-
cidence, clearance and persistence of HPV, and associated risk factors like age, sexual 
behavior, oral contraceptives and pregnancy. This prospective epidemiologic study on the 
natural behavior of the human papillomavirus (HPV) was conducted in 2007-2009. The 
first cross-sectional data on HPV prevalence were described prior to this thesis.40
In the first year of follow-up all women were asked to quarterly (i.e. month 0, 3, 6, 9, and 
month 12) fill in a questionnaire and to self-collect a cervico-vaginal sample for HPV 
DNA detection in the privacy of their own home. All high-risk HPV positive women at 
month 12 were asked to participate in a second year of follow-up and to provide two 
cervico-vaginal self-samples accompanied with a questionnaire at month 18 and 24.
Women who became pregnant during the first year of follow-up were asked to complete 
follow-up until after delivery. This way we obtained one self-sample at baseline (0-3 
months before pregnancy), one in each trimester, and one within the first 6 months after 
delivery.
First, we reviewed the literature if self-sampling may be widely implemented in cervi-
cal cancer screening programs as a tool for HPV detection, and which combination of 
sample device and HPV test are most suitable. (chapter 2)
In chapter 3 the HPV incidence rates in young females, and whether the relation with the 
sexual behavior is age-dependent was studied. This will provide baseline information for 
future studies on the effect of the recently introduced HPV vaccines, targeting high-risk 
HPV types HPV 16 and 18. Furthermore, the clearance rate of type-specific infections 
and whether re-infection with the same type takes place during 12 months of follow-up, 
(i.e. the natural type-specific short-term fluctuations) was studied. Additionally, the po-
tential factors influencing type-specific HPV clearance like age, smoking and sexual be-
havior were evaluated. In chapter 4, the data of the second year of follow-up are used to 
determine which factors influence type-specific high-risk HPV persistence, and to relate 
the results of type-specific HPV detection with available cytology results.
In chapter 5-7, factors potentially influencing the dynamics of HPV, are analyzed and 
discussed in detail. The potential influence from OCP use and sample timing within the 
menstrual cycle on HPV detection are described in chapter 5. Chapter 6 covers the poten-
18
tial influence of pregnancy on HPV detection by evaluating the natural HPV prevalence, 
incidence and clearance during pregnancy, compared with a matched-control group of 
non-pregnant women in a low parity population. Finally, the potential use of the FTA 
elute cartridge to detect premalignancies of cervical cancer is tested with the clinically 
validated Hybrid Capture (HC2) and GP5+/6+-HPV DNA detection assays. (chapter 7)
This thesis concludes with a general discussion in chapter 8, and a summary in chapter 9.
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Summary
High-risk human papillomavirus (hr-HPV) detection will become an important tool in 
the screening for cervical cancer. Self-sampling is an inexpensive, well-accepted method 
for HPV detection that will increase participation of non-responders in current screening 
programs. Even the more, as self-collected samples are as good as physician-collected 
samples for HPV detection, self-sampling might be a suitable method for future primary 
cervical cancer screening.
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Introduction
A persistent infection with high-risk human papillomavirus (hr-HPV) is a necessary factor 
in the multiple-step process of cervical cancer development.1;2 Based on this etiologic 
link and the high sensitivity and objectivity of HPV detection, testing for HPV has re-
cently been advocated as a primary cancer screening tool.3-8
Currently, physician-collected cervical specimens are considered as the gold standard for 
HPV detection.9 However, self-sampling is a specimen collection method that is highly 
accepted by women, and It may reduce costs as a visit to a physician is omitted. Studies 
already showed that self-sampling increases participation of non-responders in current 
screening programs.10-15 In the period of 2005-2007, one systematic review and two 
meta-analyses showed a high level of concordance for HPV DNA detection between self-
collected samples and physician-collected samples.16-18 Therefore, it was concluded that 
HPV DNA testing using self-sampling is promising and might be a suitable alternative 
method for studies on HPV transmission and vaccine trials.16;18 Self-sampling might also 
be an appropriate alternative for cervical screening in low-resource setting or in patients 
reluctant to undergo pelvic examination.17;18 After these meta-analyses, 20 new studies 
were published determining the value of self-sampling compared to physician-sampling 
for HPV detection. In this review, the studies in the meta-analyses and the recently 
published reports were analyzed to determine if self-sampling could be implemented in 
cervical screening as a tool for HPV detection and which combination of sample device 
and HPV test should be used.
HPV testing in primary cervical cancer screening
The development and implementation of organized and effective cytology-based cervical 
cancer screening programs has led to significant decreases in the incidence and mortality 
of cervical cancer.19 The predicted lifetime risk of cervical cancer in an unscreened 
population is 2.9% by modeling data from the Netherlands. This is comparable to other 
European countries with a lifetime risk of 2.5-3.7%. The predicted lifetime risk dropped, 
however to 0.4% when attending cervical screening.20 Still, cytology has important 
limitations. Cytology is based on subjective interpretation of morphological alterations 
of exfoliated cervical cells and is, therefore, associated with screening errors. The low 
sensitivity (about 60%) of cytology is its most critical limitation, and therefore, frequent 
screening is required.5;21
HPV testing has recently been advocated as an alternative cancer screening tool, because 
persistent infection with hr-HPV is associated with an increased risk for cervical cancer 
development.1;2 Cytology is subject to sampling errors, processing error, and laboratory 
interpretation errors. HPV testing accuracy is also subject to sampling errors and labora-
tory reproducibility. However, HPV DNA detection assays are automated and therefore 
have a greater reproducibility than cytology. Moreover, the clinical sensitivity of hr-HPV 
testing for the detection of ≥CIN2 is about 90-95%.3-5 In primary screening, this sensitivity 
for the detection of ≥CIN2 is higher compared to conventional cytology.21-26 This higher 
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clinical sensitivity may lead to earlier diagnosis of high-grade cervical lesions.23
Furthermore, the negative predictive value (NPV) of a double-negative test, that is, normal 
cytology and no presence of high-risk HPV, is close to 100%,27;28 and a negative test for 
HPV provides a greater reassurance against ≥CIN2 than a negative cytology test.19;27;29-31 
Moreover, women with abnormal cytology but negative for HPV have a low risk of CIN3+ 
lesions.4;32;33 Therefore, it is suggested that HPV DNA testing could possibly be used to ex-
tend screening intervals.7;8;26;27;30;33-35 In the Netherlands, where standard screening starts 
at age 30 with an interval of 5 years, studies have already shown that with this screening 
interval, primary HPV DNA testing or combined testing with cytology leads to higher 
sensitivity and NPV, with an earlier detection of CIN3+ lesions.7;8 This suggests that the 
screening interval may be safely extended.
HPV DNA testing alone or with cytology triage has a higher sensitivity and earlier detec-
tion of clinically relevant lesions,25;28;35 but its specificity for detection of ≥CIN2 is lower 
(86%) compared with conventional cytology.5;25;26;29 The lower specificity may be ex-
plained by the high prevalence of transient HPV infections, especially in young women. 
Because a persistent hr-HPV infection is required for the development of severe dysplas-
tic cervical lesions, a single HPV positive test by itself may be a poor predictor of a future 
intraepithelial lesion;19;30 therefore, women with an hr-HPV positive test and negative 
cytology at triage need to be monitored for hr-HPV persistence.3;24;27;29;35;36 It is suggested 
that repeating both HPV and cytology after an interval of 1 year allows early detection of 
newly developed intraepithelial lesions.6;7;32
Low specificity of an HPV DNA test may lead to increased numbers of follow-
up tests, unnecessary colposcopies, psychosocial distress, and the possibility of 
over-treatment.5;23-25;28 Therefore, a clinically validated HPV DNA test is required.37 This 
test should be sufficiently sensitive to identify all women at risk for high-grade cervical 
lesions yet sufficiently specific to avoid unnecessary referral and repeat smears.36
HPV testing alone or with cytology triage is more sensitive than cytology alone in cervical 
screening, and therefore its implementation seems to be inevitable. However, whether 
HPV DNA testing should be implemented combined with cytology or as a single primary 
screening tool (with or without cytology triage) is still a subject of study. Cotesting of HPV 
and cytology is not an issue because it is as sensitive as HPV testing alone. The triage of 
HPV-positive women with cytology is carried out to decrease the number of colposcopies 
and is dependent on the settings of screening in different countries.21;23-25;28;38
Self-collected cervico-vaginal samples have shown to be suitable for HPV testing.16;17 The 
implementation of primary HPV testing in cervical cancer screening leads to the potential 
use of self-sampling in large scale screening programs.14 The use of self-sampling requires 
fewer visits to the physician, and results in less patient inconvenience or noncompli-
ance.11;15;39;40 The use of self-sampling may therefore lead to a higher acceptability and 
may potentially lead to a reduction in costs in current screening programs.39;41 Moreover, 
provided that HPV detection tests are available, self-collection of cervico-vaginal speci-
mens for HPV DNA testing may help to enhance screening rates in countries that have 
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been unable to reduce cervical cancer incidence.11
Notably, self-sampling will only be a suitable tool if the intended woman indeed does the 
test and not someone else. In this respect, it is important that she understands the instruc-
tion on how to take a cervico-vaginal sample.
Self-sampling for HPV DNA detection
Sampling devices and transport media for HPV DNA detection
Studies with self-sampling used a great variety of collection devices including swabs, 
cervical brushes, tampons, and cervico-vaginal lavages.
Vaginal Dacron or cotton swabs and cervical brushes are small, easy to manipulate, and 
can be processed in a similar manner to that of physician-collected swabs.10;42-44 Addi-
tionally, sending and returning swabs and brushes through the mail is feasible, and thus 
the use of these devices can be home-based.45-47
Tampons and lavage mainly collect squamous epithelial cells from the walls of the va-
gina, together with shed cervical cells.42 Tampon samples need to be processed more ex-
tensively than swabs and brushes before HPV DNA detection tests can be applied.48 The 
use of a cervico-vaginal lavage is used as self-sampling method in several studies,12;13;15;49 
and the women in the studies considered the lavage acceptable.12;13 The most frequent-
ly used polymerase chain reaction (PCR) HPV DNA tests, like PGMY09/11, GP5+/6+, 
SPF10LiPA, and the Roche reverse line blot assay (RBLA), and hybrid capture 2 (HC2) can 
be used on swabs, brushes, tampons and lavage samples. Nowadays, mRNA tests are 
developed, and they appear to be more specific for the detection of diseases than DNA 
testing.50
In review, the overall sensitivity for self-collected samples, when Dacron or cotton swabs, 
or cytobrushes were used, was 74-81% with a specificity of 88-90% using clinician-
obtained samples with the same devices as a reference. Tampons performed slightly less 
well, offering a sensitivity between 67 and 94%.17
The majority of the studies assessing self-sampling have used liquid-based storage and 
transport media.13;51-53 In our own experience, the use of liquid-based self-samples has the 
impractical consequence that fluids may leak, and special precautions have to be taken 
for transport. This potentially hampers the large-scale introduction of cervico-vaginal self-
sampling methods.54;55 The use of dry transport methods may eliminate these disadvan-
tages. Samples may be transported and stored using a dry test tube56 or the indicating 
Flinders Technology Associates (FTA) elute cartridge.54 Previously, the highly sensitive 
SPF10LiPA HPV DNA test and the less known hpVIR real-time PCR have shown that HPV 
detection using the FTA elute cartridge is possible.54;57 The development and improve-
ment of devices and transport methods is still an ongoing process.
Self-collected sampling versus physician-collected sampling
Physician-collected specimens mainly contain cervical cells, whereas self-collected 
specimens generally represent a mixture of vaginal and cervical cells. However, the 
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prevalence of carcinogenic HPV types appeared to be similar in vaginal and cervical 
specimens.58;59
Three reviews comparing self-collected samples with physician-collected samples were 
published.16-18 In 2005, Ogilvie et al. used the physician-collected samples for HPV 
DNA as the gold standard, making no distinction between lr-HPV and hr-HPV.17 They 
found that self-sampling with Dacron or cotton swabs had the best performance with a 
sensitivity of 74-81% and specificity of 88-90%.17 In 2007, Petignat et al. analyzed studies 
on self-sampling and physician-sampling in which any positive HPV test was considered 
as reference standard.16 They found a concordance of 87% between self-sampling and 
physician-sampling for the detection of any-type HPV. The detection of hr-HPV resulted 
in a similar level of concordance, but lr-HPV detection was higher in self-sampling. In 
the same period, Stewart et al. published a systematic review and found a wide range 
of level of agreement (к 0.24-0.96) for HPV detection between self-collected samples 
and physician-collected samples, with little more than half of the studies reporting 
к of >0.6.18 The overall conclusion of these three reviews was that the sensitivity of self-
sampling is sufficient to be used as an appropriate alternative for physician-sampling in 
low resource settings or to increase screening rates, especially in women who are never 
or seldom screened. Therefore, more evidence is needed before self-sampling might be 
implemented in national screening.
Twenty new, not previously reviewed, studies comparing self-collected sampling and 
physician-collected sampling for HPV DNA detection were identified in Pubmed with 
the key words: self-sampling, human papillomavirus, human papillomavirus infection, 
and human papillomavirus type and limiting to studies describing research in humans 
and published since 2000 in English.39;41;49;53-56;60-72 One study could not be included in 
our analysis, because a full text version was not available.68 The characteristics of the 
remaining 19 studies are shown in Table 1.
Notably, many studies included women in wide age ranges, varying from young sexually 
active women, likely to have a higher HPV prevalence, up to women 70 years of age. For 
cervical cancer screening programs, the studies including women from 25 to 30 years 
and older are most interesting because this will be the age range in which HPV testing 
will be used.
In Table 1, it is shown that the studies used different sampling procedures. These sampling 
procedures did not only differ between the studies, but sometimes within studies, different 
sampling devices or different HPV DNA detection methods for the self-collected sample 
and physician-collected sample were used. Consequently these results might not repre-
sent the true agreement between self-sampling and physician-sampling.39;49;53;60;63;64;67;70;72
In most studies both samples are collected on the same day or with a short interval, but 
one study tested the self-collected samples and physician-collected samples alternatively 
with 2 months in between.72 Due to the natural fluctuations of HPV infections in the 
population, these results may not be directly comparable.
When studying the agreement between self-collected samples and physician-collected 
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samples, the order of sampling could potentially influence the amount of cells collected 
by the sampling method. However, previously, Harper et al. randomized the order of 
sampling for self-sampling with a tampon and physician-sampling with a swab, and they 
concluded that the order of sampling does not seem to influence the outcome.48
All studies, previously reviewed and more recently published, reporting results on the 
concordance and/or kappa (к), were used to determine the level of agreement of HPV 
detection between self-sampling and physician-sampling. Additionally, all the used 
combinations of the sample device and HPV test were compared. Studies reporting the 
concordance of self-sampling and physician-sampling for hr-HPV detection using the 
same sample device and the same HPV DNA detection method are shown in Table 2. 
Because of the potential influence of the sample device on the performance, studies using 
different devices for the self-sample and physician-sample were analyzed separately 
(Table 3). One study used different sampling devices and different HPV DNA detection 
methods for self-sampling and physician-sampling, and therefore was not included.56
The HC2 is used by many studies,39-41;43;48;63;63;64;69;73;74 and is compared with the group of 
PCR-based methods in Tables 2 and 3. The PCR methods used were mainly PGMY09/11 
and RLBA,41;51;51;52;60;63;63;69;71;75-81 other PCR based methods like SPF10LiPA,
54 GP5+/6+,13;49 
and less known tests like HPVDNAChiptm 67 and QIAamp DNA test 82 were also used. The 
most frequently used sample devices were swabs and brushes, only 2 studies used the 
lavage for self-sampling compared with physician-sampling.13;49
34
Table 1.  
Characteristics of studies comparing self-sampling with physician-collected samples
Reference Country N Inclusion Criteria   Exclusion Criteria   Self-sample   device 
Physician-sample 
device HPV test
1 Belinson China 2625 Age 16-54 Pregnancy, pelvic radiation, hysterectomy, treatment cervical cancer or HIV+ Brush Brush
HC2; typing: 
Roche RLBA
2 Bhatla et al. 60 Developing country 546 Age ≥ 30, sexually active, gynecologic symptoms NA Brush
Ayre Spatula
Brush HC2, PGMY09/11
3 Brinket al. 49 the Netherlands 96
Age 18-59, referred to gynecologist for colposcopy-
directed biopsy or healthy volunteer NA Lavage Brush GP5+/6+
4 Daponte et al. 82 Greece 98
HIV negative, referred with abnormal cervical  
cytology, with proven abnormal histology NA Cytobrush Cytobrush PCR
5 De Alba et al. 62 California, USA 1213 Age ≥ 18, hispanic
Papsmear last year, pregnancy, hysterec-
tomy, cervical cancer Cotton swab NA HC2
6 Holandaet al. 39 Brazil 878 Age 15-70, sexually active 
Menstruation, sexual intercourse < 24 h, 
using vaginal cream Brush Ayre spatula HC2
7 Joneset al. 63 South Africa 450
Age ≥ 18, sexually active, attending community 
health centre Pregnant
Half swab and half 
tampons Brush Roche RLBA, HC2
8 Karwalajtys et al. 64 NA 307
Age 15-49, HPV+ a year earlier 
Age ≥ 50; randomly NA Dacron swab
Brush (after 
papsmear) HC2
9 Khannaet al. 65 Cananda
398*
399# Age 18-69, presenting for routine gynecology care
Presenting symptoms
Abnormal Pap test, genital cancer, cervical 
surgery, or immune treatment of the cervix 
within one year
Christmass tree cervical 
sampling brush (Digene)
Christmass tree cer-
vical sampling brush 
(Digene)
HC2
10 Lacket al. 53 Gambia 210 RMS survey 83 Pregnant Dacron swab, tampons Cytobrush GP5+/6+
11 Lenselinket al. 54 the Netherlands 45
Visiting gynecologist for follow-up diethylstilbestrol 
exposition in utero, cervical dysplasia or cytology 
abnormalities
NA Viba-Brush (Rovers Medi-cal devices)
Cervex-Brush (Rov-
ers Medical devices) SPF10LiPA
12 Longatto-Filhoet al. 66 Brazil, Argentina
311*
770#
Latin female population with different risks of  
cervical abnormalities 84 NA Brush, 1 sample Brush, 2 samples HC2
13 Moscickiet al. 72 537 Age 13-21, < 5 years of sexual experience 85
immunosuppressd, pregnant, surgery 
cervix 85 Dacron swab Lavage PGMY09/11
14 Safaeianet al. 41 Uganda 606~ Age 15-49, participants RCCS 86 NA Swab Swab
HC2, RBLA, 
PGMY09/11
15 Seoet al. 67 South Korea 118 Abnormal cytology NA Dacron swab
Cervical brush 
(cytology), Dacron 
swab (HPV)
HPVDNACHipTM 
(PCR based)
16 Sowjanyaet al. 69 India 432 Age ≥ 25, intact uterus, mentally competent NA Swab 
Ayre spatual & Swab 
(cytology)
Swab Digene cervi-
cal sampler (HPV)
HC2, Roche proto-
type RLBA
17 Stenvalet al. 56 Sweden 43 Age 23-58, previous positive cytology NA Qvintip Cytobrush
Self-sample HC2
Physician-sample 
GP5+/6+
18 Szarewskiet al. 70 Great Britain 920 Attending routine cervical smear No previous cervical treatment Cotton swab
Spatual and brush 
(cytology)
Brush (HPV)
HC2
19 Wineret al. 71 Washington, USA 374
Age 18-25, newly recruited in longitudinal study of 
genital HPV infection, who never had vaginal  
intercourse or first intercourse within past 3 months
Age 23-32, recruited 5-10 years earlier to  
longitudinal study of genital HPV infection
NA Dacron swab Dacron swab Roche RLBA,PGMY09/11
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Reference Country N Inclusion Criteria   Exclusion Criteria   Self-sample   device 
Physician-sample 
device HPV test
1 Belinson China 2625 Age 16-54 Pregnancy, pelvic radiation, hysterectomy, treatment cervical cancer or HIV+ Brush Brush
HC2; typing: 
Roche RLBA
2 Bhatla et al. 60 Developing country 546 Age ≥ 30, sexually active, gynecologic symptoms NA Brush
Ayre Spatula
Brush HC2, PGMY09/11
3 Brinket al. 49 the Netherlands 96
Age 18-59, referred to gynecologist for colposcopy-
directed biopsy or healthy volunteer NA Lavage Brush GP5+/6+
4 Daponte et al. 82 Greece 98
HIV negative, referred with abnormal cervical  
cytology, with proven abnormal histology NA Cytobrush Cytobrush PCR
5 De Alba et al. 62 California, USA 1213 Age ≥ 18, hispanic
Papsmear last year, pregnancy, hysterec-
tomy, cervical cancer Cotton swab NA HC2
6 Holandaet al. 39 Brazil 878 Age 15-70, sexually active 
Menstruation, sexual intercourse < 24 h, 
using vaginal cream Brush Ayre spatula HC2
7 Joneset al. 63 South Africa 450
Age ≥ 18, sexually active, attending community 
health centre Pregnant
Half swab and half 
tampons Brush Roche RLBA, HC2
8 Karwalajtys et al. 64 NA 307
Age 15-49, HPV+ a year earlier 
Age ≥ 50; randomly NA Dacron swab
Brush (after 
papsmear) HC2
9 Khannaet al. 65 Cananda
398*
399# Age 18-69, presenting for routine gynecology care
Presenting symptoms
Abnormal Pap test, genital cancer, cervical 
surgery, or immune treatment of the cervix 
within one year
Christmass tree cervical 
sampling brush (Digene)
Christmass tree cer-
vical sampling brush 
(Digene)
HC2
10 Lacket al. 53 Gambia 210 RMS survey 83 Pregnant Dacron swab, tampons Cytobrush GP5+/6+
11 Lenselinket al. 54 the Netherlands 45
Visiting gynecologist for follow-up diethylstilbestrol 
exposition in utero, cervical dysplasia or cytology 
abnormalities
NA Viba-Brush (Rovers Medi-cal devices)
Cervex-Brush (Rov-
ers Medical devices) SPF10LiPA
12 Longatto-Filhoet al. 66 Brazil, Argentina
311*
770#
Latin female population with different risks of  
cervical abnormalities 84 NA Brush, 1 sample Brush, 2 samples HC2
13 Moscickiet al. 72 537 Age 13-21, < 5 years of sexual experience 85
immunosuppressd, pregnant, surgery 
cervix 85 Dacron swab Lavage PGMY09/11
14 Safaeianet al. 41 Uganda 606~ Age 15-49, participants RCCS 86 NA Swab Swab
HC2, RBLA, 
PGMY09/11
15 Seoet al. 67 South Korea 118 Abnormal cytology NA Dacron swab
Cervical brush 
(cytology), Dacron 
swab (HPV)
HPVDNACHipTM 
(PCR based)
16 Sowjanyaet al. 69 India 432 Age ≥ 25, intact uterus, mentally competent NA Swab 
Ayre spatual & Swab 
(cytology)
Swab Digene cervi-
cal sampler (HPV)
HC2, Roche proto-
type RLBA
17 Stenvalet al. 56 Sweden 43 Age 23-58, previous positive cytology NA Qvintip Cytobrush
Self-sample HC2
Physician-sample 
GP5+/6+
18 Szarewskiet al. 70 Great Britain 920 Attending routine cervical smear No previous cervical treatment Cotton swab
Spatual and brush 
(cytology)
Brush (HPV)
HC2
19 Wineret al. 71 Washington, USA 374
Age 18-25, newly recruited in longitudinal study of 
genital HPV infection, who never had vaginal  
intercourse or first intercourse within past 3 months
Age 23-32, recruited 5-10 years earlier to  
longitudinal study of genital HPV infection
NA Dacron swab Dacron swab Roche RLBA,PGMY09/11
~ Number of samples instead of number of patients
* Number of self-samples 
# Number of physician-collected samples  
^ Study also including immunocompromised (HIV-positive) women 
NA  Not available or not applicable; HC2, hybrid capture 2; RLBA, reverse line blot assay; HPV, human papillomavirus
RMS, reproductive morbidity survey; RCCS, Rakai community cohort study
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When using the same device for self-sampling and physician-sampling, the overall mean 
concordance is 87.1% (SD 12.3) with a nearly excellent agreement of к=0.73 (SD 0.15). 
Studies using different devices for self-sampling and physician-sampling showed a con-
cordance of 85.2% but with a lower, still fairly good, agreement of к=0.60 (SD 0.12).
In Table 2, studies that did show an excellent agreement (к> 0.75) between self-sampling 
and physician-sampling are all PCR-based. When a swab for sampling and a PCR-based 
HPV DNA test was used, the mean к was excellent (к=0.81 [SD 0.09]). The use of a brush 
combined with PCR results in a nearly excellent mean к (к=0.71 [SD 0.18]), with three 
of the five studies with an excellent agreement (к=0.76-0.88). In Table 3, only studies 
using tampons for self-sampling and a PCR HPV detection method reported an excellent 
concordance (к=0.76). The higher sensitivity to detect hr-HPV is probably the reason why 
PCR-based studies show better results than studies performed with HC2. The SPF10LiPA, 
the PCR test with the highest analytical sensitivity,87 was only used in one study. This study 
showed a concordance of 93.3% with an excellent agreement (к=0.86).54
Three studies used both HC2 and PCR-based methods for HPV detection. Bhatla et 
al. showed a higher diagnostic accuracy for both physician- and self-samples with 
PGMY09/11. The agreement between HPV testing with HC2 and PGMY09/11 was 
90.9% (к=0.64) for self-samples and 95.3% (к=0.80) for physician-samples.60 Sowjanaya 
et al. showed the concordance between HC2 and RLBA for physician-sampling and self-
sampling for HPV detection of 94.4% (к=0.8), with a better performance for RLBA.69 
Jones et al. also showed a better performance for RLBA, the к with RLBA compared to 
the к with HC2 between self-sampling and physician-sampling using swabs was к=0.71 
versus к=0.61, and when using tampons it was к=0.75 versus к=0.55.63 The stron-
gest predictor of self-sampling performance in this study was the HPV viral load in the 
physician-collected specimens, estimated by HC2 relative light units.
Based on these data, self-sampling with PCR-based HPV DNA testing is more promising 
than with HC2. Before implementation of self-sampling in cervical screening, further 
research is needed to determine if the difference in performance of HC2 and PCR on 
self-sampling is clinically relevant.
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Sample device HPV test N ConcordanceMean % [range] (SD)
Kappa
Mean % [range] (SD)
Swab
HC2 40;41;64;69 2539 91.3 [85.7-99.1] (4.9) 0.59 [0.37-0.75] (0.17)
PCR 41;51;67;69;75-77, 71~,* 2255 84.9 [51.0-98.8] (17.2) 0.81 [0.65-0.96] (0.09)
Brush
HC2 39;43;73 1177 87.5 [83.0-92.0] (6.4) 0.71 [0.70-0.71] (0.01)
PCR 54;79, 60;78*, 82^ 1362 89.5 [77.0-93.9] (8.33) 0.71 [0.51-0.88] (0.18)
Lavage PCR 13 71 75 0.47
Total 7404 87.1 [51.0-99.1] (12.3) 0.73 [0.37-0.96] (0.15)
* Any-type HPV 
^ Only HPV 16 detection 
~  Study used two different groups of participants and reported two different rates of concordance and kappa.
к=0.0, no agreement at all; к<0.4, poor, к=0.4-0.75, fairly good; к>0.75, excellent; к=1.0 = complete agreement between the test 
results.
* Any-type HPV 
~ HPV detection with HC 
к=0.0, no agreement at all; к<0.4, poor, к=0.4-0.75, fairly good; к>0.75, excellent; к=1.0 = complete agreement between the test 
results.
SD, standard deviation; HPV, Human papillomavirus; HC2, hybrid caputre 2; PCR, polymerase chain reaction
Table 2. 
Concordance of hr-HPV detection using the same sample device for self- and 
physician-sampling
Table 3. 
Concordance of hr-HPV detection using different sample devices for self- and 
physician-sampling
Self-sample 
device HPV test N
Concordance
Mean % [range] (SD)
Kappa
Mean % [range] (SD)
Swab
HC2 63;74 1637 81.8 [81.5-82.0] (0.35) 0.53 [0.45-0.61] (0.11)
PCR 63;81 475 85.6 0.66 [0.60-0.71] (0.08)
Brush PCR 52 285 NA 0.45
Tampon
HC2 63, 48~ 321 84.2 [80.5-87.8] (5.2) <0.5-0.55
PCR 63, 80* 502 88.5 [87.8-89.2] 1.0 0.76 [0.75-0.76] (0.01)
Lavage PCR 49 96 87 0.71
Total 3316 85.2 [80.5-89.2] (3.4) 0.60 [0.45-0.76] (0.13)
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Detection of cervical abnormalities by self-sampling and physician-sampling
Studies reporting data on sensitivity and specificity of HPV testing for detection of cervi-
cal intraepithelial neoplasia (CIN) lesions were included to obtain insight in the perfor-
mance of self-sampling and physician-sampling. Table 4 presents the results of studies 
performed in screening populations, mainly including HPV testing and cytology prior to 
histology, and Table 5 shows data of studies performed in colposcopy clinics on popula-
tions considered to be at high risk of CIN lesions.
The available results on the accuracy of hr-HPV detection with self-sampling compared 
with physician-sampling for detection of CIN lesions in screening populations are limited. 
From the results shown in Table 4, there was no statistically significant difference in ≥CIN1 
detection between self-sampling and physician-sampling in screening populations. For 
the detection of ≥CIN2, only studies using HC2 were available. The mean sensitivity 
(94.3%) of physician-sampling with a brush was higher than the mean sensitivity of self-
sampling (82.7%). Self-sampling with a swab had a lower mean sensitivity to detect 
≥CIN2 (73.6%), but could not be compared with physician-sampling as results were 
not available. Although the sensitivity of HPV testing for ≥CIN2 detection for both 
physician-sampling and self-sampling is high, it will not reach 100% sensitivity. This may 
be explained by the vaccine trials that showed that HPV prevalence is not necessarily 
related to HPV attribution of the ≥CIN2 lesion that developed.
Because of the limited number of data available more research is necessary to evalu-
ate the clinical performance of self-sampling for hr-HPV DNA in screening populations, 
especially since data on ≥CIN2 detection with PCR-based HPV DNA detection methods 
are lacking and HPV detection with self-sampling and PCR have a better agreement with 
physician-sampling compared to testing with HC2.
In high-risk populations for cervical abnormalities (Table 5), physician-samples for HPV 
DNA testing showed a higher sensitivity for detection of ≥CIN2 than self-sampling. 
However, the specificity did not differ between both groups. The highest sensitivity of 
98.3% for detection of ≥CIN2 was obtained when a physician-sample with a swab and 
HC2 were used. The best results on sensitivity of self-sampling for detection of ≥CIN2 
were obtained by using a swab or a brush with HC2; both had a sensitivity of 86%. 
Although the number of studies are limited, these results suggest that physician-sampling 
is therefore preferred for detecting cervical abnormalities in high-risk populations, and 
self-sampling seems to be a good alternative for women otherwise not reached.
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Table 4. 
Accuracy of hr-HPV detection with self-sampling compared with physician-sampling 
for detection of CIN lesion general screening population
Table 5.  
Accuracy of hr-HPV detection with self-sampling compared with physician-sampling 
for detection of CIN lesion in a high-risk population
CIN 
lesion
HPV DNA 
test
Sample 
Device
Self-sample Physician-sample
Sensitivity % Specificity % Sensitivity % Specificity %
Mean%
[range] (SD)
Mean%
[range] (SD)
Mean%
[range] (SD)
Mean%
[range] (SD)
≥CIN1
HC2
Brush 43 89.5 48.5 NA NA
Swab 40 96.3 91.8 NS NS
PGMY09/11 Brush 78 75.0* 95.7* 75* 97.1*
≥CIN2 HC2
Brush43;55;66;70;88
82,7 64.6 94.3 84.9
[62.5-100] (15.6) [45.2-77.2] (17.1)
[83.9-100] 
(6.4)
[79.7-90.2] 
(4.3)
Swab 70;74
73.6 82.5
NA NA[66.1-81.0] 
(10.5)
[82.0-82.9] 
(0.64)
* Any-type HPV.
NA Not available; NS, not statistically significant different from HPV testing with self-sampling; CIN1, cervical intraepithelial neo-
plasia grade 1; CIN2, cervical intraepithelial neoplasia grade 2; SD, standard deviation; HPV, human papillomavirus; HC2, hybrid 
capture 2.
CIN 
lesion
HPV DNA 
test
Sample 
Device
Self-sample Physician-sample
Sensitivity % Specificity % Sensitivity % Specificity %
Mean%
[range] (SD)
Mean%
[range] (SD)
Mean%
[range] (SD)
Mean%
[range] (SD)
≥ CIN1 HC2 Brush 73 86.0 NA 80 NA
≥ CIN2
HC2
Brush 60*, 73 86.0[80.0*-92] (8.5) 88.1*
91.0
[90.0*-92] 
(1.4)
91.7*
Swab 44 86.2 53.5 98.3 52.1
PGMY09/11 Brush 60*,79
65.8
[49.0-82.5*] 
(23.7)
93.6*
+ NS
84.9
[82.2-87.5*] 
(3.7)
93.2*
+ NS
GP5+/6+ Lavage 13 81 68 91 43
CIN3
HPVDNA 
Chiptm 
(PCR)
Swab 67 90.5 29.0 88.1 32.9
* Any-type HPV.
NA Not available; NS, specificity not statistically significant different from HPV testing with self-sampling and physician-sampling; 
CIN1, cervical intraepithelial neoplasia grade 1; CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial 
neoplasia grade 3; HPV, human papillomavirus; HC2, hybrid capture 2; PCR, polymerase chain reaction.
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Acceptance of self-sampling
Cervico-vaginal self-sampling is a user-friendly method because self-sampling eliminates 
the need of a speculum examination.77 In studies reporting acceptability of self-sampling, 
the majority of women found self-sampling devices easy to use,12;43;62 time saving, less 
embarrassing, more comfortable, and women report that they were more relaxed doing 
it.11;14;78 This potentially improves participation rates for cervical cancer screening.
Overall, moderate to high rates of acceptance, 75-93% have been reported for self-
sampling.11-13;41;78 These studies included women in wide age ranges, from 15 to 63 years 
old.12;13;41;78 The majority of women, however, was of the ages 35-44 years 12;13;78 Most 
of the studies showed that women preferred self-sampling above a physician-collected 
sample, suggesting that self-sampling is likely to provide better population coverage.11;12;41 
However, these data are based on study populations, and therefore acceptability of 
self-sampling needs to be further explored in a national cervical screening program. 
Furthermore, to be representative, the acceptability of self-sampling should only be 
examined among women ≥30 years because HPV testing in screening will be offered to 
this group of women.
Although the responses are mainly positive, one study reported an acceptance rate of 
only 46% for self-sampling. This study was performed in women aged 15-49 years, 
who were invited on their return visit for annual cervical cytology, representing a group 
of women at low risk who already participated in screening.64 Another study reported 
that, despite women reported that self-sampling was easy to use (69%) and less painful 
(62%), a majority of 68% of the women still preferred the physician-collected sample.89 
Although women respond positively to self-sampling, they also report uncertainty about 
their performance of the procedure.11;13;90;91 Even women who reported to be fairly to very 
confident, were less confident compared to when the physician-collected test was used. 
This is the main reason for the preference of physician-sampling. Although this concern 
does not stop them to use the self-sample again if offered in the future.14
Cultural and religious beliefs do not appear to influence women’s choice for 
self-sampling,90;92;93 although in a group of Muslim women attending for cervical screening, 
limited enthusiasm for self-sampling was shown. They did show a clear preference for a 
swab rather than a cervico-vaginal lavage.94 In a low-resource setting where women are 
not used to tampons, the use of swabs was preferred above the use of tampons for self-
sampling, and the use of tampons was preferred above physician-collected sampling.53
Because it is known that about 50% of the cases with invasive cervical cancer arise 
in women who are not adequately screened,95-97 non-responding women represent a 
high risk category for developing cervical cancer and are therefore important to reach.98 
Self-sampling is regarded as a possible alternative to facilitate the screening of women 
who refuse to participate in current cervical cancer screening programs.11;13;42 Recently, 
it has been shown that the participation in screening of non-responders improved with 
the use of self-sampling methods.15;75;99;100 Because the majority of all women included 
in these studies were ≥30 years of age, the high rates of acceptance in these studies 
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were promising for self-sampling as a public health option. For example, in one study, 
a group of non-responders was offered a cervico-vaginal lavage self-sample and the 
control group consisted of non-responders who received the normal recall for cytology. 
The compliance rate was significantly higher in the group offered the self-sample, 26.6% 
versus 16.4%.15 Another study invited non-responders of the national cervical screening 
program to perform a self-sample with the Qvintip; 58% of these women responded.100 
Both studies proved that self-sampling is an attractive cervical screening method for non-
responders and increases their participation.
Conclusion
Self-sampling showed a good overall agreement with physician-sampling when a swab 
or a brush was used in combination with a PCR-based test for HPV DNA detection. The 
agreement was only moderate when using other sampling devices or HC2 for HPV DNA 
detection. However, the clinical sensitivity of self-sampling with PCR based tests needs 
to be validated. A high sensitivity of HPV detection should result in a high detection of 
≥CIN2 lesions, but a highly sensitive HPV detection assay may also overestimate the 
proportion of women who have cervical abnormalities.87;101;102 Future studies should focus 
especially on general screening populations to determine if self-sampling combined with 
PCR based HPV testing is a valid tool for national screening.
In high-risk populations, although based on only a few studies, physician-sampling had 
a higher sensitivity to detect ≥CIN2 lesions than self-sampling, and HC2 seemed to be 
better than self-sampling with PCR-based HPV DNA detection. This was not expected 
because PCR-based tests performed better than HC2 in studies comparing self-sampling 
and physician-sampling for HPV detection. Moreover, in high-risk populations, there is 
a higher prevalence of lesions and a sensitive test like PCR is expected to detect those 
lesions. Therefore, future studies on self-sampling in national screening should also 
address the performance of HC2 and PCR-based tests for the detection of ≥CIN2 lesions 
in high-risk populations.
The majority of women accept a sampling method performed by the woman herself, 
in the privacy of her own home. Furthermore, self-sampling lowers the threshold and 
increases the uptake of screening in non-responders. Therefore, addition of a self-
sampling option to a national screening program may increase screening coverage, and 
thus overall efficacy.
Today self-sampling for HPV detection has proven that its sensitivity is sufficient to 
screen women otherwise not screened, and may be implemented in national screening 
to reach non-responders. Further research is necessary before a wide implementation in 
an already successful national screening program is possible.
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Abstract
Background: Human papillomavirus (HPV) is a necessary factor in the development of 
cervical intraepithelial neoplasia and cervical cancer. However, HPV is also a very com-
mon sexually transmitted virus and many women clear their infection.
Objective: To analyze HPV type-specific incidence and clearance and its relation with 
age and sexual behavior in a group of young, unvaccinated, unscreened women.
Methods and Materials: 2065 women, aged 18-29 years, were followed for 12 months 
and were asked to provide a self-collected cervico-vaginal sample and fill-out a ques-
tionnaire every three months. For HPV DNA detection the SPF10-DEIA LiPA25 system was 
used.
Results: Incidence rates of any-type high-risk HPV and low-risk HPV were 17.0 per 
1000-person months, and 14.3 per 1000-person months, respectively. HPV types 16, 
52, 51, and 31 had the highest type specific incidence rates. Co-factors independently 
influencing HPV incidence were type of relationship, having a new relationship, number 
of lifetime sex partners, frequency of sexual contacts in the past 3 months, and condom 
use. The overall clearance of the newly detected type-specific high-risk HPV infections 
and low-risk HPV infections was 61.2% and 69.0%, respectively. Having a sexual 
relationship and sexual age independently influenced the clearance of any-type high-risk 
HPV. Women with HPV 16 and co-infection with other high-risk HPV types had a lower 
proportion of clearance than women only infected with HPV 16.
Conclusion: HPV incidence rates in this young Dutch study population are comparable 
to incidence rates in young women in other western countries and not related to age. 
Independent factors significantly influencing incidence and clearance were all related to 
past or current sexual behavior.
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Introduction
It is generally accepted that a persistent human papillomavirus (HPV) infection is the 
necessary cause of cervical cancer. Acquisition of an HPV infection is therefore the main 
precursor of the series of events that eventually lead to cervical cancer.1-4 Fortunately, 
most of the acquired HPV infections are transient and clear spontaneously within 12 
months after first detection, and about 90% of the women will have cleared their HPV 
infection within 24 months.5-13
HPV is a very common sexually transmitted virus, mainly acquired early in sexual life.14;15 
Rates of acquiring an HPV infection are high following first sexual intercourse, and with 
each new sexual partner.7;16;17 The risk factors associated with acquiring an HPV infection 
are therefore mainly related to the individuals sexual behavior.18
HPV prevalence, however, is not only influenced by sexual activity but also varies by age 
and geography, as shown by the International Agency for Research on Cancer (IARC).19 
Young women have high rates of HPV acquisition, and incidence tends to decline with 
age.10;17;20;21 Whether age is also related to the duration of the infection remains contro-
versial. Some studies report that there is no influence of age on the clearance rate of the 
HPV infection.10;22;23 Whereas other studies report a lower clearance rate with increasing 
age,24;25 or in contrary a faster clearance rate in older women (> 45 year vs. < 25 year old 
women).8 These different study results are probably the result of variation in study popula-
tions with respect to age, geography and other risk factors related to cervical carcinoma 
development, as well as the sensitivity of the HPV DNA test used.
Although the majority of type-specific HPV infections clear within 24 months, some 
women may become HPV positive again for the same HPV type after one or more nega-
tive test results. These women are either newly infected by a new sexual partner with 
the same HPV genotype, re-infected by their own partner or have a reactivation of their 
initial infection.9
The objective of this 12-month prospective cohort study of young, unscreened, and un-
vaccinated women is to analyze HPV type-specific incidence and clearance and its rela-
tion to age and sexual behavior.
Methods and Materials
This study covers 12 months follow-up of a large prospective cohort study on HPV preva-
lence, incidence and clearance, performed in the Netherlands from 2007–2010. At study 
entry, 2065 unscreened women 18-29 years of age were included, as described pre-
viously.26 In the 12-month follow-up period, women were asked to provide five self-sam-
ples with a 3-month interval (study month 0, 3, 6, 9, and 12). All women received a self-
sample kit and the additional questionnaires by mail and performed the cervico-vaginal 
self-sample in the privacy of their own home. Written informed consent was obtained 
from all participants. This study was approved by the Local Medical Ethics Committee.
The self-sample kit contained an explanatory letter, a questionnaire, an illustrated in-
struction form on how to perform the cervico-vaginal self-sample, a small brush in a 
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sterile cover (Rovers Vibabrush®, Rovers Medical Devices, Oss, the Netherlands), and a 
collection tube containing medium (SurePathtm, Tripath Imaging®, Inc., Burlington NC, 
U.S.A.).26;27
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment 
assay. Extracted DNA was used for PCR amplification with the SPF10primer sets.
28;29 The 
samples were run through an HPV DNA enzyme immunoassay (DEIA) to obtain an OD 
reading, and categorized as HPV DNA negative, positive, or borderline. In the DEIA essay 
a cocktail of 9 general probes are used to identify at least 54 different HPV types in the 
anogenital region. Amplimers from SPF10-DEIA-positive samples were used to identify the 
HPV genotype by reverse hybridization on a line probe assay (LiPA25) (SPF10HPVLiPA25, 
version 1; Labo Bio-Medical Products B.V., Rijswijk, the Netherlands), which detects 25 
HPV genotypes: high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68/73 and low-risk HPV types: type 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, and 74. 
Furthermore an HPV group “X” is identified (DEIA positive and LiPA negative samples) 
and contains mucosal and cutaneous HPV types not included in the type specific list, and 
considered to be low-risk HPV.
Statistical analysis
Incidence was defined by the cumulative number of newly detected HPV per 
1000-person months. When analyzing incidence for a specific HPV type, women had 
to be negative for that type-specific HPV type at baseline to be included in the analysis. 
The type-specific positive women could still be included in the analysis of the other HPV 
types, therefore baseline HPV positive women were not excluded from the study.
HPV types were considered cleared during follow-up when a positive test was followed 
by two consecutive negative tests for the same HPV type. The duration of infection 
was defined as the time from first detection of the HPV type to the first negative test 
for the same HPV type. When an HPV type (either prevalently or newly detected) 
was considered cleared, but again detected during follow-up it was defined as a re-
infection or reactivation of that certain HPV type. The re-infection/reactivation rates per 
1000-person months of any-type hr-HPV and lr-HPV were lower when clearance was 
defined as having two consecutive HPV negative samples compared to when clearance 
was defined as having an infection followed by one negative sample, 30.8 [95% CI: 19.1-
49.5] and 39.5 [95% CI: 27.1-57.7] per 1000-person months, compared to 60.0 [95% 
CI: 49.0-73.4] and 51.7 [95% CI: 41.6-64.2] per 1000-person months. The definition of 
clearance, a positive test followed by two consecutive negative tests, gives therefore more 
certainty of clearance. This supports the use of the definition of clearance, a positive test 
followed by two consecutive negative, in an epidemiological study like ours.
To identify any potential factors influencing incidence and clearance the following fac-
tors were analyzed; age (baseline), smoking (baseline), oral contraceptive pill (OCP) 
use, age at first sexual intercourse, sexual age (number of sexually active years) (base-
line), type of sexual relationship, having a new sexual partner, lifetime number of sexual 
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partners, gender of sexual partner(s), number of sexual partners in the past 3 months, 
number of sexual contacts in the past 3 months, ever diagnosed with an STI, condom use, 
and having multiple HPV infections.
The categorical variables were individually analyzed in univariate analysis using log-
rank testing, for the continuous variables age and sexual age univariate cox-regression 
testing was used. Multivariate analysis was performed using cox-regression analysis with 
forward stepwise selection. A variable entered the model when its p-value was <0.15. All 
statistical analysis was performed using Stata/IC (version 11.2 for Windows; StataCorp LP, 
College Station, TX, USA).
Due to small numbers of re-infection/reactivation, potential factors of influence could 
not be analyzed.
Results
Of the 2065 women initially included, 1871 (90.6%) completed 12 months of follow-up. 
The median follow-up time was 12.3 months [0.0-17.0], with a median period of 3.0 
months [1.4-15.0] between samples. A total of 1798 women provided all 5 samples, and 
267 women had one or more missing samples (total 541 missing samples).
The mean age of the women was 23.5 years [18-29]. At baseline almost all women 
(94.3%) were sexually active and the mean sexual age (i.e. years of being sexually active) 
was 6.8 years [0-23]. Previously, the baseline demographic characteristics have been 
described extensively.26
Human papillomavirus incidence
HPV type-specific incidence is shown in Table 1. There were 687 type-specific hr-HPV 
incident infections in total and 482 type-specific lr-HPV infections. The incidence rate of 
any-type hr-HPV was 17.0 infections per 1000-person months. Hr-HPV types 16, 52 51, 
31 and 18 have the highest incidence rates, 4.8, 3.5, 3.4, 3.0, and 2.4 per 1000-person 
months, respectively. Figure 1 shows the Kaplan-Meier curves of the cumulative inci-
dence rates of any-type hr-HPV and the five most prevalent hr-HPV types (HPV 16, 51, 
52, 31, and 18). This figure shows that during the 12 months of follow-up the cumulative 
incidence of the five most prevalent hr-HPV types is almost as high as the incidence rate 
of any-type hr-HPV. Indicating that the remaining hr-HPV types only have a small contri-
bution to hr-HPV incidence.
The incidence rate of any-type lr-HPV was 14.3 infections per 1000-person months. 
Generally, hr-HPV infections have a higher incidence rate than lr-HPV infections. The 
95% confidence interval for the difference between the incidence rates of any-type hr-
HPV and any type lr-HPV does not contain the value zero [95% CI: 0.37-5.15] and is 
therefore significant. The lr-HPV types 53, 66, 6, 54, and 74 have the highest incidence 
rates, 2.9, 2.4, 1.9, 1.7, and 1.3 per 1000-person months, respectively. The Kaplan-Meier 
curves of incidence rate of any-type lr-HPV and the five most prevalent lr-HPV types, 66, 
53, 54, 6, and 42 are displayed in Figure 2.
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Table 1.  
HPV type-specific prevalence at baseline and incidence
HPV-type
Prevalent infec-
tions 
N (%)
Total person months 
at risk
Incident infections 
N
Incidence rate per 
1000-person months 
(95% CI)
Hr-HPV* 254 (12.3) 20445.0 348 17.0 (15.3-18.9)
16 57 (2.8) 24356.6 118 4.8 (4.0-5.8)
18 30 (1.5) 25072.8 59 2.4 (1.8-3.0)
31 31 (1.5) 25008.7 74 3.0 (2.4-3.7)
33 18 (0.9) 25473.6 23 0.9 (0.6-1.4)
35 6 (0.3) 25625.6 17 0.7 (0.4-1.1)
39 20 (1.0) 25259.1 54 2.1 (1.6-2.8)
45 3 (0.1) 25636.9 25 1.0 (0.7-1.4)
51 51 (2.5) 24763.6 85 3.4 (2.8-4.2)
52 52 (2.5) 24599.2 86 3.5 (2.8-4.3)
56 15 (0.7) 25391.6 50 2.0 (1.5-2.6)
58 6 (0.3) 25541.6 31 1.2 (0.9-1.7)
59 9 (0.4) 25578.1 22 0.9 (0.6-1.3)
68/73 12 (0.6) 25428.4 43 1.7 (1.3-2.3)
Lr-HPV# 179 (8.7) 21800.2 311 14.3 (12.8-15.9)
6 12 (0.6) 25352.6 47 1.9 (1.4-2.5)
11 4 (0.2) 25697.3 8 0.3 (0.2-0.6)
34 0 (0.0) 25755.3 9 0.3 (0.2-0.7)
40 3 (0.1) 25701.0 12 0.5 (0.3-0.8)
42 5 (0.2) 25627.9 25 1.0 (0.7-1.4)
43 1 (0.0) 25698.8 19 0.7 (0.5-1.2)
44 2 (0.1) 25648.8 23 0.9 (0.6-1.3)
53 35 (1.7) 24982.3 73 2.9 (2.3-3.7)
54 14 (0.7) 25398.6 44 1.7 (1.3-2.3)
66 39 (1.9) 24996.4 61 2.4 (1.9-3.1)
70 4 (0.2) 25687.2 14 0.5 (0.3-0.9)
74 3 (0.1) 25613.1 34 1.3 (0.9-1.9)
X 72 (3.5) 24374.1 113 4.6 (3.9-5.6)
n number; 
* Any-type hr-HPV; 
# Any-type lr-HPV  
Total type-specific incident hr-HPV infections: 687  
Total type-specific incident lr-HPV infections: 482  
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Figure 1
Figure 2
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Only risk factors associated with sexual behavior; the type of sexual relationship, having 
a new sexual partner in the past 3 months, the lifetime number of sexual partners, the 
number of sexual contacts in the past 3 months and condom use, independently influ-
enced HPV incidence, as shown in Table 2.
Couples living apart (HR: 0.3 [95% CI: 0.1-1.0]), living together (HR: 0.4 [95% CI: 0.1-
1.0]), or who are married (HR: 0.3 [95% CI: 0.1-0.9]) have a lower risk of acquiring any-
type hr-HPV, compared to being single. Married women also have a lower risk (HR: 0.2 
[95% CI: 0.0-0.7]) of acquiring any-type lr-HPV infection compared to single women. 
Having a new sexual relationship in the past 3 months increases the risk of acquiring any-
type hr-HPV (HR: 2.6 [95% CI: 1.7-3.9]), HPV 18 (HR: 4.5 [95% CI: 2.1-9.5]) or any-type 
lr-HPV (HR: 2.2 [95% CI: 1.4-3.6]).
Higher numbers of lifetime sexual partners increase the risk of having a newly detected 
HPV type. Compared to having 1 lifetime sexual partner at baseline, women with 2-5, 
6-10, and >10 lifetime sexual partners have an increased risk for acquiring any-type 
hr-HPV (HR: 1.5 [95% CI:1.0-2.3], HR: 1.8 [95% CI: 1.1-2.8], and HR: 3.6 [95% CI: 
2.1-6.2], respectively), for acquiring any-type lr-HPV (HR: 1.5 [95% CI: 0.9-2.2], HR: 
2.4 [95% CI:1.5-3.9], HR: 2.4 [95% CI:1.4-4.2], respectively), and for acquiring HPV 16 
(HR: 2.1 [95% CI: 1.0-4.3], HR: 3.0 [95% CI:1.4-6.3], and HR: 4.3 [95% CI: 1.9-9.4], 
respectively). Additionally, compared to women with 1 lifetime sexual partner at base-
line, women with 6-10 partners had an increased risk (HR: 3.7 [95% CI:1.0-13.3]) for 
acquiring HPV 18. This risk was not significantly different compared to women with 2-5 
and >10 lifetime sexual partners.
Compared to women with 1-6 sexual contacts in the past 3 months, frequent sexual con-
tacts (>54 times) had a higher risk of having a newly detected any-type hr-HPV (HR: 2.8 
[95% CI: 1.5-5.2]). Condom use only influenced a woman’s risk of acquiring any-type 
lr-HPV, but not the acquisition of hr-HPV. The risk of having a newly detected any-type 
lr-HPV infection was lower (HR: 0.6 [95% CI: 0.3-1.0]) in women using condoms most 
of the times (>50%) compared to women who never used condoms.
Figure 3 displays the relation of age with the detection of a newly acquired hr-HPV 
type, in this young group of women. Within the Cox-regression model, where age was 
analyzed as a continuous variable and not categorical, the relation between age and 
acquiring a new hr-HPV type was not significant. However, women aged 24-29 years 
(except for women 26 years) have a higher hr-HPV incidence rate compared to women 
18-23 years of age (p-value < 0.0001).
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Any-type Hr-HPV HPV 16 HPV 18 Any-type Lr-HPV
HR [95% CI]
P-
value HR [95% CI]
P-
value HR [95% CI]
P-
value HR [95% CI]
P-
value
Relationship
Single 1.0 NS NS NS NS 1.0
Married 0.3 [0.1-1.0] 0.047 NS NS NS NS 0.2 [0.0-0.7] 0.012
Living 
together 0.4 [0.1-1.0] 0.044 NS NS NS NS 0.4 [0.1-1.4] 0.151
Couple  
living apart 0.3 [0.1-0.9] 0.025 NS NS NS NS 0.6 [0.2-1.9] 0.351
New sexual 
relationship
No 1.0 NS NS 1.0 1.0
Yes 2.6 [1.7-3.9] <0.001 NS NS 4.5 [2.1-9.5] <0.001 2.2 [1.4-3.6] 0.001
Lifetime sex 
partners (N)*
1 1.0 1.0 1.0 1.0
2-5 1.5 [1.0-2.3] 0.042 2.1 [1.0-4.3] 0.038 1.9 [0.5-6.5] 0.332 1.5 [0.9-2.2] 0.089
6-10 1.8 [1.1-2.8] 0.021 3.0 [1.4-6.3] 0.005 3.7 [1.0-13.3] 0.043 2.4 [1.5-3.9] <0.001
>10 3.6 [2.1-6.2] <0.001 4.3 [1.9-9.4] <0.001 3.8 [1.0-15.1] 0.055 2.4 [1.4-4.2] 0.001
N sex contacts 
< 3 months
1-6 1.0 NS NS 1.0 NS NS
7-24 1.0 [0.6-1.8] 0.870 NS NS 0.2 [0.1-0.9] 0.029 NS NS
25-54 1.2 [0.7-2.1] 0.402 NS NS 0.8 [0.3-1.9] 0.538 NS NS
>54 2.8 [1.5-5.2] <0.001 NS NS 0.9 [0.3-3.1] 0.902 NS NS
Condom use
Never NS NS NS NS NS NS 1.0
Always NS NS NS NS NS NS 0.7 [0.4-1.3] 0.302
Sometimes 
(<50%) NS NS NS NS NS NS 0.9 [0.6-1.3] 0.423
Most times 
(>50%) NS NS NS NS NS NS 0.6 [0.3-1.0] 0.044
Table 2. 
Factors independently associated with acquiring HPV
Cox regression multivariate analysis; HR: Hazard ratio’s; CI: confidence interval
Factors not included in the table do not significantly influence acquiring a newly detected HPV infections: age, smoking, oral 
contraceptive pill (OCP) use, age at first sexual intercourse, sexual age (number of sexually active years), gender of sexual 
partner(s), number of sexual partners in the past 3 months, ever diagnosed with an STI, and having multiple HPV infections.
NS=not significantly associated with HPV incidence
* baseline data
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Human papillomavirus clearance
In the 12-month follow-up of this young group of women an overall clearance proportion 
of 61.2% [95% CI: 56.3-65.9] for type specific hr-HPV infections and 69.0% [95% CI: 
63.1-74.5] for lr-HPV infections was found. Table 3 shows the type-specific time to 
clearance of incident infections. Overall, the clearance proportion between hr-HPV types 
and lr-HPV types was not significantly different.
Fifty three percent of the incident any-type hr-HPV infections cleared with a median time 
to clearance of 6.4 months. This clearance was significantly higher than the clearance 
of prevalently detected (i.e. already present at the first sample) any-type hr-HPV infec-
tions, who had a median clearance time of 9.0 months (data not shown). The clearance 
proportions of incident hr-HPV types 16, 51, 52, 31, and 18 were 62.0%, 44.7%, 63.8%, 
61.4%, and 59.5%, respectively, with a median time to clearance of 3.9, not estimable 
(NE), 3.2, 3.7, and 5.8 months, respectively. Figure 4 displays the Kaplan-Meier curves 
of the clearance of any-type hr-HPV and HPV 16, 51, 52, 31, and 18. The figure shows 
that HPV 16 had the highest clearance and that the clearance of HPV 18, 31, and 51 are 
almost identical after six months of follow-up.
Sixty percent of the incident any-type lr-HPV infections cleared after a median time of 
3.5 months, which was faster, however not significant, than the median time to clearance 
(6.0 months) of prevalently detected any-type lr-HPV (data not shown). The clearance 
rates of incident lr-HPV types, 66, 53, 54, 6, and 42 were 61.3%, 56.1%, 54.2%, 81.3%, 
and 64.3% respectively, with a median time to clearance of 3.5, 3.4, 5.9, 3.2, and 3.0 
months, respectively. Figure 5 displays the Kaplan-Meier curves of the clearance of any-
type hr-HPV and HPV 66, 53, 54, 6, and 42. The figure shows that HPV 6 clears twice as 
fast as any-type lr-HPV.
Figure 3: Hr- en lr-HPV incidence and age.
Incidence: proportion of subjects with an incident infection
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Table 3. 
HPV type-specific clearance
HPV-type
Incident infec-
tions 
N
Clearance portion 
N (%) [95% CI]
Time (months) 
Median [95% CI]
Hr-HPV* 233 123 (52.8) [46.2-59.3] 6.4 [3.9-NE]
16 79 49 (62.0) [50.4-72.7] 3.9 [3.3-7.0]
18 37 22 (59.5) [42.1-75.2] 5.8 [3.4-NE]
31 44 27 (61.4) [45.5-75.9] 3.7 [3.1-NE]
33 9 4 (44.4) [13.7-78.8] NE [2.7-NE]
35 11 6 (54.5) [23.4-83.3] 6.1 [3.0-NE]
39 31 16 (51.6) [33.1-69.8] 7.5 [3.0-NE]
45 16 8 (50.0) [24.7-75.3] 3.9 [3.0-NE]
51 38 17 (44.7) [28.6-61.7] NE [3.1-NE]
52 58 37 (63.8) [50.1-76.0] 3.2 [3.1-5.6]
56 26 18 (69.2) [48.2-85.7] 3.1 [3.0-6.7]
58 22 16 (72.7) [49.8-89.3] 3.0 [3.0-4.4]
59 15 12 (80.0) [51.9-95.7] 3.0 [3.0-3.8]
68/73 26 20 (76.9) [56.4-91.0] 3.2 [3.0-3.9]
Lr-HPV# 190 113 (59.5) [52.1-66.5] 3.5 [3.2-6.2]
6 32 26 (81.3) [63.6-92.8] 3.2 [3.0-3.9]
11 6 2 (33.3) [4.3-77.7] NE [3.0-NE]
34 7 5 (71.4) [29.0-96.3] 3.7 [3.0-NE]
40 8 8 (100.0) [63.1-100] 3.0 [2.8-3.2]
42 14 9 (64.3) [35.1-87.2] 3.1 [3.0-NE]
43 11 11 (100.0) [71.5-100] 3.1 [2.8-3.6]
44 16 11 (68.8) [41.3-89.0] 3.0 [2.8-NE]
53 41 23 (56.1) [39.7-71.5] 3.4 [3.0-NE]
54 24 13 (54.2) [32.8-74.4] 5.9 [3.0-NE]
66 31 19 (61.3) [42.2-78.2] 3.5 [3.0-NE]
70 8 5 (62.5) [24.5-91.5] 3.2 [2.8-NE]
74 17 11 (64.7) [38.3-85.8] 3.1 [3.0-NE]
X 56 44 (78.6) [65.6-88.4] 3.0 [3.0-3.2]
n: number; NE: not estimable; *: Any-type hr-HPV; #: Any-type lr-HPV
Mean clearance type-specific hr-HPV: 61.2% [56.3-65.9]
Mean clearance type-specific lr-HPV: 69.0% [63.1-74.5]
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Figure 4
Figure 5
63
3
Any-type Hr-HPV HPV 16 HPV 18 Any-type Lr-HPV
HR [95% CI] P-value HR [95% CI]
P-
value HR [95% CI]
P-
value HR [95% CI]
P- 
value
Relationship
Single 1.0 NS NS NS NS 1.0
Married 7.3 [3.3-15.7] <0.001 NS NS NS NS 1.6 [0.6-4.8] 0.361
Living 
together 4.0 [2.2-7.3] <0.001 NS NS NS NS 1.8 [1.1-3.1] 0.028
Couple  
living 
apart
2.9 [1.6-5.0] <0.001 NS NS NS NS 2.1 [1.3-3.4] 0.003
Sexual age# 0.9 [0.9-1.0] 0.031 NS NS NS NS NS NS
Lifetime sex 
partners (N)
1 NS NS NS NS 1.0 NS NS
2-5 NS NS NS NS 0.1 [0.0-0.8] 0.029 NS NS
6-10 NS NS NS NS 0.3 [0.1-1.6] 0.169 NS NS
>10 NS NS NS NS 0.2 [0.0-1.3] 0.100 NS NS
Multiple  
hr-HPV  
infections
No NE NE 1.0 NS NS NE NE
Yes NE NE 0.1 [0.0-0.6] 0.007 NS NS NE NE
Table 4. 
Factors independently associated with HPV clearance of incident infections
Cox regression multivariate analysis; HR: Hazard ratio’s; CI: confidence interval; NS=not significantly associated with HPV 
clearance; NE= not estimable; none of the women infected with more than 1 infection were cleared from all of their infections
Factors not included in the table do not significantly influence acquiring a newly detected HPV infections: age, smoking, OCP 
use, age at first sexual intercourse, having a new sexual partner, gender of sexual partner(s), number of sexual contacts in the 
past 3 months, ever diagnosed with an STI, and condom use.
* baseline data
# number of years being sexually active
The clearance of both any-type hr-HPV and any-type lr-HPV is not affected by age in this 
group of young women (see Figure 6). Factors that did independently influence clearance 
of newly detected HPV types are shown in Table 4. This table shows that women with 
increasing sexual age (i.e, the number of sexual active years) are less likely to clear their 
infection (HR: 0.9 [95% CI: 0.9-1.0]). Additionally, women with a sexual relationship, 
married, living together or a couple living apart are more likely to clear their any-type 
hr-HPV infection compared to single women (HR: 7.3 [95% CI: 3.3-15.7], HR: 4.0 [95% 
CI:2.2-7.3], and HR: 2.9 [95% CI: 1.6-5.0], respectively). Women with a sexual relation-
ship, either living together or a couple living apart were also more likely to clear their 
any-type lr-HPV infection compared to single women (HR: 1.8 [95% CI: 1.1-3.1] and HR: 
2.1 [95% CI: 1.3-3.4], respectively).
The only factor influencing the clearance of HPV 16 was whether a woman had multiple 
hr-HPV infections or not. If a woman had multiple hr-HPV infections she was not likely 
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to clear her HPV 16 infection (HR: 0.1 [95% CI: 0.0-0.6]). The clearance of HPV 18, 
however, was only influenced by the number of lifetime sexual partners. Women with 
2-5 lifetime sexual partners at baseline compared to women with 1 lifetime sexual partner 
were less likely to clear their HPV 18 infection (HR: 0.1 [95% CI: 0.0-0.8). This lower 
clearance rate ceased when a woman had more lifetime sexual partners.
For the prevalently detected HPV types (i.e. already present at the first sample), clearance 
of any-type hr-HPV infections, HPV 16 and HPV 18 was not related to a woman’s sexual 
behavior. However, the clearance of any-type lr-HPV was associated with the type 
of sexual relationship. Women living together with their sexual partner had a higher 
clearance rate compared to single women (HR 1.9 [95% CI 1.1-3.2]). (Data not shown 
in table)
Human papillomavirus re-infection/reactivation
The re-infection/reactivation rates of any-type hr-HPV and any-type lr-HPV were 30.8 
and 39.5 per 1000-person months, respectively. These re-infection/reactivation rates of 
the type-specific hr-HPV infections and lr-HPV infections are based on small numbers 
and vary from 0.0 to 41.1 and 0.0 to 87.5 infections per 1000-person months, respec-
tively. Notable, no re-infection/reactivation is detected in this one year follow-up study 
for the hr-HPV types 35, 45, 56, and 59, and the lr-HPV types 6, 11, 34, 40, 42, 70.
Due to the small rates of re-infection/reactivation we were not able to identify any risk 
factors associated to re-infection or reactivation of HPV.
Figure 6: Hr- en lr-HPV clearance and age
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Discussion
This is the first Dutch prospective epidemiological study analyzing the incidence and 
clearance of HPV among unscreened young women in the pre-vaccine era. This study 
therefore provides important baseline information on the natural behavior of HPV for 
future studies analyzing the impact of HPV vaccination on HPV incidence and clearance 
and whether type-replacement and cross-protection takes place.
Incidence
The incidence of any-type hr-HPV in this prospective 12-month follow-up study of 2065 
young women was 17.0 per 1000-person months. This was significantly higher than the 
incidence of any-type lr-HPV, which was 14.3 per 1000-person months. Coinciding 
incidence rates of hr-HPV, 14.0 per 1000-person months, and lr-HPV, 12.4 per 
1000-person months were reported in a follow-up study of female university students.9 In 
the past, several other studies also found a higher incidence of hr-HPV types compared to 
the incidence of lr-HPV types.13;30 Whereas Goodman et al. reported the same incidence 
rate for hr-HPV and lr-HPV.8 In this study population, HPV types 16, 51, 52, and 31 
had the highest type specific incidence rates, which has also been reported in other 
studies.7-9;30;31
We found that sexual behavior related co-factors were the only factors independently 
influencing HPV incidence, this supports the conclusion of previous studies that HPV is 
basically a sexually transmitted disease.18;32 Interestingly, incidence was related to both 
recent as well as past sexual behavior factors. The recent sexual behavior factors were, 
type of relationship, having a new relationship, frequency of sexual contacts in the past 
3 months, and condom use. These factors have been described before in other studies 
and fit in with the concept that with new sexual partners, or risk-full sexual behavior the 
chances of acquiring a new HPV type are increased.16;18 Additionally, HPV incidence was 
related to the number of lifetime sex partners, which in fact is past sexual behavior. The 
number of lifetime sex partners was an independent factor related to the incidence of any-
type hr-HPV, any-type lr-HPV, as well as to type specific HPV 16 and HPV 18 incidence. 
Several other studies also associated past sexual behavior with HPV incidence.14;16;33-35 
Generally, one would expect past sexual behavior to be related to HPV prevalence (as 
shown before by our group) but not to HPV incidence.26 A possible explanation could 
be that women with a high number of sexual partners in the past may potentially date 
men who also have a high number of sexual partners in the past, a group likely to have 
a higher HPV prevalence, and therefore increase the risk of acquiring HPV. However, 
another possible explanation for the influence of past sexual behavior on current HPV 
incidence may be that the infection was acquired in the past and has remained present 
in levels of low copy numbers, normally not detectable by current HPV DNA detection 
methods (i.e. viral latency). Accidental detection of this latent virus will thus be regarded 
as an incident infection, while in fact it is a non-productive virus residing in cells, or a 
reactivated previous infection. Past sexual behavior is related to past HPV incidence, and 
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thus related to the risk of having one or multiple latent HPV infections. So, the probability 
to detect a latent HPV accidentally, or detect a re-activated HPV infection, mimicking an 
incident HPV infection, is increased with increasing number of lifetime sexual partners. 
Therefore, we can only measure presumed incidence because it is presently impossible 
to distinguish a new infection from an accidental pick-up or reactivation of a latent 
infection.13;36
Although women aged 24-29 years had a higher incidence rate compared to 18-23 years 
old women, age was not an independent risk factor for HPV incidence. When analyzing 
the age groups compared to the variable ‘having a new sexual partner during follow-up’, 
women in the age group 24-29 years have more new sexual partners compared to the 
younger women (p-value = 0.145). This may potentially explain why age as continuous 
factor is not an independent factor influencing HPV incidence in this young group of 
women.
Some studies, however, do report a decline of incidence with increasing age in women 
<30 years, but they found the lowest risk for women 30 years and older.21;36
Clearance
In this 12-month follow-up study the overall clearance rate of the newly detected (i.e. 
incident) hr-HPV and lr-HPV infections was 61.2% and 69.0%, respectively. Confirming 
the finding that most incident HPV types are not detected 6-12 months later.14
The overall clearance rate of hr-HPV types and lr-HPV types was not significantly 
different. Other studies, however, often reported a higher clearance rate for lr-HPV.9;13;21 
This may possibly be explained by the duration of follow-up, because it was found that 
the difference between the clearance rate of lr-HPV and hr-HPV types became significant 
after a follow-up of 12 months.13
The time to clearance was not significantly different between incident hr-HPV and lr-HPV 
infections in this study, varying from 3.0-7.5 months for hr-HPV types and 3.0-5.9 months 
for lr-HPV types. Several studies, on the other hand, have reported that infections with hr-
HPV types tend to have a longer duration compared to lr-HPV types.9;13;21;37 Especially HPV 
16 and associated types like HPV 31, tend to persist longer than other genotypes.9;15;21;25;38
Factors independently related to HPV clearance were type of sexual relationship, sexual 
age, and number of lifetime sexual partners. Single women had a lower clearance of 
hr-HPV and lr-HPV infections compared to women with a partner, or living together/
married. Women, living together with their sexual partner or married, may probably have 
more accidental pick-up of latent HPV. An accidental pick-up is much more likely to be 
detected only once and considered cleared during follow-up, whereas single women may 
have more new (true incident) infections, likely to remain detected for a longer duration 
before the immune system clears the infection, or before it is maintained in a latent state. 
Furthermore, the fact that an increasing sexual age decreases the clearance rate of any-
type hr-HPV, and that an increasing number of lifetime sexual partners decreases the 
clearance of HPV 18, underlines the influence of past sexual behavior on current HPV 
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dynamics.
Interestingly, the clearance rate of HPV 16 is not related to sexual behavior in this study. 
Women with multiple HPV infections were less likely to clear their HPV 16 infection. 
The fact that multiple HPV types are detected may indicate that the host immune system 
is failing in some respect, which may be responsible for a slower clearance of HPV 16 
in these patients. This relation may also exist for other type-specific HPV infections, but 
the numbers were too small in this study to analyze this for all individual HPV types. The 
presence of multiple infections in a woman may potentially be an indicator of a (partially) 
failing immune system.
No relation between age and HPV clearance was found in this young study population. 
This was probably due to the young age of the women and the small age range. In 
literature some studies report that women, older than 45 years clear their HPV infections 
faster than women <25 years,8 and vice versa.25 However, many other studies did not find 
a difference in clearance among different age groups.10;22
Factors like OCP use, condom use and smoking, reported by some authors to be 
associated with HPV clearance and persistence were not identified as independent risk 
factors within this study population.
Considering that we only found either past sexual behavior to influence clearance or 
having multiple infections, we suggest that HPV clearance is likely to be mainly related 
to the host immune response, or other intrinsic host factors and not to present behavior 
factors.
Previous studies showed that detection or reactivation of latent HPV exists, even in the 
absence of sexual activity. For example, Trottier et al. found that in women >40 years of 
age, 39.2% with no new sexual partners and 71,4% with new sexual partners became 
HPV-positive during follow-up.35;39 The risk of reactivation was found highest in immune 
compromised women.40;41 This supports our theory that newly detected HPV types must 
be distinguished in true incident infections, accidental pick-up of latent virus, and re-
activation of latent virus. Only when we are able to identify these subgroups, true HPV 
incidence and clearance data can be studied in relation to behavioral factors. This will be 
the challenge for future epidemiological HPV studies.
In conclusion, HPV incidence rates in this young Dutch study population are comparable 
to incidence rates in young women from other western countries. HPV types 16, 51, 52, 
31, and 18 had the highest type specific incidence rates. The high clearance rates and 
short duration of infections in this study confirm that most HPV infections are cleared 
within 6-12 months. The fact that incidence and clearance were not only related to 
current sexual behavior, but also to past sexual behavior indicates that accidental pick-up 
or re-activation of a latent HPV may be common. HPV clearance is probably more related 
to host immune factors, as clearance did show a relation with multiple infections. Future 
studies should therefore try to distinguish accidental pick-up, or reactivation, from true 
HPV incidence in order to be able to investigate the influence of intrinsic host factors on 
HPV dynamics.
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Abstract
Objective: To evaluate hr-HPV persistence and associated risk factors in a prospective 
cohort of young unscreened women. Additionally, the relation between hr-HPV status 
and cytology/histology results is examined.
Methods and Principal Findings: Two year follow-up of 235 out of 2065 young 
women (18–29 years), participating in a large, one year epidemiological study, with 
questionnaires, self-collected cervico-vaginal samples (Vibabrush), and SPF10LiPA for 
HPV detection. Only women hr-HPV positive at sample month 12 were invited for a 
second year of follow-up. After study follow-up, available cytology/histology data were 
requested from PALGA (the national network and registry of histo- and cytopathology 
in the Netherlands). These data were compared with available cytology/histology data 
of the month 12 hr-HPV negative women from the same cohort. 44.1% of the hr-HPV 
types detected at study month 12, persisted during follow-up. HPV types 45, 31, 16 and 
18 were most likely to persist with percentages of 60.0%, 56.8%, 54.4%,and 50.0%, 
respectively. Compared to newly detected infections at month 12, infections present 
since 6 months or baseline had an increased risk to persist (OR 3.09 [95% CI: 1.74-5.51] 
and OR 4.99 [95% CI: 2.67-9.32], respectively). Other co-factors influencing persistence 
were, multiple HPV infections, smoking and multiple lifetime sexual partners. The 
percentage of women with a HSIL/CIN2+ (12.1%) in the persistent HPV group, was not 
significantly different (p=0.107) from the 5.3% of the women who cleared the hr-HPV 
infection, but was significantly (p 0.000) higher than to the 1.6% of women in the hr-HPV 
negative control group.
Conclusion: We showed that HPV genotype, multiple infections, smoking, and multiple 
lifetime sexual partners are co-factors that increase the risk of hr-HPV persistency. Most 
importantly, we showed that hr-HPV infections are more likely to persist the longer they 
have been present and that women with a persistent hr-HPV infection have a high risk of 
HSIL/CIN2+ development.
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Introduction
It has been well established that a human papillomavirus (HPV) infection is a neces-
sary cause in the development of cervical intraepithelial neoplasia (CIN) and cervical 
cancer.1-3 HPV appears to be the most common sexually transmitted infection and about 
80% of all sexually active women will acquire an HPV infection during their lifetime.2 
Fortunately, only a small proportion of these infections lead to CIN and cervical cancer. 
A persistent high risk (hr) HPV infection is necessary for the development of cervical 
carcinoma. Therefore the detection of a persistent hr-HPV infection represents an impor-
tant marker of an increased risk of CIN and cervical carcinoma.4-6 However, there is no 
consensus on the definition of persistence.
Most investigators define a persistent HPV infection as detection of the same HPV type, 
or group of types, on two consecutive visits, but these could be from 2 months up to 72 
months apart.7,8 Several studies have shown that most infections become undetectable 
within 1-2 years.5,9-11 Additionally, infections lasting more than 1 year appear to be as-
sociated with a lower clearance rate.5,9 Therefore it is more informative to monitor the 
duration of the infection rather than the number of positive tests.12
Several risk factors have been identified that are associated with HPV persistence. 
Especially viral characteristics like viral load, and HPV genotype are linked to 
persistence.13,14 Given that HPV16 and 18 are the most carcinogenic HPV genotypes, 
it would be useful to know whether their risk of persistence differs from other hr-HPV 
genotypes.15 Additionally, some authors have shown that multiple HPV infections are 
associated with an increased duration of high-risk HPV infections,9,16 whereas others have 
failed to show such an increase.11,17 Other co-factors like age, condom use, smoking, 
long-term use of oral contraceptives, high parity, number of sex partners, and exposure to 
other sexually transmitted diseases have also been associated with HPV persistence.9,18,19
In this study, a prospective cohort of young unscreened women (18-29 years) in the pre-
vaccine era was followed for 2 years, to examine the influence of viral factors (i.e. dura-
tion of infection, HPV-type and co-infection), and co-factors (i.e. sexual behavior and 
smoking) on hr-HPV persistence. Additionally we examined the relation between hr-HPV 
status and follow-up cytology/histology results.
Methods and Materials
A large prospective cohort study on HPV prevalence, incidence and clearance was per-
formed in the Netherlands, in 2007–2010. At study entry, 2065 unscreened women 18 
to 29 years of age were included.20 Exclusion criteria were, being pregnant, or not fluent 
in Dutch. Of the 2065 women initially included, 1871 (90.6%) completed the first year 
of follow-up. Women, who were hr-HPV positive at month 12 (n=257 (13.7%)), were 
invited to participate in a second year of follow-up in order to study hr-HPV persistence. 
In total 235 (91.4%) of the invited women, completed the second year of follow-up 
and were included in this analysis of persistence. The study was closed after the sample 
at month 24, therefore all the hr-HPV positive women were referred to their general 
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practitioner or gynaecologist for additional follow-up or treatment. Written informed con-
sent was obtained from all participants. This study was approved by the Local Medical 
Ethics Committee.
Specimen collection and HPV DNA detection and genotyping
The women provided five self-samples with a 3-month interval (month 0, 3, 6, 9, and 12) 
during the first year of the study. In the second year of follow-up, women provided two 
additional self-samples with a 6 month interval (month 18 and 24). All women received 
the self-sample kit and the additional questionnaires by mail.
The self-sample kit contained an explanatory letter, a questionnaire, an illustrated instruc-
tion form on how to perform the cervico-vaginal self-sample, a small brush in a sterile 
cover (Rovers Vibabrush®, Rovers Medical Devices, Oss, the Netherlands), and a collec-
tion tube containing medium (SurePathtm, Tripath Imaging®, Inc., Burlington NC, U.S.A.), 
as described previously.20,21
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment as-
say. Extracted DNA was used for PCR amplification with the SPF10primer sets.
22,23 The 
samples were run through an HPV DNA enzyme immunoassay (DEIA) to obtain an 
OD reading, and categorized as HPV DNA negative, positive, or borderline. The same 
SPF10 amplimers were used on SPF10-DEIA-positive samples to identify HPV genotype 
by reverse hybridization on a line probe assay (LiPA) (SPF10HPVLiPA25, version 1; Labo 
Bio-Medical Products B.V., Rijswijk, the Netherlands), which detects the following HPV 
genotypes: low-risk HPV types: type 6, 11, 34, 40, 42, 43, 44, 53, 54, 55, 66, 70, 74, and 
“X” (DEIA positive and LiPA negative samples); and high-risk HPV types 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.
Type-specific hr-HPV; clearance, persistence, and history
An HPV infection was considered cleared when a woman had two consecutive HPV 
negative samples.11,24,25 Therefore, hr-HPV positive women with one intermittent type-
specific hr-HPV negative sample were considered persistent for that hr-HPV type. All 
women included in the second year of follow-up were hr-HPV positive at sample month 
12, thus only women who were negative for hr-HPV at sample month 18 and 24 were 
considered to have cleared their hr-HPV infection. (see Table 1)
The sampling interval in the 2nd study year was 6 months and persistence is generally 
defined as two consecutive HPV positive samples. Thus, a type–specific hr-HPV infection 
was considered persistent when it was detected for at least 6 months. Women who were 
positive at sample month 18 and/or month 24 were therefore considered to have a per-
sistent type-specific hr-HPV infection in the 2nd study year (see Table 1). Four of the 235 
women were treated for abnormal cytology (and one cervical carcinoma) and cleared 
hr-HPV before sample month 18, therefore the natural course of clearance or persistence 
was disturbed. The data of these women were excluded in the analysis of persistence.
To analyze whether the duration of the type-specific hr-HPV infection (the history) prior 
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to sample month 12 influences persistence in the 2nd study year, we determined at which 
sample moment the hr-HPV infection was first detected. In order to calculate with the 
same time interval between the samples in the 1st and the 2nd study year, the cut-off point 
for first detection of the type-specific hr-HPV were made at baseline (month 0), sample 
month 6 and sample month 12 (see Table 1). This analysis was performed for the total 
number of type-specific hr-HPV infections.
Hr-HPV status related to cytology and histology
The study protocol was based on self-sampling for HPV detection. Gynecologic histo- 
and cytopathology data were thus not available at the end of the study. To be able to 
evaluate the relation between HPV status and cervical lesions, we requested informa-
tion from PALGA (the national network and registry of histo- and cytopathology in the 
Netherlands).26 To compare data of the hr-HPV positive women included in the 2nd study 
year, a control group was selected from the women who were hr-HPV negative at sample 
month 12. These women were 27-29 years at study baseline, and had received an invita-
tion of the Dutch national cervical cancer screening program. In order to relate cytology/
histology results to the hr-HPV status, information of all sample points in the 1st and 2nd 
study year had to be available. The four women who were treated for abnormal cytology 
before sample month 18, were also excluded in the analysis of persistence related to 
cytology. This resulted in 224 women hr-HPV positive at sample month 12 and 336 
women hr-HPV negative at sample month 12 (control group). PALGA data on 
Study sample month
Type-specific hr-HPV 
history Month 0 Month 6 Month 12* Month 18 Month 24
Type-specifc hr-HPV  
during 2nd study year
Detected since baseline + + +
+ - +
Detected since study 
month 6 - + +
Newly detected at study 
month 12 - - +
- - Clearance
+ -
Persistence+ +
- +
* only women positive for hr-HPV at sample month 12 are included in the 2nd study year and in the analysis of HPV persistency
Table 1. 
Definitions of duration of type-specific hr-HPV detection
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gynecologic histo- and cytopathology, test date, and age of the woman at time of the 
test, were available for 166 (74.1%) hr-HPV positive women and 246 (73.2%) women of 
the control group. Due to privacy legislation, identification data were made anonymous 
by a Third Trusted Party (ZorgTTP, Houten, the Netherlands). To relate these anonymous 
gynecologic histo- and cytopathology test results with the hr-HPV status, women were 
grouped.
1) Month 12 hr-HPV positive women:
 a. type-specific hr-HPV type persistent in the 2nd study year
 b. cleared type-specific hr-HPV type in the 2nd study year
2) Control group: Month 12 hr-HPV negative women.
Statistical analysis
The baseline characteristics of the study population were analyzed and presented in 
frequencies, mean and standard deviation (SD). The percentage and 95% confidence 
interval (95% CI) of the hr-HPV prevalence at sample month 12 and persistence in the 
second year of follow-up were calculated using the number of infections instead of the 
number of women. Data from the questionnaires were used to determine, with simple 
logistic regression analysis, whether co-factors like OCP use, smoking and sexual be-
havior influenced the persistence in the 2nd study year. To analyze the relation between 
hr-HPV status and histo- and cytopathology test results significance was calculated with 
the Fischer’s exact test. All statistical analyses were performed using SPSS version 16.0 
(SPSS Inc., Chicago, IL).
Results
The 235 hr-HPV positive women included in this analysis had a mean follow-up time 
of 25.3 months (SD 1.5) and were all born in the Netherlands. At study baseline these 
women were 18-29 years of age with a mean age of 24 years (SD 3.2), and 233 (99.1%) 
women reported to ever have had sexual intercourse. Sixty six (28.1%) women reported 
that they were current smokers, and there were 165 (70.2%) current oral contraceptive 
pill (OCP) users. These baseline data are shown in Table 2.
In order to be included in the 2nd study year, women had to be hr-HPV positive at sample 
month 12. Of the 235 women, 163 had one hr-HPV type, 54 had two hr-HPV types, 15 
had 3 hr-HPV types, two had 4 hr-HPV types and one woman had 6 hr-HPV types at 
sample month 12. This resulted in a total of 330 type-specific hr-HPV infections detected 
at sample month 12. HPV 16 had the highest prevalence of 30.2%, followed by HPV 51 
(19.1%), HPV 31 (16.6%), and HPV 52 (14.9%). HPV 18 was prevalent in 11.1% of the 
women. (see Table 3)
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Sample size
N (%)
Total 235
Age (years), mean (SD) 24 (3.2)
18 8 (3.4)
19 16 (6.8)
20 19 (8.1)
21 16 (6.8)
22 25 (10.6)
23 15 (6.4)
24 25 (10.6)
25 24 (10.2)
26 18 (7.7)
27 33 (14.0)
28 23 (9.8)
29 13 (5.5)
Ethnicity
Dutch 235 (100)
Other 0 (0.0)
Education
Lower secondary/Lower vocational training 5 (2.1)
Higher secondary/Vocational training 46 (19.6)
Higher vocational training/University 184 (78.3)
Current Smoking
Yes 66 (28.1)
No 169 (71.9)
Using OCP
Yes 165 (70.2)
No 70 (29.8)
Ever had sexual intercourse
Yes 233 (99.1)
No 2 (0.9)
Table 2. 
Baseline demographics
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The percentage of the type-specific hr-HPV infections, present at sample month 12, per-
sisting in the 2nd study year are shown in Table 3. For 315 of the 330 type-specific hr-HPV 
infections data were available on persistence. Of these 315 type-specific infections, 139 
(44.1%) infections were persistent in the 2nd study year. HPV 45 was the most persistent 
type, with a persistence rate of 60.0%, followed by HPV 31 (56.8%), HPV 16 (54.4%), 
and HPV 18 (50.0%). Notably, HPV 45 was only number 10 in prevalence with 11 
(4.7%) type-specific infections at month 12, whereas HPV 51 (second in prevalence with 
45 infections) was one of the least persistent infections with a persistence rate of 25.0%.
Not only the hr-HPV type, but also the duration of the infection prior to sample month 
12, seemed to influence persistence in the 2nd study year. Overall, a type-specific infec-
tion detected since baseline had an odds ratio (OR) of 4.99 (95% CI: 2.67-9.32) to persist 
in the 2nd study year, compared to infections newly detected at month 12. Infections first 
detected at sample month 6 also had an increased risk, OR of 3.09 (95% CI: 1.74-5.51), 
to persist in the 2nd study year, compared to newly detected infections (see Table 4).
Rank HPV 
type
Prevalence at month 12 HPV 
type
Persistence in 2nd study year *
N % (95% CI) N % (95% CI)
1 16 71 30.2 (24.4-36.5) 45 6/10 60.0 (26.2-87.8)
2 51 45 19.1 (14.3-24.8) 31 21/37 56.8 (39.5-72.9)
3 31 39 16.6 (12.1-22.0) 16 37/68 54.4 (41.9-66.5)
4 52 35 14.9 (10.6-20.1) 18 13/26 50.0 (29.9-70.1)
5 56 28 11.9 (8.1-16.8) 33 5/10 50.0 (18.7-81.3)
6 18 26 11.1 (7.4-15.8) 56 12/26 46.6 (26.6-66.6)
7 39 25 10.6 (7.0-15.3) 39 10/25 40.0 (21.1-61.3)
8 68 21 8.9 (5.6-13.3) 68 7/19 36.8 (16.3-61.6)
9 33 12 5.1 (2.7-8.7) 52 12/34 35.3 (19.7-53.5)
10 45 11 4.7 (2.4-8.2) 35 2/7 28.6 (3.7-71.0)
11 59 9 3.8 (1.8-7.1) 51 11/44 25.0 (13.2-40.3)
12 35 8 3.4 (1.5-6.6) 59 2/9 22.2 (2.8-60.0)
Total 330 140.4 % Total 139/315 44.1 (38.6-49.8)
* Four of the 235 women were treated for abnormal cytology before sample month 18, therefore the natural fluctuation of clearance 
and persistence was disturbed. The data of these women were excluded in the analysis of persistence in the 2nd study year
Table 3. 
Ranking of type-specific hr-HPV prevalence at month 12 and type-specific hr-HPV 
persistence in 2nd study year
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Having multiple HPV infections at sample month 12, irrespective whether these infections 
were only hr-HPV or also lr-HPV types, increased a woman’s risk to have a type-specific 
hr-HPV persistent infection in the 2nd study year. This was almost a twofold increased risk, 
OR 1.93 (95% CI: 1.14-3.26). (See Table 5)
Furthermore, Table 5 shows that smoking and number of lifetime sexual partners are co-
factors influencing hr-HPV persistence. Smokers have an almost twofold increased risk of 
persistence than non-smokers (OR: 1.87 [95% CI: 1.03-3.39]) and women with multiple 
lifetime sexual partners at baseline have an increased risk of persistence compared to 
women with 1 lifetime sexual partner. The OR’s for 2-5, 6-10 and more than 10 lifetime 
sexual partners were 4.29 [95% CI: 1.13-16.26], 6.82 [95% CI: 1.76-26.33] and 4.15 
[95% CI: 1.05-16.34], respectively. Of the 15 women with 1 lifetime sexual partner at 
baseline, only three had a type-specific persistent infection during follow-up. Of the three 
persistent infections in women with 1 lifetime sexual partner, one (HPV 16) was newly 
detected at month 12, and two (HPV 16 and HPV 56) were detected since month 6.
Twelve of the 15 women with 1 lifetime sexual partner at baseline reported to have a new 
sexual partner during the study follow-up. Together they had 16 type-specific hr-HPV 
infections detected at sample month 12, of whom 10 were newly detected, four were 
first detected at month 6, and two at baseline. Because most hr-HPV types were newly 
detected at month 12 and newly detected hr-HPV infections are less likely to persist, 
this might be a confounding factor. However, confounding could not be ruled out with 
multiple logistic regression analysis because ‘duration of hr-HPV detection’ and ‘number 
of lifetime partners’ are based on different dependent variables, ‘number of infections’ 
and ‘number of women’, respectively.
The following variables; age, OCP use, age of first sexual intercourse, sexual age, having 
a new sexual partner during study follow-up, current type of relationship, current number 
of sexual partners, current frequency of sexual intercourse, current condom use and 
having a STI during study follow-up, did not influence persistence of a type-specific hr-
HPV infection in the 2nd study year (see Table 5).
Table 4. 
Influence of the duration of type-specific hr-HPV detection on persistence in 2nd 
study year
Type-specific hr-HPV history N persistent N (%) OR (95% CI) P-value 
Detected since baseline 63 43 (68.3) 4.99 (2.67-9.32) 0.000
Detected since study month 6 70 40 (57.1) 3.09 (1.74-5.51) 0.000
Newly detected at month 12 166 50 (30.1) 1 (ref)
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N*
(n=231)
Persistent
N (%) OR (95% CI) P-value
Age
      Mean: 24.0 years
      SD: 3.16
231 122 (52.1) 1.07 (0.99-1.16) 0.106
Education
     Lower secondary / Lower vocational training
     Higher secondary / Vocational training
     Higher vocational training/University
5 3 (60.0) 1.31 (0.21-8.04) 0.769
45 23 (51.1) 0.92 (0.48-1.76) 0.898
180 96 (53.3) 1 (ref)
Current Smoking
     No 166 81 (48.8) 1 (ref)
     Yes 64 41 (64.1) 1.87 (1.03-3.39) 0.039
OAC at T12
     No 75 36 (48.0) 0.72 (0.41-1.25) 0.240
     Yes 151 85 (56.3) 1 (ref)
Age at first sexual intercourse
     ≤ 13 8 6 (75.0) 2.57 (0.37-17.83) 0.339
    14-16 119 61 (51.3) 0.90 (0.29-2.84) 0.859
    17-19 90 48 (53.3) 0.98 (0.31-3.15) 0.972
    ≥ 20 13 7 (53.8) 1 (ref)
Sexual Age^
     Mean: 7.5 228 122 (52.6) 1.07 (0.99-1.16) 0.197
     SD: 3.37
Lifetime sexual partners
     1 15 3 (20.0) 1 (ref)
     2-5 87 45 (51.7) 4.29 (1.13-16.26) 0.032
     6-10 73 46 (63.0) 6.82 (1.76-26.33) 0.005
     >10 55 28 (50.9) 4.15 (1.05-16.34) 0.042
New sexual partner during study period?
     No 55 35 (63.6) 1.75 (0.90-3.43) 0.103
     Yes 102 51 (50.0) 1 (ref)
Type of relationship at study month 12
     Married or Living together 47 28 (59.6) 1.47 (0.73-2.98) 0.281
     Couple, living apart 83 44 (53.0) 1.13 (0.63-2.03) 0.686
     Single 98 49 (50.0) 1 (ref)
Number of sexual partners past 3 months at 
study month 12
0 32 14 (43.8) 1.36 (0.33-5.59) 0.669
1 161 86 (53.4) 2.01 (0.57-7.12) 0.281
2 26 18 (69.2) 3.94 (0.89-17.37) 0.070
≥3 11 4 (36.4) 1 (ref)
Table 5. 
Woman’s risk of having a persistent type-specific hr-HPV type in the 2nd study year
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Hr-HPV persistence related to cytology and histology
The results from PALGA on cytology and histology related to the hr-HPV status of the 
women are presented in Table 6. The mean age of the women with available cytology 
results was 28,4 (SD: 2.8). It was not possible to measure the exact time interval between 
sample month 12 and first cytology because the cases were made anonymous. 
However, all dates of self-sampling and cytology were available. We calculated the time 
interval between the date when 50% of the women had taken their self-sample en when 
50% of the women had their cytology performed. For the study group women (1a and 
1b) this interval was 13 months and for the control group women (2a and 2b) the interval 
was 12 months.
In the study group 1a; 11 (12.1%) of the 91 women with a persistent hr-HPV infection 
were identified with HSIL/CIN2+. Four of the 75 women (5.3%) in group 1b, who cleared 
their type-specific hr-HPV infection in the 2nd study year had HSIL/CIN2+. This difference 
between both groups was, not significant (p 0.107). In the control group, 4 of the 246 
women (1.6%) developed HSIL/CIN2+. Women with a persistent hr-HPV type were 
significantly more often diagnosed with HSIL/CIN2+ compared to women in the control 
group (p 0.000).
N*
(n=231)
Persistent
N (%) OR (95% CI) P-value
Sexual frequency past 3 months at T12
     1-3 42 26 (61.9) 1.49 (0.68-3.26) 0.318
     4-12 25 10 (40.0) 0.61 (0.24-1.55) 0.299
     13-27 61 35 (57.4) 1.23 (0.62-2.47) 0.552
     >27 69 36 (52.2) 1 (ref)
Condom use at study month 12
     Never 101 60 (59.4) 1.13 (0.45-2.81) 0.800
     Sometimes 39 18 (46.2) 0.66 (0.23-1.86) 0.431
     Most of times 34 16 (47.1) 0.68 (0.24-1.98) 0.484
     Always 23 13 (56.5) 1 (ref)
Having multiple infections at study month 12? #
     Yes 107 66 (61.7) 1.93 (1.14-3.26) 0.015
     No 123 56 (45.5) 1 (ref)
Other STI during study period?
     No 209 112 (53.6) 1.27 (0.52-3.12) 0.602
     Yes 21 10 (47.6) 1 (ref)
Table 5. Continued
SD: standard deviation
* Number = based on available data, as not all 231 women completely filled-in the questionnaire.
^ Sexual age = years of sexual activity (current age minus age of first sexual intercourse)
# Multiple infections = irrespective whether these infections were only hr-HPV or also lr-HPV
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Discussion
In this 2-year prospective cohort study among young unscreened women, we showed 
that an already persistent hr-HPV infection has an increased risk to persist during follow-
up compared to newly detected infections. Hr-HPV types persistent for 6 and 12 months 
or longer had a respective, threefold or fivefold, increased risk of persistence. Other 
studies also reported that HPV infections are more likely to persist the longer they have 
been present.4,5,11,14,27 Of the newly detected infections 70% were cleared before the next 
sample (6 month interval). This is a slightly higher clearance rate than reported in some 
other studies, who found a mean time to clearance of 6-8 months for newly acquired 
HPV infections.9,28
Persistence was also influenced by the genotype. The overall persistence of type-specific 
hr-HPV in this study is 44.1%, HPV types 45, 31, 16, and 18, had the highest rate of 
persistence and the highly prevalent HPV type 51 had a low tendency to persist. In agree-
ment with our findings, other studies also showed that HPV 16, 18, 31, and 45 have an 
Table 6. 
Histo- and cytopathology follow-up results
Cytology Histology
classification n (%) Normal CIN 1 CIN 2 CIN 3+ No histology
1. Study group*
a. Persisting type specific 
hr-HPV (n=91)
No cytology 1 (1.1) 1
Normal 55 (60.4) 55
ASCUS 16 (17.6) 4 2 1 9
LSIL 10 (11.0) 1 6 1 6
HSIL 9 (9.9) 3 5 1
b. Cleared type-specific 
hr-HPV (n=75)
Normal 52 (69.3) 52
ASCUS 15 (20.0) 3 1 11
LSIL 5 (6.7) 1 1 1 1 1
HSIL 3 (4.0) 1 1 1 0
2. Control group#
(n=246)
Normal 227 (92.3) 227
ASCUS 14 (5.7) 1 13
LSIL 2 (0.8) 1 1
HSIL 3 (1.2) 2 1
* Study group: study month 12 hr-HPV positive women. Mean interval between study month 12 and cytology=13 months
# Control group: study month 12 hr-HPV negative women. Mean interval between study month 12 and cytology=12 months
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increased risk to persist compared to other HPV types.11,17,29-32 Additionally, the IARC 
multicentre case-control study showed that HPV 16, 18, 45 and 31 were the most com-
mon HPV types in cervical carcinoma.33
Having multiple HPV infections is a risk factor for hr-HPV persistence. The risk to have 
a persistent type-specific hr-HPV infection during follow-up increased almost twofold 
in women with multiple (hr- and/or lr-HPV) HPV types at month 12. These results are in 
agreement with other studies showing that women with multiple infections have a higher 
risk to have a persistent type-specific HPV infection during follow-up.9,16,18 A possible 
explanation may be that the multiple infections increase the overall viral load of the in-
fection which by sheer volume overcomes immune control. Whether this only happens 
in women with a lower immunity or also in the general population is not well known. 
Another explanation may be that there are specific interactions between different HPV 
genotypes. The impact of having multiple infections on persistence, however, probably 
ceases in time. Cuschieri et al., showed that over a period of two to three years multiple 
hr-HPV infections did not constitute a higher risk factor for the development of cervical 
neoplasia compared with single hr-HPV infections.34
Only two co-factors, smoking and number of lifetime sexual partners, were found to 
correlate with the likelihood that a hr-HPV type would persist. Smokers had a two-fold 
increased risk of hr-HPV persistence. Smoking is a known immune suppressor and a risk 
factor for cervical carcinoma.35 However, some studies did not find a difference in HPV 
persistence between current and non-current smokers.27.36 In our study only smoking at 
baseline was registered, therefore we could not identify differences in the risks between 
current or past smokers, nor for the duration of smoking, or number of cigarettes a day.
Women with 1 lifetime sexual partner at baseline were at lower risk for a persistent infec-
tion than women with multiple lifetime sexual partners. The highest risk was found for 
women with 6-10 lifetime sexual partners at baseline. It should be noted, however, that 
the majority of the women with 1 lifetime sexual partner at baseline, had a new sexual 
partner during study follow-up and newly identified hr-HPV types. Newly detected hr-
HPV types are less likely to persist, so this might be a confounding factor. In literature, 
the number of lifetime sexual partners is not a consistent risk factor for hr-HPV persis-
tency.36,37 Therefore, the potential influence of the number of lifetime sexual partners on 
hr-HPV persistency still needs to be elucidated.
The use of OCP’s is also a potential risk factor for the development of cervical carcino-
ma.38 However, results from our study and others did not find a relation between OCP use 
and persistence.21,27,36 This increased risk is reported to be strongly related to the duration 
of use and the effect proved reversible after cessation. This influence of OCP use on HPV 
persistence, however, is still controversial.35
Previously it has been shown that women with a persistent type-specific hr-HPV infection 
are significantly more likely to have or develop CIN than those who were sequentially 
infected by different hr-HPV types or who cleared their infection.34,39,40 We also found 
that having a persistent type-specific hr-HPV infection is associated with a higher (not 
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significant) rate of HSIL/CIN2+ development (12.1%) compared to women who cleared 
the type-specific hr-HPV infection (5.3%), and significantly higher (p 0.000) compared to 
women who were hr-HPV negative at study month 12 (1.6%).
Due to the anonymous histo- and cytopathology data, we were not able to correlate the 
histo- and cytopathology results to the type-specific hr-HPV types, nor if the woman had 
multiple HPV types. Therefore we could not confirm whether the infections with HPV 
types 45, 31, 16, and 18 were more likely to cause HSIL/CIN2+ and whether the number 
of infections was correlated to the severity of the lesion as described previously.41
There is considerable interest in the possibility of using HPV testing as a primary cervical 
cancer screening tool.42,43 Our data support that following prevalently detected hr-HPV 
types for persistence is useful to identify women with an increased risk of CIN in the fol-
lowing years.44 In order to do so, a clear definition of a clinically relevant persistent HPV 
infection should be determined. This definition should be based on the duration of the 
type-specific hr-HPV presence that is predictive of CIN development rather than based 
on two consecutive hr-HPV positive visits.
Based on our results in this population of young women, we suggest that this interval 
should be a minimal of 6 months, because a 6 month persistent hr-HPV type had a 
threefold increased risk to persist during follow-up compared to a newly detected hr-
HPV infection. However, this interval may be extended to 12 months, because 68.3% of 
the hr-HPV types already persistent for 12 months or longer continued to persist during 
follow-up. Therefore a 12 month interval for detection of type-specific hr-HPV persistency 
will select a group of women that needs close surveillance for HSIL/CIN2+ development 
in the following year(s).
In conclusion, we showed that co-factors increasing the risk of hr-HPV persistency are, 
genotype specific (45, 31,16, and 18, are most likely to persist), multiple infections, 
smoking, and multiple sexual lifetime partners. Most importantly, we showed that hr-
HPV infections are more likely to persist the longer they have been detected and that 
women with a persistent hr-HPV infection have a higher rate of HSIL/CIN2+ detection in 
the following year. Thus, women with a persistent hr-HPV infection should be monitored 
for HSIL/CIN2+ development.
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Abstract
Objective: To estimate the effect of the menstrual cycle and oral contraceptive pill (OCP) 
use on the prevalence, incidence, and persistence of human papillomavirus (HPV).
Methods and Materials: A longitudinal study was conducted among 2065 women aged 
18-29 years. The women returned a self-collected cervicovaginal sample and filled out 
a questionnaire. A total of 1812 women participated at all three time points, month 0, 
month 6 and month 12.
Results: Low- and high-risk Human papillomavirus (lr- and hr-HPV) prevalence at study 
entry was 8.9% and 11.8%, respectively. The annual incidence of lr-HPV infections was 
12.5% and the persistence was 2.0%. For hr-HPV, the incidence and persistence was 
12.1% and 4.5%, respectively. These results did not differ between OCP users and non-
users. A significant relation between hr-HPV detection and the timing of sampling was 
found when OCP users and nonusers were analyzed separately. In the second half of the 
menstrual cycle hr-HPV detection decreased in nonusers (P=.007) and increased in OCP 
users (P=.021). When women used OCPs continuously, hr-HPV detection returned to 
level of the first half of the menstrual cycle.
Conclusion: Hr-HPV detection was significantly influenced by sample timing in the men-
strual cycle when analyzed separately for OCP users and women with a natural menstru-
al cycle. This may have implications in the future, when hr-HPV detection may become 
a primary screening tool in cervical cancer prevention.
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Introduction
Human papillomavirus (HPV) infection is a necessary event in the carcinogenesis of cer-
vical cancer. However, only a small fraction of women infected with high-risk HPV types 
will eventually progress to high-grade intraepithelial lesions and cervical cancer. High-
parity, long-term oral contraceptive pill (OCP) use, smoking, and coinfection with other 
sexually transmitted diseases, are the most consistently identified co-factors in cervical 
carcinogenesis.1-3
Oral contraceptive use is associated with invasive cervical cancer. The international 
collaboration of epidemiological studies of cervical cancer (International Agency for 
Research on Cancer) showed that for current users of OCP, the risk of invasive cervical 
cancer increased with increasing duration of use with a relative risk of 1.90 (95% confi-
dence interval [CI] 1.69-2.13) for 5 years or more. This increased relative risk returned to 
normal after stopping OCP use for 10 years or more.4 Although OCPs are defined as a risk 
factor for cervical cancer, there is no evidence for an association with HPV positivity.5
Despite the lack of proof for a relation between OCP use and HPV positivity, there are 
indications that hormonal factors might influence HPV detection. The detection of HPV 
related to a woman’s last menstrual period (LMP) has been examined in a number of 
studies. Some studies found a relation between the LMP and HPV detection. However, 
their results were not concordant because they found different phases of the menstrual 
cycle to be optimal for HPV detection.6-9 On the other hand, studies that found no rela-
tion between HPV detection and the menstrual cycle suggest that only the sampling 
technique or the materials used may affect HPV detection.10-12 These studies on HPV 
prevalence and LMP are summarized in Table 1.
The mucosal immunity of the female genital tract, which is influenced by immunoglobin, 
cytokines and reproductive hormones, may explain this possible effect of the menstrual 
cycle on HPV detection. Exogenous and endogenous hormones increase the production 
of immunoglobin-producing cells in cervical secretions.13 Total immunoglobulin (Ig) A 
and IgG levels were higher in OCP users than in woman with a natural menstrual cycle 
(nonusers).13;14 In OCP users, the immunoglobin titer in the cervical mucus lowest during 
the week OCP use is stopped and increases with the start of use, whereas in nonusers, 
the IgA and IgG levels were highest during the follicular phase and lowest around ovula-
tion.13-15 These patterns in Ig levels during the menstrual cycle suggest an important role 
for reproductive hormones in the regulation of mucosal immunity.14
Because the use of OCP is associated with an increased relative risk of cervical cancer, 
we expected that the prevalence and persistence of high-risk HPV is higher in women 
using OCPs compared with nonusers. According to a previous study from our group,8 
we would expect to find a higher high-risk (hr) HPV detection rate in the second week 
of the menstrual cycle in nonusers. Whether fluctuating Ig levels truly influence HPV 
detection and the mode of this potential influence needs to be explored. When OCP 
use and sample timing within the menstrual cycle do affect HPV detection, this may 
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have implications in the future as HPV testing using self-samples becomes an important 
tool in cervical cancer screening programs. We analyzed cervicovaginal self-samples 
and questionnaires of a large population of young, unscreened women to estimate any 
potential influence from OCP use and sample timing within the menstrual cycle on HPV 
detection. Additionally, we investigated the HPV prevalence, incidence, and persistence 
in this group of young, unscreened women. Furthermore, we investigated the potential 
difference in the HPV prevalence, incidence, and persistence between OCP users and 
nonusers.
Methods and Materials
Study population & study design
This study is part of a 1-year prospective longitudinal study on HPV prevalence, clearance 
and persistence, performed in the Netherlands in 2007–2008 among 2065 unscreened 
women 18-29 years of age.16 Participants were recruited through advertisements, posters, 
flyers, the Internet, and active recruitment sites. Exclusion criteria were: not being in 
the age range of 18-29 years, being pregnant, or not being fluent in Dutch. Of the 2297 
women who responded, 2065 (90%) were eligible for participation and provided an 
informed consent. A total of 253 (12.3%) women were excluded from further analyses 
Author Sampling Technique HPV Detection Test used HPV Types Number subjects Result
Fairly, C.K., et al. Single tampon specimen (in/out specimen) PCR amplification High-risk: 16, 18 Low-risk: 6,11 298
Pellet volume of tampon speci-
men, but not HPV detection, 
vary during the menstrual cycle
Harper, D.M., et al. 
5 HPV screening test: clinician-directed ectocervical 
swab, clinician-directed endocervical swab, a self-
sampled synthetic polyester fiber swab (Dracon), a 
second self-sampled Dracon swap, and a self-sample 
tampon, in random order
PCR amplification 
High-risk: 16,18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 
58, 59, 68, NM4, NM7, NM9) 
 
Low-risk: 6, 11, 40, 42, 53, 54, 57, 66, MM8)
103
Percentage of positive samples 
for HPV did not differ by week 
of the menstrual cycle
Schneider, A., et al. Single point cervical swabs cumulative every 5 weeks in 1 year by clinician PCR mixture High-risk: 16 21
HPV 16 detection significantly 
(P= 0.019) higher in luteal 
phase
Sherman, M.E., J.D. 
Carreon, and M. 
Schiffman
2 samples:  Papette tm broom (Wallach Surgical, 
Orange, CT, USA) and a Dracon swab by clinician PCR-based assay 
High-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59 and 68 5060
Small effect of mid-cycle speci-
mens on highest HPV load
Van Ham, M.A., et al. 4 samples in one mentrual period by clinician with the Cervix brush (Rovers, Oss, the Netherlands) SPF10-PCR LiPA 25 different HPV types 20
Significantly (P=0.02) higher 
rate of HPV positive samples 
in the follicular phase (7th to 
11th day)
Wheeler, C.M., et al.
12 weekly vulvar and cervical swabs were taken by 
clinician as well as cervicovaginal saline lavage s. 10 
were used for evaluation.
PCR and the ViraPap (Digene 
Diagnostics, Silver Spring, MD) DNA 
dot-blot assay 
High-risk; 16, 18, 31, 33, 35, 39, 45, 51, 52, 59 
Low-risk: 6, 11, 53, 54 72
No correlation between HPV 
DNA detection and phase of 
menstrual cycle was observed
HPV, human papillomavirus; PCR, polymerase chain reaction.
Table 1.  
Studies on Human Papillomavirus prevalence and menstrual cycle
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from the 2065 participants at study entry. These women became pregnant (n=63, [3.0%]), 
were vaccinated against HPV (n=9, [0.4%]), or were lost to follow-up (n=181, [8.8%]). 
This resulted in a final number of 1812 (87.7%) participating women, of whom 1703 
(94.0%) reported to be sexually active at study entry. An additional 26 women became 
sexually active during the follow up, i.e. 13 every 6 months. Results of the sexually active 
women were used for further analyses.
Written informed consent was obtained from all participants. This study was approved by 
the local medical ethics committee.
All women received a questionnaire and a self-sample kit by mail. The self-sample 
kit contained an explanatory letter, an illustrated instruction form on how to perform 
the cervicovaginal self-sample, a small brush in a sterile cover (Rovers Vibabrush®, 
Rovers Medical Devices, Oss, the Netherlands), and a collection tube containing medium 
(SurePathtm, Tripath Imaging®, Inc., Burlington NC, U.S.A.). To return the self-sample, 
a leakproof sealed bag, absorption sheet, and a recloseable plastic return envelope 
(easyslider, Transposafe Systems Holland BV, Sassenheim, the Netherlands) were added, 
as described before.16 The accuracy of cervico-vaginal self-samples is highly comparable 
to physician-taken samples and it is inexpensive, feasible, and viewed by women as a 
convenient and acceptable method.17;18
The questionnaire consisted of two parts. One part concerned demographic information 
and the other part included questions on sexual behavior as well as questions about 
current OCP use and the LMP. To ensure privacy, the questionnaires were provided with 
Author Sampling Technique HPV Detection Test used HPV Types Number subjects Result
Fairly, C.K., et al. Single tampon specimen (in/out specimen) PCR amplification High-risk: 16, 18 Low-risk: 6,11 298
Pellet volume of tampon speci-
men, but not HPV detection, 
vary during the menstrual cycle
Harper, D.M., et al. 
5 HPV screening test: clinician-directed ectocervical 
swab, clinician-directed endocervical swab, a self-
sampled synthetic polyester fiber swab (Dracon), a 
second self-sampled Dracon swap, and a self-sample 
tampon, in random order
PCR amplification 
High-risk: 16,18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 
58, 59, 68, NM4, NM7, NM9) 
 
Low-risk: 6, 11, 40, 42, 53, 54, 57, 66, MM8)
103
Percentage of positive samples 
for HPV did not differ by week 
of the menstrual cycle
Schneider, A., et al. Single point cervical swabs cumulative every 5 weeks in 1 year by clinician PCR mixture High-risk: 16 21
HPV 16 detection significantly 
(P= 0.019) higher in luteal 
phase
Sherman, M.E., J.D. 
Carreon, and M. 
Schiffman
2 samples:  Papette tm broom (Wallach Surgical, 
Orange, CT, USA) and a Dracon swab by clinician PCR-based assay 
High-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59 and 68 5060
Small effect of mid-cycle speci-
mens on highest HPV load
Van Ham, M.A., et al. 4 samples in one mentrual period by clinician with the Cervix brush (Rovers, Oss, the Netherlands) SPF10-PCR LiPA 25 different HPV types 20
Significantly (P=0.02) higher 
rate of HPV positive samples 
in the follicular phase (7th to 
11th day)
Wheeler, C.M., et al.
12 weekly vulvar and cervical swabs were taken by 
clinician as well as cervicovaginal saline lavage s. 10 
were used for evaluation.
PCR and the ViraPap (Digene 
Diagnostics, Silver Spring, MD) DNA 
dot-blot assay 
High-risk; 16, 18, 31, 33, 35, 39, 45, 51, 52, 59 
Low-risk: 6, 11, 53, 54 72
No correlation between HPV 
DNA detection and phase of 
menstrual cycle was observed
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an anonymous code and all the data were entered in a computer program. The self-
samples were stored at room temperature and were sent to the Department of Medical 
Microbiology for processing and HPV detection.
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment 
assay (SPF10 HPV PCR, Laboratory Biomedical Products B.V., Rijswijk, the Netherlands) 
as described before.19;20 HPV types 6, 11, 34, 40, 42, 43, 44, 53, 54, 55, 58, 66, 70, 74, 
and “X” are defined as low-risk types and HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, 
68, 73, and 82 as high-risk types.
Data at study entry, month 0, were used for the analysis of HPV prevalence. The annual 
incidence of HPV was a result of the women acquiring a new HPV type at month 6 
or month 12. Women positive for any HPV type or group (lr- or hr-HPV) at all three 
measuring points were defined as persistent.
To investigate whether there were any potential confounding factors influencing hr-HPV, 
the data on demographics and sexual behavior at study entry were compared between 
the OCP users and nonusers. At study entry 72.7% (n=1315) of the 1812 women were 
using OCPs.
During the follow-up period of 1 year, 61.1% (n=1108) of the women were using OCPs 
during the whole year of follow-up and 20.9% (n=378) never used OCPs. This results in 
18.0% (n=326) women changeably using OCPs. These changeable users were excluded 
from the analysis when comparing the incidence and persistence between OCP users 
and nonusers. Women who reported using the Nuvaring® were registered as OCP users, 
because this creates local exogenous hormonal fluctuations comparable to OCP use.
The menstrual cycle was divided into the first half (days 1-14) and the second half (days 
15-28) of the cycle to examine if the timing of sampling related to the LMP or oral 
contraceptive withdrawal bleeding influences the HPV detection. The cycle was divided 
into four weeks (days 1-7, 8-14, 15-21 and 22-28) for further analysis of these results. The 
high-risk HPV detection rate in women on continuous OCP use, with a cycle of more 
than 28 days, was also analyzed.
Of the 5436 samples (at three time points, 1812 samples) taken during the follow-up 
period, 3904 samples (71.8%) had data on the LMP and oral contraceptive withdrawal 
bleeding and were taken within 28 days or less of the menstrual cycle. Data on OCP 
use also needed to be available for the analysis of the combined effect of sample timing 
related to the LMP and oral contraceptive withdrawal bleeding and OCP use on hr-HPV 
detection. This resulted in 3893 (99.7%) self-samples taken within 28 days or less of 
the menstrual cycle. Specified for OCP users and nonusers, there were 2893 and 1000 
samples, respectively. From women on continuous OCP use, samples taken more than 
28 days after the oral contraceptive withdrawal bleeding, 684 samples were available for 
analysis.
Analysis on demographic data and HPV prevalence, incidence and persistence were 
performed using frequencies, cross tables, and chi-square. Data on LMP and OCP use 
were calculated separately and combined. The binary logistic regression model was used 
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as univariable test to see if there was a potential confounder between OCP users and 
nonusers. Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL).
Results
Of the 1812 participants, 1750 (96.6%) were of Dutch ethnicity with a mean age of 23.2 
years (standard deviation 3.3), 335 (18.5%) women smoked, and 1315 (72.7%) women 
used OCPs. In total, 1703 (94.0%) women were sexually active at study entry. From these 
sexually active women 356 (20.9%) had one lifetime partner, 809 (47.5%) had two to 
five, 347 (20.4%) had six to 10, 183 (10.7%) had more than 10 lifetime partners and for 
eight (0.5%) women no data were available on the number of lifetime partners. As shown 
in Table 2, there are no confounding factors within the demographic characteristics and 
data on sexual behavior that could have significantly influenced the odds ratio for hr-HPV 
prevalence between OCP users and nonusers. Interestingly, this table shows that condom 
use did not differ significantly between OCP users and nonusers. Thus, condom use was 
not considered a confounding factor for hr-HPV detection between these two groups.
No effect of the sampling period on hr-HPV detection was found when analyzing the 
total group of women and all three sampling times together. However, a significant dif-
ference was found in hr-HPV detection with regard to the sampling time when analyzing 
OCP users (3577 samples) and nonusers (1000 samples) separately. Hr-HPV detection in-
creased significantly in the second half of the cycle for the OCP users (P=.021), whereas 
a significant (P=.007) decrease in the hr-HPV detection was observed in the second half 
of the menstrual cycle for the nonusers (data shown in Table 3).
After dividing the menstrual cycle into four sampling weeks, the decrease of hr-HPV 
detection in nonusers remained significant (P=.049), although the increase of hr-HPV 
detection during the contraceptive cycle became a non significant linear trend (P=.073), 
as shown in Figure 1.
At study entry, HPV DNA was detected in 18.9% (95% CI: 17.15-20.81) of all 1812 
women. For lr-HPV and hr-HPV, the prevalence was 8.9% (95% CI: 7.61-10.29) and 
11.8% (95% CI: 10.31-13.33), respectively. No significant difference in HPV prevalence 
between OCP users and nonusers was found. Furthermore, the prevalence of lr-HPV 
and hr-HPV was also equally divided within the OCP users and nonusers, 9.1 % (95% 
CI: 7.62-10.81) compared with 8.1% (95% CI: 5.84-10.84) and 11.7 % (95% CI: 10.02-
13.57) compared with 11.9% (95% CI: 9.20-15.10), respectively.
Of all women, 67.2% (95% CI: 65.00-69.38) never had any type of HPV at time months 0, 
6, and 12. This was 80.0% (98% CI: 78.11-81.84) for lr-HPV and 77.3% (95% CI: 75.32-
79.23) for hr-HPV. Newly detected HPV at months 6 and 12 was 16.1% (95% CI: 14.45-
17.89) for any-type HPV and 12.5% for (95% CI: 11.04-14.14)for lr-HPV and 12.1% (95% 
CI: 10.67-13.73) for hr-HPV. At months 0, 6, and 12, HPV DNA was persistently detected 
in 8.7% (95% CI: 7.41-10.06) of all women in the year of follow-up. For lr-HPV and 
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n OCP users n Nonusers OR (95%CI) of OCP users for hr-HPV
Age 1315 22.8 ± 3.1 495 24.5 ± 3.2 1.13 (0.82-1.58)
Ethnicity 1315 495
     Dutch 1277 (97.1) 471 (95.2) 0.98 (0.71-1.35)
     Other 38( 2.9) 24 (4.8)
Current smoking 1308 494
     Yes 231 (17.7) 104 (21.1) 1.01 (0.73-1.40)
     No 1077 (82.3) 390 (78.9)
Living with parents 1309 492
    Yes 264 (20.2) 52 (10.6) 1.02 (0.74-1.41)
    No 1045 (79.8) 440 (89.4)
Relationship 1311 494
     Married 43 (3.3) 35 (7.1) 0.87 (0.62-1.22)
     Living together 294 (22.4) 123 (24.9)
     Living apart together 632 (48.2) 122 (24.7)
     Single 342 (26.1) 214 (43.3)
Sexual activity ever 1314 494
     Yes 1274 (97.0) 428 (86.6) 0.89 (0.64-1.23)
     No 40 (3.0) 66 (13.4)
Age at first intercourse 1274 426
     13 or younger 22 (1.7) 14 (3.3) 0.91 (0.66-1.27)
     14–16 626 (49.2) 200 (46.9)
     17–19 524 (41.1) 173 (40.6)
     20 or older 102 (8.0) 39 (9.2)
Lifetime sexpartner(s) 1269 425
     1 293 (23.1) 63 (14.8) 1.24 (0.88-1.75)
     2–5 628 (49.5) 181 (42.6)
     6–10 240 (18.9) 106 (24.9)
     More than10 108 (8.5) 75 (17.7)
Gender of sex partner(s) 1271 523
     Male 1261 (95.7) 381 (90.1) 0.95 (0.68-1.33)
     Female 2 (0.1) 3 (0.7)
     Both 53 (4.2) 39 (9.2)
Table 2.  
Demographic characteristics and data on sexual behavior for OCP users and nonusers
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n OCP users n Nonusers OR (95%CI) of OCP users for hr-HPV
Sex partner(s) in past 6 
mo (number) 1268 428
     0 98 (7.7) 56 (13.1) 0.94 (0.67-1.31)
     1 990 (78.1) 301 (70.3)
     2 123 (9.7) 46 (10.7)
     More than 2 57 (4.5) 25 (5.9)
Sexual contact in past 6 
mo (frequency) 1234 420
     0 83 (6.7) 50 (11.9) 0.98 (0.71-1.40)
     1-6 127 (10.3) 75 (17.9)
     7-24 140 (11.3) 59 (14.0)
     25-54 502 (40.7) 138 (32.9)
     More than 54 382 (31.0) 98 (23.3)
Ever diagnosed a STI? 1273 425
     No 1168 (91.8) 365 (85.9) 1.00 (0.71-1.38)
     Yes 105 (8.2) 60 (14.1)
Condom use 1270 423
     Never (0%) 639 (50.3) 159 (37.6) 0.88 (0.63-1.24)
     Sometimes (0–50%) 351 (27.6) 93 (22.0)
     Most of the times
     (50-100%) 198 (15.6) 88 (20.8)
     Always (100%) 82 (6.5) 83 (19.6)
Sexual Age (y) 1273 6.1 ± 3.3 526 8.1 (3.4) 1.06 (0.75-1.49)
Table 2. Continued
OCP, oral contraceptive pill; OR, odds ratio; CI, confidence interval; HPV, human papillomavirus; STI, sexually transmitted 
infection.
Data are n, mean ± standard deviation, or n (%) unless otherwise specified.
hr-HPV, this was 2.0% (95% CI: 1.40-2.74) and 4.5% (95% CI: 3.62-5.59), respectively. 
The results on HPV incidence and persistence did not significantly differ between OCP 
users and nonusers.
Concluding, OCP use did not influence HPV prevalence, incidence or persistence. 
Additionally, sample timing related to the menstrual cycle had no significant effect 
on HPV detection in the total group. However, a significant relation between hr-HPV 
detection and sample timing related to the menstrual cycle was found when separate 
analysis for OCP users and nonusers was performed. In the second half of the menstrual 
cycle hr-HPV detection decreased in nonusers (P=.007) and increased in OCP users 
(P=.021).
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Figure 1: Human papillomavirus detection for oral 
contraceptive pill users and nonusers with respect to the last 
menstrual period and withdrawal bleeding.
Menstrual cycle is divided in 4 weeks for nonusers; the decrease of hr-HPV detection in the second half of the menstrual cycle is 
significant (P=.049). The increase of hr-HPV detection in the second half of contraceptive cycle lost significance (P=.073). OCP, oral 
contraceptive pill.
Day of Last Menstrual Period 
or Day After Start of Last OCP Withdrawal 
Bleeding
OCP users 
(n=3577)
Nonusers 
(n=1000)
0-14 159/1378 (11.5%) 65/500 (13.0%)
15-28 219/1515 (14.5%) 39/500 (7.8%)
More than 28 75/684 (11.0%) N.A.
P 0.021 0.007
Table 3.  
Hr-HPV prevalence in sample moments of total group and for OCP users and 
nonusers divided by LMP sample moments
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Discussion
The findings of this longitudinal study among unscreened, young women support the 
idea that reproductive hormones may influence high-risk HPV detection. In women with 
a natural menstrual cycle, hr-HPV detection decreased with the duration of the cycle, 
whereas in OCP users, the hr-HPV detection increased during the second half of the 
OCP cycle, as depicted in Figure 1. This opposite trend in hr-HPV detection during the 
menstrual cycle between OCP users and nonusers explains why hr-HPV detection in the 
total study population was not significantly influenced by the sample timing within the 
menstrual cycle. Another large study investigating hr-HPV detection within the menstrual 
cycle showed a small midcycle increase of HPV detection.9 However, data on OCP use 
are not reported and therefore it is difficult to compare this study with our results. A 
smaller study by our group, in nonusers, found a higher rate of HPV-positive samples in 
the follicular phase. Because the follicular phase is in the first half of the menstrual cycle 
these data are similar to our findings in the nonusers.8 This may have implications in the 
future, when hr-HPV detection may become a primary screening tool in cervical cancer 
prevention.
An explanation for the fluctuation in hr-HPV detection in the natural menstrual cycle 
may be found in the changes in the mucosal immunity. The mucosal immunity is 
influenced by reproductive hormones and reaches the lowest level around ovulation in 
the natural menstrual cycle.13-15 A lower mucosal immunity may lead to an increase of 
HPV replication and therefore HPV detection. However, there is no direct evidence for 
this assumption in the literature. We hypothesize that there may be some delay between 
the actual fluctuations in the mucosal immunity and the level of hr-HPV detection. The 
higher mucosal immunity in the follicular phase may lead to the decrease of hr-HPV 
detection in the second half of the natural menstrual cycle, whereas the lower mucosal 
immunity during ovulation may induce increased hr-HPV detection in the first half of 
the next menstrual cycle. According to this hypothesis, the increase of hr-HPV detection 
shown during the second half of the OCP cycle may be a delayed effect of the lower 
mucosal immunity in the week OCP use is stopped. To illustrate this hypothesis, we used 
the results on the mucosal immunity (IgG and IgA levels) as previously shown by Franklin 
et al. and displayed them in Figure 2.13 As shown in this figure, the mucosal immunity 
shows opposite patterns for OCP users and nonusers.
Another possible explanation for the increase of hr-HPV detection in the second half of 
the OCP cycle may be a result of the positive influence of estrogens on the viral tran-
scription and the expression of the viral oncogenes (E6 and E7).21 However, these two 
explanations do not explain the decrease of hr-HPV detection in women on continuous 
OCP use. Perhaps the continuous positive stimulation of OCP on the mucosal immunity 
and the influence of the estrogens on the viral oncogenes balance each other after several 
weeks.
The lack of evidence for an association between OCP use and hr-HPV prevalence is 
confirmed in several other studies. In some of these studies only the median number of 
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sex partners seemed to influence the hr-HPV prevalence significantly.7;16;22-25 Additionally, 
studies that did show a significant association between hr-HPV prevalence and OCP use 
suggested a greater exposure to HPV resulting from a presumed association between OCP 
use and sexual behavior.26-28 Because we did not detect a difference in sexual behavior 
between the groups of OCP users and nonusers, sexual behavior was not a confounding 
factor in this study.
Mouse models have shown that exogenous estrogens play an essential role in the 
carcinogenesis of cervical cancer. The estrogens stimulate the viral oncoproteins E6 
and E7 and the coexpression of these oncoproteins contributes to the development of 
cervical cancer.29 Additionally they have shown that estrogens, besides their role in 
the development of cervical lesions also contribute in the persistence and continued 
development of cervical cancer.30 Because epidemiological studies support the 
carcinogenic effect of OCP use, it does not prove that OCPs influence hr-HPV prevalence 
per se.5;7;16;31 The role of OCPs in the carcinogenesis might be explained with a possible 
role in facilitating HPV reactivation or persistence.1;24;30;32 Exogenous hormones enhance 
HPV transcription and decrease HPV clearance in women, which may lead to more 
persistent hr-HPV infections resulting in cervical neoplasia and cervical cancer.4;33
Despite that HPV persistence is expected to be higher among OCP users, we did not 
Figure 2: Fluctuation of the IgA and IgG levels during the 
menstrual cycle.
This figure displays the weeks of three menstrual cycles to visualize the fluctuations. OCP, oral contraceptive pill. (Based on data 
from Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokine in human cervical mucus: influence of exog-
enous and endogenous hormones.13)
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find any significant difference in HPV incidence and persistence between OCP users 
and nonusers. This finding is supported by others and may be explained by the short 
duration of follow-up (1 year), or a lack of data on OCP use in our study.24;34-36 Because 
the questionnaire only asked about current OCP use, data on previous use for nonusers 
or the duration of use for OCP users were not available. Because a longer duration of 
OCP use is associated with an increased risk of cervical cancer, the lack of data on the 
duration of OCP use might be a caveat in this study.37;38 This relatively young group of 
women may have a shorter duration of OCP use compared to women with cervical 
abnormalities. However, the increased risk with the duration of OCP use is relative, 
because the risk is reversible 10 years after use has stopped.4;38
In conclusion, hr-HPV detection measured with the highly sensitive SPF10 LiPA is influenced 
by the sampling period related to the LMP or OCP withdrawal bleeding. Further studies 
need to investigate whether this effect remains with a less sensitive test to elucidate the 
clinical implications of HPV detection in primary cervical cancer screening. Because 
OCP use does not significantly influence HPV prevalence, incidence or persistence, its 
increased risk for cervical cancer may be explained by a direct hormonal effect on the 
carcinogenesis.
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Abstract
The objective of this study is to study prevalence, incidence and clearance of human 
papillomavirus (HPV) in pregnant and non pregnant women.
In this prospective matched cohort study; 51 women, falling pregnant during follow-up 
of an HPV epidemiology study (n=2065), and 51 matched non-pregnant women were 
included. All women provided 3-monthly cervico-vaginal self-samples and completed a 
questionnaire. The PCR SPF10 LiPA25 was used for HPV testing. Matching was performed 
using a propensity score. The cumulative prevalence of hr-HPV was 19.6% (n=10) of the 
pregnant and 17.6% (n=9) of the matched-control women. The time-point prevalence 
of any-type HPV and high-risk (hr-) HPV was not significantly different for pregnant and 
matched-control women. After baseline, there were 10 newly detected hr-HPV types in 
6 (11.8%) of the pregnant women, and there were 11 newly detected hr-HPV types in 
8 (15.7%) of the matched-control women. There was no difference in HPV clearance 
between pregnant and matched-control women.
In conclusion, this study shows that in a low-parity population of young, unscreened 
women, pregnancy does not seem to influence HPV prevalence, incidence and clearance.
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Introduction
It is now well established that infection with high-risk (hr-) human papillomavirus (HPV) 
types is the necessary cause of cervical cancer. Although essential, hr-HPV is not the only 
factor in the multi-step process to cervical cancer development. Two of the co-factors 
that have been associated with cervical carcinoma include high parity and younger age 
at first full-term pregnancy.1-6
Indeed, the International Agency for Research on Cancer (IARC) reported in a pooled 
analysis an increased risk of squamous-cell cervical carcinoma for women with high 
parity. Women with seven full-term pregnancies (FTP) or more had an odds ratio of 3.8 
(95% CI: 2.7-5.5) compared to nulliparous women, and 2.3 (95% CI: 1.6-3.2) compared 
to women with 1-2 FTP.7
It has been described that parous women have a slower HPV clearance,8 but HPV 
prevalence does not seem to be influenced by high parity and early age at first FTP.9;10 
Moreover, some studies showed that having been pregnant was associated with reduced 
hr-HPV infection risk.10;11 Studies that did not find an association between parity and 
the risk for cervical intraepithelial neoplasia (CIN) or cervical carcinoma were mostly 
investigating a low-parity population.12-14
Hormonal, traumatic, and immunologic mechanisms have been hypothesized as possible 
explanations for the association between parity and cervical abnormalities in women 
infected with HPV.3 The hormonal changes in pregnancy (increased levels of estrogen 
and progesterone) may influence the immune response to HPV and influence the risk of 
persistence of HPV or progression to CIN lesions and cervical carcinoma.3;15
Studies, reporting HPV prevalence during pregnancy are not conclusive. Some studies 
did not find evidence for a higher detection rate of HPV in pregnant women compared 
to non pregnant women,16-18 whereas others did show a higher HPV prevalence during 
pregnancy.19;20 A trend of increasing clearance of HPV post partum was also described.18;21 
To explain the potential increase of HPV prevalence during pregnancy with a catch-up 
clearance post partum, it is suggested that the immune-response against HPV is decreased 
during the first two trimesters of pregnancy with a catch-up in the third trimester and 
postpartum.18;22
Most of the studies performed on the relationship of HPV and pregnancy are 
cross-sectional, and in the majority of the prospective studies no data were available on 
the HPV status prior to the pregnancy.
The aim of this prospective matched cohort study is to evaluate the natural HPV preva-
lence, incidence and clearance during pregnancy, compared with a matched-control 
group of non pregnant women in an unscreened low parity population.
Materials and Methods
This prospective matched cohort study is part of a longitudinal study on HPV prevalence, 
incidence, clearance and persistence among young (18-29 years) unscreened women, as 
described previously.23 Exclusion criteria at study entry were, being outside the age range 
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of 18-29 years and pregnancy. Women also had to be fluent in Dutch, because they had 
to be able to understand and fill-out the questionnaire. In total, 2065 (90%) women were 
eligible for participation and provided an informed consent. The cervico-vaginal samples 
for HPV detection were obtained using self-sampling. This study was approved by the 
local Medical Ethical Committee.
Of the 68 women who became pregnant during the first year of this longitudinal study, 6 
women had a miscarriage. The remaining 62 women were invited for follow-up until post-
partum, 57 (92%) agreed and participated with this follow-up study. To obtain a matched 
control group we used a propensity score. The goal of the propensity score analysis is to 
balance two nonequivalent groups on observed covariates to get more accurate estimates 
of the effects on which the two groups differ, i.e to remove bias due to all observed 
covariates in question. The propensity score is the conditional probability of assignment 
to a particular group (i.e. pregnancy) given the observed covariates, using (multivariable) 
logistic regression to estimate the strength of each variable. As a consequence, values of 
a specific covariate may differ between the groups as long as the conditional probabilities 
are equal. This in contrast to a one to one matching on some covariates itself.24;25 The 
propensity score was constructed on the basis of pregnancy as an outcome.
The propensity score was based on variables significantly influencing HPV prevalence 
that we found previously.23 This included the following variables; age, smoking, type of 
current sexual relationship (i.e., married, living together, couple living apart, or single), 
sexual age (number of years between age of first sexual intercourse and current age), 
sexual frequency in the past 6 months, number of sex partners in the past 6 months, life-
time number of sex partners, gender of sex partners, condom use and whether they were 
ever diagnosed with an sexually transmitted infection (STI).
We were able to match 51 of the 57 pregnant women with 51 non-pregnant women from 
the original study population.
Data collection
All women, pregnant and matched-control, received a questionnaire and a self-sample 
kit by mail. The self-sample kit contained an explanatory letter, an illustrated instruction 
form on how to perform a cervico-vaginal self-sample, a small brush in a sterile cover 
(Vibabrush®, Rovers Medical Devices Oss, the Netherlands), and a collection tube 
containing medium (SurePathtm, Tripath Imaging®, Inc., Burlington NC, U.S.A.). To return 
the self-sample, a leak-proof seal bag, absorption sheet, and a reclosable plastic return 
envelope (easyslider, Transposafe Systems Holland BV) were included, as described 
before.23
The questionnaire consisted of two parts. One part concerned demographic information 
and the other part included questions on sexual behavior as well as questions about 
current or past pregnancy. To ensure privacy the questionnaires were provided with 
an anonymous code and all the data were entered in a computer program. The self-
samples were stored at room temperature and were sent to the Department of Medical 
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Microbiology for processing and HPV detection.
The matched-control women provided five self-samples with a 3 month interval, one at 
baseline (month 0), month 3, month 6, month 9 and month 12.
The pregnant women were asked to provide one self-sample in the first trimester, second 
trimester, third trimester and one within the first 6 months after delivery. The baseline 
sample was the last sample in the original study before the women became pregnant. To 
have a complete follow-up until after delivery the women consented to provide samples 
after the original study stopped. Unfortunately, not all women were completely compli-
ant to the study protocol. Therefore, 4 pregnant women had a missing sample at baseline 
(3 months prior to falling pregnant) and not all women provided a self-sample at each 
sample moment. The amendment for extra follow-up after the original protocol for preg-
nant women was approved by the local Medical Ethical Committee.
Human papillomavirus incidence and clearance
Women were considered to have an incident infection if they tested positive for a type-
specific HPV during follow-up, and this HPV type was not detected at baseline or in 2 
previous consecutive samples.
When the type-specific infection was not detected in 2 consecutive samples during 
follow-up, or when the last available sample was negative, the infection was considered 
cleared. Time to clearance could only be estimated in women negative for that specific 
HPV type at baseline, since there is no information on the duration of the infection before 
start of the study.
A persistent infection is defined as a type-specific infection present in ≥2 sample moments, 
with a maximum of 1 negative sample in between.
HPV testing
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment assay. 
Extracted DNA was used for PCR amplification with the SPF10 primer sets, as described 
earlier.26;27 The samples were run through an HPV DNA enzyme immunoassay (DEIA) to 
obtain an OD reading, and categorized as HPV DNA negative, positive, or borderline. 
The same SPF10 amplimers were used on SPF10-DEIA-positive samples to identify HPV 
genotype by reverse hybridization on a line probe assay (LiPA) (SPF10HPVLiPA25, version 
1; Labo Bio-Medical Products B.V., Rijswijk, the Netherlands), which detects 25 HPV 
genotypes: lr-HPV types: type 6, 11, 34, 40, 42, 43, 44, 53, 54, 55, 66, 70, 74, and “X” 
(DEIA positive and LiPA negative samples); and hr-HPV types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68, 73, and 82.
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Pregnant women  
n=51 
(%)
Matched-control women 
n=51 
(%)
Age, mean (SD)   [range] 27.4 years (1.6) [23-30] 27.6 years (1.3) [24-29]
Ethnicity
Dutch 98 88
Other 2 12
Education
 Lower secondary / Lower vocational
 training
4.1 8.2
 Higher secondary / Vocational training 34.1 26.5
 Higher vocational training 61.2 65.3
Current smoking
Yes 13.7 9.8
No 86.3 90.2
Type of relationship
Married 45.1 37.3
Living together 51.0 56.9
Couple, living apart 2.0 -
Single 2.0 5.9
Age at first sexual intercourse mean (SD) 17.1 (2.0) 17.1 (1.9)
Sexual agea mean (SD) 10.3 (2.6) 10.5 (2.3)
Number of lifetime sex partners
1 21.6 23.5
2-5 50.9 56.8
6-10 19.7 13.8
>10 7.8 5.9
Number of sex partners in the past 6 
months
0 2.0 2.0
1 94.1 94.1
2 3.9 3.9
>2 - -
Sexual frequency in the past 6 months
0 - -
1-6 3.9 3.9
7-24 17.6 17.7
25-54 41.2 51.0
>54 37.3 27.4
Ever had STI?
Yes 11.8 15.7
No 88.2 84.3
Table 1.  
Demographic and sexual behavior baseline characterisitics
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Statistical analyses
The test of McNemar was used to test differences in HPV prevalence at each time point 
of sampling, between the pregnant women and their matched controls for statistical sig-
nificance. A non-linear mixed model was used to analyze differences in HPV prevalence 
between pregnant women and their matched controls over time. The non-linear mixed 
model was used in order to account for the repeated data in the matched design. The 
dependent variable was the logarithmic transformed odds of HPV prevalence (any HPV, 
low-risk HPV and high-risk HPV, respectively) and the dependent categorical variables 
were pregnancy (yes, no) and time point of sampling (baseline, first, second, third and 
fourth). The matched stratum was treated as a random variable. Initially the interaction 
term between the two categorical variables was also included in the model, but was 
omitted from the final model as this never reached the level of statistical significance. The 
adjusted odds ratios with the 95% confidence intervals of the final model are presented.
Statistical analysis was performed using SPSS 16.0 for Windows and SAS 9.2 for 
Windows.
Results
Characteristics of participants
Because the pregnant and the matched-control women were matched with the propensity 
score no significant difference exists at baseline, see Table 1. The mean age of the pregnant 
women was 27.4 years [23-30 years], and non-pregnant women 27.6 years [24-29 years]. 
Both groups had a mean age at first sexual intercourse of 17.1 years. Of the pregnant 
women 21.6% had one lifetime partner and 50.9% had 2-5 lifetime partners, this was 
23.5% and 56.8% for the matched-controls, respectively. This difference in number of 
lifetime partners was not statistical significant. Almost all of the pregnant (96.1%) and 
matched-control women (94.2%) were married or were living together. At baseline 11.8% 
Pregnant women n=51 
(%)
Matched-control women 
n=51 
(%)
Condom use
Never (0%) 71.4 68.6
Sometimes (0-50%) 12.2 9.8
Most of times (50-100%) 8.2 11.8
Always (100%) 8.2 9.8
Gender of sex partner(s)
Male 98.0 100
Female - -
Both 2.0 -
Table 1. Continued
a Sexual age: number of years between age of first sexual intercourse and current age
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of the pregnant women and 15.7% of the matched-control group reported to ever have 
had an STI and the majority of both groups reported no condom use in the past 6 months.
Forty-five pregnant women reported their number of pregnancies. Of them, 29 (64.4%) 
were primiparous, 13 (28.9%) were pregnant for the second time, 2 (4.4%) were pregnant 
for the third time, and 1 (2.2%) was pregnant for the fourth time. Past pregnancy history 
of the current non-pregnant women is not available.
Human papillomavirus prevalence
The prevalence of any-type HPV at baseline, was 12.8% in the pregnant group and 9.8% 
of the matched-control group. The prevalence for hr-HPV at baseline was 12.8% and 
5.9%, respectively.
During the whole study follow-up, 21.6% (11/51) of the pregnant and 23.5% (n=12) of 
the matched-control women were ever positive for any-type HPV. For hr-HPV this was 
19.6% (n=10) of the pregnant women and 17.7% (n=9) of the matched-control women. 
In total, the 10 pregnant women with hr-HPV had 18 type-specific hr-HPV infections 
and the 9 matched-control women with hr-HPV had 13 type-specific hr-HPV infections. 
The time-point type specific prevalence of any-type HPV, and hr-HPV for the pregnant 
and matched control women is shown in Table 2. The prevalence was not significantly 
different between the pregnant and matched-control women (McNemar, p >0.05) at the 
specific time-points.
Table 3 displays whether hr-HPV detection is related to pregnancy or to the sample 
moment in time. The overall prevalence of hr-HPV during study follow-up (all sample 
moments together) was not influenced by pregnancy. Timing of sampling (i.e. the 
influence of time on HPV prevalence) did also not influence hr-HPV detection. Although, 
hr-HPV prevalence at the last sample moment (12 months), was slightly lower compared 
to the second sample moment (3 months) with an odds ratio of 0.23 (95% CI: 0.06-0.99) 
(see Table 3).
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Follow-up time Any HPV Hr-HPV
Baseline
Pregnant 12.8% (6/47) 12.8% (6/47)
Matched-control 9.8% (5/51) 5.9% (3/51)
3 months
Pregnant 17.4% (8/46) 10.9% (5/46)
Matched-control 19.6% (9/46) 15.2% (7/46)
6 months
Pregnant 10.5% (4/38) 7.9% (3/38)
Matched-control 8.5% (4/47) 8.5% (4/47)
9 months
 Pregnant 7.0% (3/43) 7.0% (3/43)
 Matched-control 8.5% (4/47) 8.5% (4/47)
12 months
Pregnant 6.2% (3/48) 4.2% (2/48)
Matched-control 15.2% (7/46) 8.7% (4/46)
-  There is no significant difference in time-point HPV prevalence (any-type, or high-risk) between pregnant and matched-
control women, measured with McNemar
-  Not all of the 51 pregnant women and 51 matched-control women provided a sample at each sample moment, therefore the 
number of samples tested for HPV DNA fluctuate
Adj. OR: adjusted odds ratio; adjusting for the other variable in the model 
CI: confidence interval
Ref: reference
Hr-HPV
Adj. OR CI
Pregnant
     Yes 1.09 (0.20-5.82)
     No 1.00 (ref) -
Timepoint
     Baseline 0.51 (0.14-1.87)
     Month 3/ First trimester 1.00 (ref) -
     Month 6/ Second trimester 0.38 (0.09-1.52)
     Month 9/ Third trimester 0.38 (0.09-1.52)
     Month 12/ Post partum 0.23 (0.06-0.99)
Table 2. 
Time-point HPV prevalence
Table 3. 
The adjusted odds ratio with 95% confidence interval of pregnancy and of time point 
of sampling for the prevalence of high-risk HPV and using non-linear mixed model
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Human papillomavirus incidence and clearance
All type-specific hr-HPV types detected at baseline and during study follow-up are dis-
played in Table 4a for the pregnant women, and in Table 4b for the matched-control 
women.
Duration of detection of prevalent infections is uncertain because we do not know the 
duration of infection before baseline. In the pregnant women, five of the eight prevalently 
detected hr-HPV types were cleared the next sample moment (first trimester), one per-
sisted until the first trimester, one until the third trimester and one was still present at the 
end of study follow-up (post partum). In the matched-control women, one of the three 
prevalently detected hr-HPV types was cleared the next sample (month 3) but again de-
tected at the last sample (month 12). Another hr-HPV type persisted until sample month 6 
and the last one was continuously persistent until the end of study follow-up.
After baseline, there were 10 incident hr-HPV types in 6 (11.8%) of the pregnant women 
and 11 hr-HPV types in 8 (15.7%) of the matched-control women. These incidence rates 
were not statistically significant different between pregnant and matched-control women.
Seven of the 10 (70.0%) incident hr-HPV infections in pregnant women were only de-
tected once during pregnancy and two incident hr-HPV types were detected during the 
whole pregnancy, but they were cleared in the post partum sample. One incident hr-HPV 
type was first detected in the last sample (post-partum) and therefore the duration of in-
fection could not be measured.
In the group of matched-control women seven of the 11 (63.6%) incident hr-HPV types 
were detected only once during follow-up. One hr-HPV type was detected from month 
3 until month 12, and another was detected from month 9 till month 12. Three incident 
hr-HPV types were newly detected at month 12. Because 5 infections were present at the 
last sample of the follow-up (month 12), the time to clearance could not be calculated 
for these infections.
Discussion
No difference in the time-point HPV prevalence between pregnant and matched-control 
women was detected in this prospective matched cohort study. This is in accordance with 
other studies, mainly performed among low-risk populations for HPV.16;17;28-30 Studies that 
did show a difference in HPV prevalence between pregnant and non pregnant women 
were cross-sectional and had a higher detection rate (24.9-37.2%) of hr-HPV in pregnant 
women.19;20 Additionally, these studies were based on large selected populations, one 
from a family clinic only matching on age,19 and the other was a non matched population 
selected from an STI and gynecology clinic.20 We performed extensive matching, based 
on factors influencing HPV prevalence.23 Therefore we excluded any known potential 
confounding factors influencing HPV prevalence and thus were able to solely study the 
influence of current pregnancy on HPV detection.
We did not find an increased HPV prevalence among the pregnant women during the 
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N Baseline 1st Trimester 2nd Trimester 3th Trimester Post Partum
1 52 -- 52 -- 52
1 16, 31 31, 58 -- 31 --
1 52 52, 59 -- -- --
1 51 -- -- NA 59
1 31 NA -- NA --
1 52, 68 -- -- -- --
1 NA 56 NA NA --
1 -- 31 31, 58 31 --
1 -- 16 NA 16, 52 --
1 -- -- 33, 56 -- NA
41 -- -- -- -- --
Table 4a. 
Type specific hr-HPV detection in pregnant women
Table 4b. 
Type specific hr-HPV detection in matched-control women
-- : negative for hr-HP
NA : sample for HPV DNA detection not available
-- : negative for hr-HPV
N Baseline Month 3 Month 6 Month 9 Month 12
1 31 16, 31 31 31 16, 31
1 33 33 33 56 --
1 16 -- -- -- 16, 18
1 -- 16 16 16 16
1 -- 31 -- 18 18
1 -- 16 -- -- --
1 -- 31 -- -- --
1 -- 68 -- -- --
1 -- -- 33 -- --
42 -- -- -- -- --
120
Chapter 6
Human papillomavirus detection in pregnant women, a prospective matched cohort study
first and second trimester compared to the third trimester and post-partum. Therefore we 
could not confirm the hypothesis that the changed immune-response during pregnancy 
influences HPV incidence, prevalence and clearance. A study among pregnant women 
in Uganda also showed a balance between acquisition and clearance of HPV during and 
after pregnancy among their young study women.22 They concluded that pregnancy does 
not seem to be a period of special vulnerability to HPV infection, despite a high burden 
of infection (60%) among young primiparous pregnant women in Uganda.22 In contrast, 
some studies show that many pregnant patients with detectable HPV will have an in-
creased clearance and become negative for HPV again later in pregnancy or in the post 
partum period.16;18;21 Again, confounding factors, mainly associated with sexual behavior, 
may influence HPV detection in these studies.
The difference in HPV prevalence, incidence and clearance between different studies 
might also be explained by the HPV DNA detection test used. In this study we used the 
highly sensitive PCR test SPF10LiPA25. This test is known for its high analytical sensitiv-
ity and detects HPV with low viral load.31 If the immune-response during pregnancy 
influences the replication of an HPV type already present with a low viral load, this HPV 
type would already have been detected with the SPF10LiPA25. Whereas a more clinical 
sensitive test like the hybrid capture 2 (HC2) would have only detected the HPV type later 
in time when the viral load is increased.
Another factor potentially influencing the HPV DNA detection is the sampling method 
that is used. This study is based on self-sampling, which has a comparable sensitivity for 
hr-HPV detection with physician-sampling.32;33 Most studies with self-sampling excluded 
pregnant women by protocol. Only 3 other studies using self-sampling for HPV detection 
included pregnant women. Two studies compared self-sampling with physician-sampling, 
including pregnant women (10.7-12.0% of their study population).34;35 They did not 
report a difference in performance between pregnant and non-pregnant women. The 
third study used self-sampling to compare HPV prevalence between pregnant and non-
pregnant women in an age-matched study population in Mexico. In contrast to our study, 
they reported a higher hr-HPV prevalence in pregnant women,19 but other confounding 
factors could not be ruled out. Results of these three studies suggest that the use of self-
sampling for HPV detection may not explain the lack of difference in HPV detection in 
our study population.
If pregnancy is not a vulnerable period for HPV infections, the delivery process might be 
an explanation for the association between multi-parity and cervical carcinoma. Besides 
hormonal and immunologic mechanisms, traumatic mechanisms have been previously 
hypothesized as possible explanations.3;20 During delivery, the cervical canal and the 
transformation zone will dilate causing many micro abrasions. Therefore any present 
HPV may easily enter the epithelium and infect the parabasal layer on multiple sites, 
possibly making these women extra at risk for cervical cancer development.
Currently it is proposed to use HPV DNA testing as a primary screening tool with 
cytology as triage for HPV DNA positive women.36-38 Nowadays pregnant women are 
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excluded from primary screening with cytology because cytology is considered to be of 
less quality during pregnancy. In the future, when HPV DNA testing is implemented as 
a primary screening tool, pregnant women may not have to be excluded from screening 
because we did not find any difference in time-point prevalence between pregnant 
and matched-control women. Additionally previous data showed that HPV prevalence 
in cytomorphologically normal smears is hardly influenced by pregnancy.30 However, 
further research is needed to confirm our data and to evaluate if pregnant women are 
willing to participate in screening based on self-sampling.
This prospective matched cohort study shows that, although based on a small study 
group, pregnancy does not seem to influence HPV detection in a low-parity population 
of young, unscreened women. Potential confounding factors influencing HPV prevalence 
were excluded by 1:1 matching and thus we were able to solely study the influence of 
current pregnancy on HPV detection.
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Abstract
The clinically validated high-risk human papillomavirus (hr-HPV) Hybrid Capture (HC2) 
and GP5+/6+-PCR assays were analyzed on an Indicating FTA elute cartridge (FTA 
cartridge). The FTA cartridge is a solid dry carrier that allows safe transport of cervical 
samples. FTA cartridge samples were compared with liquid-based samples for hr-HPV 
and high-grade cervical intraepithelial neoplasia (CIN) detection. One cervical sample 
was collected in a liquid-based medium and one was applied to the FTA cartridge. 
DNA was eluted directly from the FTA cartridge by a simple elution step. HC2 and the 
GP5+/6+-PCR assay were performed on both the liquid-based and the FTA-eluted DNA 
of 88 women. Overall agreement between FTA and liquid-based samples for the presence 
of hr-HPV was 90.9% with GP5+/6+-PCR and 77.3% with HC2. The sensitivity for high-
grade CIN of hr-HPV testing on the FTA cartridges was 84.6% with GP5+/6+-PCR and 
only 53.8% with HC2. By comparison, these sensitivities on liquid-based samples were 
92.3% and 100% for GP5+/6+-PCR and HC2, respectively. Therefore, the FTA cartridge 
shows a reasonably good overall agreement for hr-HPV detection with liquid-based 
media when using GP5+/6+-PCR, but not for HC2 testing. Even with GP5+/6+-PCR, the 
FTA cartridge is not yet capable of detecting all high-grade CIN lesions.
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Introduction
Infection with human papillomavirus (HPV) is indicated as the causal role in cervical 
cancer development. Primary high-risk (hr) HPV screening appeared to be more sensitive 
than cytology in detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) 
and, therefore, displayed superior protection against cervical precancer and cancer.1,2 
Interestingly, material from cervico-vaginal lavages or cervico-vaginal brushes proved to 
be highly representative of cervical hr-HPV status.3,4,5,6,7,8 Moreover, analysis of cervico-
vaginal self-samples appears to be as reliable as physician taken samples for detecting 
cervical (pre)malignant disease following hr-HPV analysis.9,10
Screening via self-samples obtained in the privacy of women’s own homes, is likely to 
result in a better attendance than screening via samples obtained by physicians or other 
health care providers.11,12 Therefore, cervico-vaginal self-sampling is an attractive alterna-
tive for physician taken cervico-vaginal material.5,13
Most previous studies used cervical samples with liquid-based collection systems.3,11,12,14,15,16 
In principle, the use of liquid-based self-samples has the impractical consequence that 
fluids may leak; in addition, special precautions have to be taken for transport. In case 
alcohol-containing preservation fluids are used, problems like inflammability and harm 
to eyes and skin may occur. These problems may be circumvented when applying self-
sampled specimens to a solid dry carrier, the Whatman® Indicating FTA® Elute cartridge 
(FTA cartridge). FTA cartridges are biohazard free, because the sample is denaturized on 
application. These properties solve storage and transport problems often seen with liquid 
samples. More important, the FTA cartridge indicates dye changes from purple to white 
when a sample is applied, thereby confirming that women performed the procedure 
properly. This solid dry carrier might be beneficial for specimens collected by non-
physicians in remote areas, which would need transportation to the laboratories. A proof-
of-principle study was previously performed to assess the potential of HPV detection 
directly on eluted DNA from the FTA cartridge. The SPF10 Line Blot 25 assay was used, and 
98% agreement with physician-obtained samples was found.17 However, the SPF10 Line 
Blot 25 assay is sensitive in HPV detection, and it is unknown how clinically validated hr-
HPV assays with a lower analytical sensitivity would perform on FTA cartridge samples. 
In the current study, we evaluated the clinically validated Hybrid Capture 2 (HC2) and 
GP5+/6+-PCR18 methods on physician-obtained cervical samples applied to the FTA 
cartridge for the detection of hr-HPV and cervical premalignancies in women visiting a 
gynecological outpatient clinic.
130
Chapter 7
The indicating FTA elute cartridge: a solid sample carrier to detect high-risk HPV and high-grade cervical lesions
Materials and Methods
Study subjects
Between May 25 and December 18, 2009, 94 women were recruited at the department 
of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, 
the Netherlands. The cohort consisted of women with different risk factors for HPV 
infection and CIN. All women visited the gynecologist at the outpatient department 
and two cervical samples, for liquid-based and cartridge collection were obtained, as 
specified later. The volume of liquid-based samples of six women was not sufficient to 
perform the two different hr-HPV tests in addition to liquid-based cytology. These women 
were therefore excluded. The remaining 88 patients constituted the study population.
Sample collection
Two Cervex-brushes (Rovers Medical Devices B.V., Oss, the Netherlands) were used to 
obtain cervical samples. The first brush was rinsed in a Thinprep vial (Cytyc corp. Box-
borough MA, USA) on which regular liquid-based cytological examination and HPV 
testing by HC2 and GP5+/6+-PCR was performed. The second brush was applied to the 
FTA cartridge (the Indicating FTA elute micro card, Whatman/GE Healthcare, Kent, UK), 
as previously described.17 Again, HC2 and GP5+/6+-PCR HPV testing was performed on 
the DNA eluted from these FTA cartridges.17
In to assess the samples anonymously, all FTA cartridge samples and cervical liquid-based 
samples were labeled with a unique patient code before sending them to the laboratory. 
Histological results were retrieved from the medical records in case a biopsy specimen 
was obtained from the cervix during colposcopy or in case of surgery. Histological results 
were considered superior to cytological results.
Liquid-based samples
All Thinprep vials were used for regular cytological examination. Papanicolaou smear 
abnormalities were interpreted and classified by using the Bethesda system.
For the HC2 assay, 5 ml liquid-based homogenized medium was used according to the 
manufacturer’s instructions (Qiagen, Gaithersburg, MD).
For the hr-HPV GP5+/6+-PCR, DNA was isolated out of 500 µl medium of the liquid-
based cervico-vaginal samples, using the MagNAPure LC Isolation station (Roche 
Diagnostics GmbH, Roche Applied Science, Mannheim, Germany). Nucleic acids were 
resuspended in a final volume of 50 µl; 10 µl were used for the GP 5+/6+ assay, as 
previously described.19,20
FTA cartridges
The Indicating FTA Elute matrix contains an indicating dye that changes from purple 
to white upon application of a colorless sample, such as a cervico-vaginal swab. The 
white parts on the FTA cartridges were punched using a sterilized perforator specifically 
designed for the FTA cartridges (3mm Harris Uni-core device, Whatman). DNA was 
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recovered from the FTA elute matrix through a simplified elution process using heat and 
water. Inhibitory components, such as hemoglobin, are retained on the FTA elute matrix.
For elution, four 3 mm punches from the matrix were transferred into a 2.0 ml Microfuge 
tube; and 2.0 ml of sterile H2O was added to the punches and immediately pulse 
vortexed three times, for 5 seconds each. The H2O was removed with a sterile fine-tipped 
pipette. Sterile H2O, 75 µl, was added to the punches; and the tube was transferred 
to a heating block at 95°C for 30 minutes. At the end of the incubation period, the 
sample was removed from the heating block and pulse vortexed approximately 60 times. 
Subsequently, the tube was centrifuged for 30 seconds and the supernatant with eluted 
DNA was transferred to a new microcentrifuge tube. The eluted DNA was stored at 
-80°C for further use. Finally, according to protocol, 10 µl of the eluate was used for the 
GP5+/6+-PCR, and 50 µl for the HC2.
HPV detection by Hybrid Capture 2 and GP 5+/6+-PCR
Liquid-based homogenized medium, 5 ml, and separate 50 µl of eluted DNA from the 
cartridges were used for the HC2 according to the manufacturer’s instructions. The HC2 
assay included a mixture of probes for the HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, and 68. RNA/DNA hybrids were captured with antibodies and a secondary 
signaling antibody created a chemiluminicent signal that was ultimately expressed as rel-
ative light units per cut-off value (RLU/CO), representing the ratio between the emission 
from a sample to the average of three positive controls (i.e. 1 pg/ml of cloned HPV 16 
DNA). Samples were considered HC2 positive in case of an RLU/CO value ≥ 1.0 (equiva-
lent to signal of 1 pg/ml HPV 16 DNA). Repeat testing is recommended for RLU/CO ratios 
between 1.0 and 2.5. Because priority was given to clinical testing, in the context of this 
study material was limited. Therefore, the primary test result was considered definitive.
Separately, 10µl of isolated DNA from the liquid-based specimens and 10µl of DNA 
eluted from the FTA cartridges were used for HPV testing by the GP5+/6+-PCR assay. 
The GP5+/6+-PCR was performed using the enzyme immunoassay readout system with 
a probe cocktail of 14 hr-HPV types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66, and 68) as described previously.19,20 The standard cutoff value of three times the 
mean OD value of the PCR-negative controls was used.20,21
Statistics
All data were analyzed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL). 
Agreement was measured by absolute agreement and Cohen’s к statistics, a measure of 
the agreement between two methods that is in excess of that due to chance.
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Results
The study group consisted of 88 women (median age, 37 years; SD, 10 years; range 
24 to 72 years). In 18 of the 88 cases, histological specimens of the cervix were 
obtained. Histological feature was indicated by a liquid-based cytological result of at 
least a low-grade squamous intraepithelial lesion (LSIL). However, in 10 LSIL cases, no 
biopsy specimen were obtained because of nonsuspicious colposcopy results. Of the 
18 histological specimens, four showed normal tissue, one showed a low-grade CIN 
lesion (CIN1), and 13 specimens showed a high-grade CIN lesion (CIN2-3). In total, the 
cervical samples were within normal limits in 46 cases (52.3%), and atypical squamous 
cells (ASC-US) in 18 cases (20.5%); in 24 cases (27.3%), the smear appeared to be LSIL 
or more severe.
Table 1.  
Liquid-based and FTA cartridge samples analyzed with the two different hr-HPV  
assays (HC2 and GP5+/6+-PCR), according to cytological/histological features
liquid-based samples FTA cartridge samples
cytology histology
HC2  
(RLU/CO)
GP5+/6+-PCR
HC2
(RLU/CO) 
1 WNL - 1.23 neg neg neg
2 WNL - 1.23 pos neg pos
3 WNL - 2.91 neg neg neg
4 WNL - 2.93 pos neg neg
5 HSIL Normal 4.50 neg neg neg
6 WNL - 8.98 pos neg neg
7 WNL - 76.00 neg neg pos
8 WNL - 213.00 pos 16.24 pos
9 LSIL Normal 783.58 pos 2.61 pos
10 ASC-US - 1.09 neg neg pos
11 ASC-US - 1.45 neg neg pos
12 ASC-US - 2.99 pos neg pos
13 ASC-US - 4.36 neg neg neg
14 ASC-US - 95.00 neg neg neg
15 ASC-US - 460.00 pos 19.41 pos
16 ASC-US - 543.00 pos 218.43 pos
17 ASC-US - 635.00 pos 34.83 pos
18 ASC-US - 737.00 pos 140.70 pos
19 LSIL - neg pos neg neg
GP5+/6+-PCR
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Table 1. Continued
Bold text indicates positive result
-, no histological specimen taken; * = histology; ASC-US, atypicalsquamous cells; HSIL, high-grade squamous intraepithelial lesion; 
LSIL, low-grade squamous intraepithelial; Neg, negative result; Pos, positive result; WNL, within normal limits.
liquid-based samples FTA cartridge samples
cytology histology
HC2
(RLU/CO)
GP5+/6+-PCR
HC2
(RLU/CO)
20 LSIL - 2.24 pos neg neg
21 LSIL - 2.73 pos 1.47 pos
22 LSIL - 13.59 neg neg neg
23 LSIL - 35.92 pos 4.49 pos
24 LSIL - 196.00 pos 6.38 pos
25 LSIL - 238.94 pos 2.61 pos
26 LSIL - 318.00 pos 185.67 pos
27 LSIL - 552.60 pos 10.34 pos
28 LSIL - 771.27 pos 1.37 pos
29 ASC-US CIN1 4.74 pos 4.94 pos
30 LSIL CIN2 11.15 neg neg neg
31 L/HSIL CIN2 13.40 pos 1.73 pos
32 L/HSIL CIN2 73.19 pos 1.43 pos
33 ASC-US CIN2 1085.49 pos neg pos
34 HSIL CIN3 1.34 pos neg pos
35 HSIL CIN3 1.90 pos neg neg
36 HSIL CIN3 27.07 pos 18.28 pos
37 HSIL CIN3 100.75 pos 4.20 pos
38 ASC-US CIN3 108.72 pos 3.04 pos
39 HSIL CIN3 294.65 pos 8.12 pos
40 HSIL CIN3 422.95 pos neg pos
41 HSIL CIN3 467.28 pos 8.85 pos
42 HSIL CIN3 794.08 pos neg pos
43-79 WNL -* neg neg neg neg
80-88 ASC-US - neg neg neg neg
GP5+/6+-PCR
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GP5+/6+-PCR
Table 1 shows that in 32 (36.4%) of the 88 liquid-based samples, hr-HPV was detected 
using the GP5+/6+-PCR. By comparison, 30 (34.1%) of the 88 FTA cartridge eluted 
DNA samples, were hr-HPV positive with GP5+/6+-PCR. Of the 32 GP5+/6+-PCR 
positive liquid-based samples, 27 (84.4%) showed concordant hr-HPV positive results 
on the eluted DNA from the corresponding FTA cartridge samples. Five women had 
GP5+/6+-PCR positive liquid-based samples but negative FTA cartridge samples. Two of 
these five women had normal cytological results, two had LSIL cytological results, and 
one had a histological CIN3 lesion. In three women, hr-HPV was detected on the eluted 
DNA from the cartridge but was negative on the liquid samples with GP5+/6+-PCR. One 
of these women had a normal cytological result, and the other women had ASC-US. In 
the total group of 88 samples, 80 FTA cartridge samples showed concordant hr-HPV test 
results with the liquid-based samples [concordance, 90.9%; к, 0.80; 95% confidence 
interval (CI), 0.67 to 0.93] when the GP5+/6+-PCR was used for detection (Table 2).
There were 13 histologically confirmed high-grade CIN lesions. The liquid-based samples 
of 12 of these 13 lesions were hr-HPV positive with GP5+/6+-PCR (sensitivity 92.3%). 
The FTA cartridges showed 11 hr-HPV positive samples with GP5+/6+-PCR (sensitivity 
84.6%).
Hybrid Capture 2 Assay
Using the HC2 assay for the detection of hr-HPV, 41 (46.6%) of 88 liquid-based samples 
were found positive (Table 1). These included all samples with high-grade CIN (sensitivity, 
100%). Of the positive samples, only 21 were also positive with HC2 using the eluted 
DNA from the FTA cartridge samples. Of the 67 women with a negative FTA cartridge 
sample, 54 had a normal or ASC-US cytological result and four had a normal histology 
result. However, of 13 HC2 hr-HPV liquid-based-positive women with hystologically 
confirmed high-grade CIN lesions, six were missed using the HC2 on eluted DNA 
(sensitivity, 53.8%). The RLU of the FTA cartridge samples detected with four punches 
was low (mean, 33.1; SD, 63.9) compared with the corresponding RLU of the liquid-
based samples (mean, 225.3; SD, 296.7). Indeed, 13 of the 20 hr-HPV positive liquid-
based samples with a negative result on the FTA cartridge samples had a low RLU (< 10).
In 68 of the total 88 samples, concordant hr-HPV HC2 results were found between the 
liquid-based samples and the FTA cartridge samples (concordance, 77.3%; к, 0.53; 95% 
CI, 0.37 to 0.69) (Table 2).
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GP5+/6+-PCR versus HC2
Only one liquid-based sample was negative by HC2 but positive by GP5+/6+-PCR. 
This was a LSIL sample. Ten samples were positive with HC2 but negative with the 
GP5+/6+-PCR. Most (8 of 10) of these HC2-positive but GP5+/6+-PCR-negative 
liquid-based samples were within the normal cytological or histological group (n = 4) or 
ASC-US (n = 4). One high-grade CIN lesion (ie, CIN2), positive by HC2 on liquid, was 
negative by GP5+/6+-PCR on liquid. Absolute agreement between the two hr-HPV tests 
was 87.5% (к, 0.75; 95% CI, 0.61 to 0.88) for the liquid-based samples (Table 2).
All FTA cartridge samples that were positive with HC2 were also positive with the 
GP5+/6+-PCR. Nine FTA cartridge samples were negative with HC2 but positive with 
GP5+/6+-PCR. These comprised samples that were cytologically classified as normal 
(n = 2) or ASC-US (n=3) or histologically classified as CIN2 (n = 1) or CIN3 (n = 3). Abso-
lute agreement between the two hr-HPV tests results was 89.8% (к, 0.76; 95% CI, 0.61 
to 0.90) for the FTA cartridge samples (Table 2).
Table 1 and 2 show a summary of the hr-HPV results of the HC2 and GP5+/6+-PCR tests 
of both the liquid-based and the FTA cartridge samples, as well as the concordances.
FTA versus LB 
(HC2)
FTA versus LB 
(GP5+/6+)
GP5+/6+ versus 
HC2 (LB)
GP5+/6+ versus 
HC2 (FTA)
cytology/
histology c d c d c d c d
normal* 39 7 43 3 42 4 44 2
ASC-US* 13 5 16 2 14 4 15 3
LSIL* 8 2 8 2 8 2 10 0
CIN1† 1 0 1 0 1 0 1 0
CIN2† 2 2 4 0 3 1 3 1
CIN3† 5 4 8 1 9 0 6 3
Total 68 20 80 8 77 11 79 9
concordance 77.3%
к 0.53, CI 0.37-0.69
concordance 90.9%
к 0.80, CI 0.67-0.93
concordance 87.5%
к 0.75, CI 0.61-0.88
concordance 89.8%
к 0.76, CI 0.61-0.90
Table 2.  
Concordant and discordant results for lesion type, sample type, and assay used
c=concordant, d=discordant, FTA=FTA cartridge sample, LB=liquid-based sample, HC2=Hybrid capture 2
* cytology, without subsequent histology
† histology after abnormal cytology
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Discussion
We aimed to test whether the clinically validated HC2 and GP5+/6+-PCR systems could 
be performed on the FTA cartridge material to detect high-grade CIN lesions. We found 
a reasonably good concordance in hr-HPV detection between liquid-based and FTA car-
tridge systems when using the GP5+/6+-PCR. This concordance was much lower using 
HC2. Moreover, the sensitivity of hr-HPV detection on the FTA cartridge for high-grade 
CIN lesions was 84.6% with GP5+/6+-PCR but only 53.8% with HC2.
Although more liquid-based samples were hr-HPV positive with HC2 than with 
GP5+/6+-PCR (41 versus 32), only 21 of the 41 FTA cartridge samples were hr-HPV 
HC2 positive. A possible explanation for this is that the amount of DNA eluted from the 
punches is insufficient to allow reliable HC2 testing, a method that does not use target 
amplification. Optimization of the processing steps (eg, by increasing the number of 
punches) may improve the HC2 outcome. However, increasing the number of punches is 
labor intensive and the H2O volume used needs to be increased equivalently. In addition, 
we used the accepted RLU/CO value of 1.0 for signifying a positive HPV HC2 test result. 
This is arbitrary because these values were developed and validated in conjunction with 
liquid-based tests. It might be possible that values <1.0 RLU/CO represent positive test 
results when other media and different amounts of DNA are used. Moreover, results with 
RLU/CO values between 1.0 and 2.5 are not repeated within this study, as recommended 
according to protocol. Because priority was given to clinical tests, there was limited 
availability of sampled material. These samples could have been negative with repeat 
testing.
Based on the results so far, HC2 might not be the preferred method for hr-HPV detection 
using FTA cartridges. To obtain sufficient (clinical) sensitivity, amplification based 
methods might be more suitable. Results for the FTA cartridge with the SPF10LiPA-PCR 
were previously.17 With an overall agreement for hr-HPV between the FTA cartridges and 
the liquid-based samples of 98% (к, 0.94), the SPF10LiPA proved to be a highly reliable 
method for hr-HPV testing on the FTA cartridges. In addition, Gustavsson et al22 reported 
an agreement in hr-HPV positivity between the Cytobrush and FTA samples of 94% 
(к, 0.88; 95% CI, 0.748 to 1), again by using a real-time PCR-based assay. Although the 
results of the clinically validated GP5+/6+-PCR in this study are promising, they do not 
completely confirm previous findings on PCR-based hr-HPV testing on FTA cartridges.
Because the sensitivity of detecting hr-HPV and high-grade cervical lesions on the 
FTA cartridge is still not sufficient, there are aspects that need further consideration. 
Transferring a sample collected with a sampling device onto the surface of a solid sample 
carrier, such as the FTA cartridge, might cause the same problems that plagued the 
conventional Papanicolaou test (ie, not all cells collected are transferred, but they remain 
on the sampling device). This may result into a nonrepresentative sample. Moreover, in 
case of high-grade CIN, the HPV copy number per cell tends to be lower as the HPV 
tends to be integrated. Especially then, showing that there is DNA in the sample does 
not necessarily mean that the HPV-infected cells are transferred to the FTA cartridge. 
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Previous studies have shown that cells from dysplastic cervical lesions are more likely 
to show aberrant expression of adhesion molecules and might fail to exfoliate. Similarly, 
such cells might be relatively less likely to be transferred to a solid substrate, like the FTA 
cartridge.
Given the cross-sectional nature of this study, only 18 women had a histological specimen. 
Women who do not have colposcopically detectable lesions, regardless of whether they 
are hr-HPV positive, are not usually subjected to blind biopsies. The biopsy specimens 
would be highly unlikely to show significant pathological features.
Furthermore, only physician-collected cervical samples were used in this study to 
enable an optimal comparison between liquid-based and FTA cartridge samples. The 
aim of this study was to compare the use of two collection methods (ie, FTA cartridge 
versus liquid) and to avoid any influence from sampling different sides. Therefore, only 
physician-collected cervical samples were analyzed. For self-sampling, vaginal rather 
than cervical samples are brushed. Consequently, no direct applicability of this study 
to self-sampling is legitimate. In addition, the fact that the two Cervex brushes were 
obtained consecutively because of diagnostic reasons might have induced a bias against 
the FTA cartridge method. The second brushes were used for the FTA cartridges. Most of 
the relevant material might already have been sampled by the first brush.
This study concerns a population of women who visited the gynecological outpatient 
department and consequently involved an hr-HPV group. Therefore, to consider the use 
of the FTA cartridge in a screening population, a thorough analysis of the FTA cartridge 
in such a population is necessary.
Nevertheless, our data have shown that, in the context of GP5+/6+-PCR, but not 
HC2 testing, the FTA cartridge holds promise as a collector of cervical specimens for 
screening. However, an ultrahighly or a highly sensitive method for HPV detection, such 
as PCR-based HPV DNA testing, is required. The clinical implication of those tests must 
be further assessed. The sensitivity is still not equal to that of hr-HPV testing by HC2 on 
Thinprep vials; therefore, further optimization is recommended.
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In this thesis the dynamics of human papillomavirus (HPV) in young women in the pre-
vaccine era is described. This thesis thereby provides insight into the short-term natural 
history of HPV infections. Particularly, chapter 3 and 4 evaluate the acquisition of infec-
tion, its clearance, and persistence and chapter 5 and 6 evaluate the potential co-factors 
like pregnancy, oral contraceptive pill (OCP).1 These results on HPV dynamics represent 
a baseline for future research on the potential shift in HPV epidemiology due to HPV 
vaccination.
In most individuals, the immune response eventually leads to clearance of the virus, or to 
its maintenance in a latent or asymptomatic state in epithelial basal cells. It remains to be 
elucidated which proportion of HPV eventually clears or is maintained in a latent state. 
Latency implies that the virus may remain within basal epithelial cells, either arrested or 
very slowly replicating, but hardly detectable by current DNA technology. The existence 
of a latent state is supported by studies in immunosuppressed individuals. Particularly 
studies among women with defective cell-mediated immunity as with HIV infection or 
use of immunosuppressive medication, showed an increase in cervical precancerous 
lesions or genital warts without new exposure to HPV infection.2;3 This indicates that an 
HPV type may be in a latent state for a certain period and may become reactivated and 
(again) detected.
Whether the presence of HPV may be detected depends, among other factors, upon the 
sensitivity of the HPV DNA test used.4 Based on the cut-off value of the viral load level 
still detected by the HPV test, Hybrid Capture 2 (HC2) has the lowest sensitivity and SPF10 
the highest, whereas GP5+/6+-PCR and PGMY-PCR have intermediate sensitivities.5 
When HPV DNA tests are applied into clinical practice and routine population-based 
screening programs, they should be able to detect women at greater risk of having high-
grade cervical intraepithelial neoplasia (CIN),6 and an HPV negative result should provide 
sufficient reassurance against development of a high-grade CIN during the screening 
interval. Snijders et al. introduced the terms analytical and clinical sensitivity. Analytical 
sensitivity of a test refers to the proportion of HPV-positive women correctly identified. 
Clinical sensitivity indicates the proportion of women with disease (i.e., women with 
≥CIN3) correctly identified by a positive HPV test.5
The short-term fluctuations in HPV (described in chapter 3 and 4) and the fluctuations 
in HPV within the menstrual cycle (chapter 5),1;7 raise new questions; (1) When does a 
woman have a productive (replicating) infection in case an HPV type is detected? (2) 
When is the detected HPV type infectious? (i.e., when is there a high risk of transmission 
to a sexual partner?) (3) When is a newly detected HPV type truly a new infection and 
when does it represent a re-infection or reactivation? In order to answer these questions 
we must consider the role of the immune system and the role of the detected viral load.
Productive human papillomavirus infection
The presence of HPV may indicate a productive (replicating) infection or not. It is impor-
tant to realize that an infection is more than simply the detection of a pathogen. Infection 
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is invasion by and multiplication of pathogenic microorganisms in body tissue, which 
may produce subsequent tissue injury and progress to overt disease through a variety of 
cellular or toxic mechanisms.
When studying the HPV life cycle, initial infection requires access of infectious particles 
to cells in the basal layer through micro abrasions. After cell division, one daughter cell 
migrates and undergoes differentiation. This induces the productive phase in which ex-
pression of E6 and E7 deregulates cell cycle control, allowing viral genome amplifica-
tion. When reaching the uppermost layer of the epithelium the virions are shed.8;9 At 
this point, depending on the amount of virions shed (i.e., viral load), the virus may be 
detected and the virus may be transmitted to others. In women who do not successfully 
resolve their chronic productive HPV infection, CIN may develop, progress to CIN3 and 
eventually to cervical carcinoma (i.e., clinically relevant infection).10;11
Some studies showed that an increased viral load is associated with an increased risk 
of clinically relevant cervical lesions.12;13 However, this potential relationship between 
viral load and disease is not shown for every HPV type. Studies mainly showed that HPV 
type 16 viral load increases with increasing disease severity.13-15 Snijders et al. showed 
that viral load was also significantly higher for HPV types 18, 31 and 33, in scrapes 
of women with ≥CIN2 when compared with those of women with normal cytology.12 
On the other hand, longitudinal studies showed that baseline viral load did not relate 
to outcome of CIN2/3 and that only changes in viral load correlated with risk of CIN 
2/3 development.16;17 Furthermore, there exists a wide range in viral DNA load levels 
and a substantial overlap between women with and without CIN3.13;18 Setting a clinical 
significant viral load cut-off value, predictive for disease, is therefore difficult and viral 
load is not a preferable tool in clinical practice.
Transmission of the human papillomavirus
Our immune system is important in the natural control of the spread of HPV-associated 
disease. The immune system may clear the infection or control the virus by keeping it at 
a low copy number.
Transmission dynamics are dependent on both pathogen and host factors and are defined 
by three components: (1) transmissibility from an infected to an uninfected partner upon 
exposure, (2) the likelihood of exposures between infected and uninfected persons, and 
(3) the duration that a person is infectious.19 When studying genital HPV prevalence, 
the main factors associated with HPV prevalence are related to sexual behaviour.20 In 
a simulation model, based on likelihood of sexual exposures between infected and 
uninfected persons, and the duration of the infection, the transmissibility of genital HPV 
from an infected to an uninfected partner upon exposure was estimated to be at the 
median of 40% per sexual act. The probability of male-to-female transmission would 
reach virtually 100 percent with only 11 acts of intercourse. This estimated high rate of 
transmission of HPV implicates that the potential protective effect of condoms would 
disappear over multiple intercourse acts.19 However, condom use does partially prevent 
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HPV transmission and therefore reduces the spread of HPV in a sexually active population. 
It even may promote HPV clearance and regression of CIN and penile lesions.21;22
In a meta-analysis by Reiter et al., it was shown that in 37.7% of couples, both partners 
were infected with any type of HPV. Of these couples, 63.2% were infected with 1 or 
more of the same HPV types.23 The mucosal epithelium of the cervix is likely to be more 
susceptible to HPV infection, which may cause this difference in concordance. Addi-
tionally, positive concordance was higher for studies using PCR and for the studies that 
recruited men with HPV related penile lesions.23 However, Bleeker et al. showed that 
the concordance rate of HPV in couples is also higher when cervical lesions are present. 
They also showed that concordance is higher in couples in which one of the partners 
has a high genital viral load than in couples with low viral load. 24;25 This implicates that 
infections with a higher viral load are more likely to be transmitted.26
These results on HPV transmission underline the importance of the sex partner in the 
viral dynamics of HR HPV infection of the genital tract. Longitudinal studies on genital 
HPV transmission dynamics should follow-up sexual couples from first contact. This 
way insight on transmission, re-infection, and back-and-forward transmission between 
couples, may be obtained.23 Additionally data should be recorded on cervical and penile 
lesions and sexual behavior, frequency and condom use.
Human papillomavirus; when is it newly acquired, a re-infection or a 
reactivation?
Short term fluctuations of HPV in an individual suggest that some detected HPV types 
might be newly acquired whereas others might have been acquired in the past and 
remained latent below detection level for a certain period and are reactivated.
Reactivation of latent HPV infections was observed in HIV-infected women. However, 
few reactivation events were identified in HIV-uninfected women. The most important 
factor consistently associated with reactivation in HIV-infected women is a CD4 count 
less than 200/mm3.2 This suggests that functional immune systems keep HPV infections 
in a sub-clinical state and that they may be reactivated by immunosuppressive condi-
tions.
Unfortunately we do not know how frequently latency occurs among immune-competent 
individuals, how long it may last, what causes reactivation into a detectable state, and 
what fraction of cancer arises after a period of HPV latency. Because of the apparent low 
rate of reactivation, large studies would be needed to adequately address reactivation 
in a immune-competent group.2 Studying HPV reactivation in cervical infection is also 
complicated by the inability to distinguish reactivation of an existing infection from re-
infection with the same HPV type through sexual contact with an infected partner. There-
fore, knowledge of previous infection, sexual behavior within the HPV testing interval, 
and testing the sexual partner, is required to exclude the possibility of re-infection.
It is unclear if clearance of carcinogenic HPV infections may result in type specific 
immunity and whether it needs boosting overtime. Studies do not coincide whether a 
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sustained natural high level of IgG antibodies reduces the risk for subsequent infection 
with the same HPV type.27-29 Moreover, only about 50-60% of women with carcinogenic 
HPV infection develop detectable serum antibodies.27;30 Potentially a certain number of 
seroconversions might be missed due to testing interval, short time of seroconversion, 
and a low titre that may not be detected by tests used.27 Suggesting that HPV serology is 
a poor marker of current infections or related lesions.
Some studies report a relation between viral load and seroconversion of IgG,15;27 whereas 
others identified a persistent HPV infection to be a significant factor.30;31 A high viral 
load may provide an acute and rapid immune response, whereas a persistent infection 
maintains a slow gradual boosting effect.27 Another factor, potentially related to serocon-
version of IgG , was OCP use.27;31 Hormones, may induce transcription of the integrated 
viral oncogenes and influence the mucosal immunity in the genital tract.32 As discussed 
in chapter 5, the influence of the endogenous and exogenous hormones on the mucosal 
immuneresponse most likely explained the differences in HPV detection within and be-
tween the OCP cycle and the natural menstrual cycle.1
This variety in data on seroconversion demonstrates that the host immune response 
against HPV is only partially understood and that the relation with clearance, re-infection 
and reactivation still needs to be resolved.27;29
Human papillomavirus DNA detection in cervical cancer screening
Until now HPV DNA testing has been used in most cervical screening programs as a 
triage test for women who have abnormal cytology. However, HPV DNA based primary 
screening has proven to be more sensitive than cytology in detecting high-grade CIN, but 
with a lower specificity.33;34 Additionally, HPV DNA based primary screening may also 
improve the participation rate, especially when self-sampling is used for specimen col-
lection, and therefore increasing the overall effectiveness of the screening program.35;36 
Until now, however, self-sampling has proven to have a sufficient sensitivity to screen 
women otherwise not screened, but further research is necessary before wide implemen-
tation in a national screening program is possible. (chapter 2)
HPV dynamics should be taken into account to improve the specificity of HPV DNA 
based primary screening.4 Indicating that, as discussed in chapter 3 and 4, a detected 
high-risk HPV type may be considered as (1) a newly acquired infection, or re-infection, 
or reactivation, that could be a transient infection or potentially persisting and causing 
CIN within several years, (2) an already persistent infection, likely to cause/have caused 
a CIN or cervical carcinoma (i.e., a chronic productive infection) or (3) an accidental 
pick-up of a latent infection.
The available data on cytology/histology and hr-HPV status in chapter 4 of this thesis 
underline the value of HPV persistence as a clinical marker to identify women who are 
at high risk of cervical cancer. Repeat (genotype specific) HPV DNA testing at 12 months 
may therefore be a valuable way to identify women at increased risk of CIN and cervical 
cancer.37 HPV genotyping might be used as additional tool to decide whether to treat or 
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not, because some types are more likely to persist than others (chapter 4).37 Especially for 
women <30 years of age, it will be important for clinicians to be conservative and wait 
for evidence of a persistent (chronic productive) hr-HPV infection rather than act on the 
first positive test for hr-HPV. Because these women are more likely to have a transient 
infection and the lesion (if present) may regress.37-40
Novel biomarkers, immunologic and genetic or viral factors, may be useful for triage in 
HPV DNA detection based primary screening, to support decision making on treatment 
or wait and see policy.41;42 Currently developed biomarkers are; E6 and E7 HPV mRNA 
transcripts; methylation of several genes; markers for viral integration and of chromo-
somal instability; and markers of increased cell proliferation such as Ki-67, and p16.43-45
The high negative predictive value (NPV), of an HPV DNA test for developing CIN3, 
means that very few relevant lesions are missed.33;46 However, as shown in chapter 3 and 
4, we know that in natural HPV dynamics a sequence of positive hr-HPV samples may be 
interrupted with a single hr-HPV negative sample.47;48 Within these fluctuations we may 
assume that either the viral load is below detection level (depending on the replication 
rate of the virus, latency, or the sensitivity of the used HPV DNA test), or that there may 
be a sampling error. When a non-productive hr-HPV infection is ‘missed’ there are most 
probably no clinical consequences. When an active hr-HPV infection is missed due to 
low sensitivity of HPV test or sampling error, this leads to inadequate follow-up and treat-
ment if necessary. Therefore the sensitivity of the HPV DNA detection test used in primary 
cervical cancer screening should be sufficiently high to detect CIN3 or a chronic produc-
tive hr-HPV infection likely to produce CIN3 within the screening interval, in order to 
safely extend this cervical screening interval in case of a negative test.
Influence of HPV vaccination on HPV dynamics
As an increasing proportion of the population is vaccinated, the prevalence of cervical 
abnormalities will decrease. However, given the lag in time between HPV infection and 
the development of cervical cancer, (universal) vaccination is likely to have only a mini-
mal impact on CIN and cervical cancer rates until 10-20 years from now.49 Additionally, 
vaccination against HPV cannot provide 100% protection against cervical carcinoma 
and its precursor lesions, and still little is known about the potential long-term benefit of 
(cross-) type immune response. Therefore vaccinated women still need to be followed, 
and cervical cancer screening programs must continue.
The potential impact of HPV vaccination on the epidemiology of HPV and the rate of 
abnormal cytology depends on the following variables: (1) vaccination coverage, (2) the 
duration of vaccine induced immune protection, (3) the target high-risk HPV types of the 
vaccine, (4) rate of cross-protection, and (5) whether HPV type-replacement takes place.
In 2009, the UK and Australia used school-based vaccination programs and achieved 
a high three-dose completion rate of approximately 80% and 70%, respectively.50;51 In 
the Netherlands, however, only 52% of the girls in the target age-group received the 
HPV vaccine (HPV nieuws nr3;8march2011;www.rivm.nl). When vaccination coverage 
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is less than 90%, herd immunity obtained by only vaccinating women may be insufficient 
to eradicate the targeted HPV types.52 When considering vaccinating boys, to increase 
herd immunity, the potential gain in a further reduction of cervical cancer must also be 
carefully weighed against extra costs. It appears that when female programs obtain high 
(>75%) coverage, the vaccination of males provides only small additional benefit and is 
not cost effective.53
In the future, long-term follow-up studies should determine the true efficacy and duration 
of both vaccines. However, up till now, there were no cases of infection or cytohistologi-
cal lesions associated with HPV 16/18 observed in 7.3 years follow-up after vaccination 
with the bivalent vaccine (HPV 16/18 AS04-adjuvanted; Cervarix; GlaxoSmithKline).54 
Vaccination with the quadrivalent vaccine (HPV 6/11/16/18; Gardasil; Merck) had a high 
prophylactic efficacy against low grade cervical and vulvovaginal neoplasia and condy-
lomata associated to the vaccine types through 42 months of follow-up. Vaccine efficacy 
against CIN 1 was 96%.55
The percentage of all cervical cancers attributable to HPV 16/18 in Europe has been 
estimated at 71%.56 The percentage of prevented cervical cancer is potentially higher 
as both vaccines have reported cross-protection against other high-risk HPV types. As 
summarized by Szarewski;57 the efficacy provided by the bivalent vaccine against CIN2+ 
lesions was 100% for HPV 31 or 45, 66.1% for non-HPV 16 species 9, and 77.3% for 
non-HPV 18 species 7;58 and the efficacy provided by the quadrivalent vaccine against 
CIN2+ lesions was 58.7% for HPV 31 or  45, 35.4% for non-HPV 16 species 9, and 
47.0% for non-HPV 18 species 7.59 Although these results are encouraging, the duration 
of cross-protection is unknown.
Furthermore, currently the efficacy of a broad spectrum vaccine, against nine HPV types 
including seven oncogenic HPV types, is studied in a randomized Phase III trial (Merck, 
USA). When a polyvalent vaccine against 9 HPV types is implemented, the prevalence 
of the majority of cervical cancer associated HPV types will be drastically decreased and 
the discussion on cross-protection will change.
There is a possibility that the distribution of HPV types may gradually change in vacci-
nated populations to fill the vacated ecologic niches after the elimination of HPV type 16 
and 18.60;61 Type replacement is a viral population dynamics phenomenon and is defined 
as elimination of some types causing an increase in incidence of other types. This effect 
can only occur if two conditions apply: (1) there exists partial competition among dif-
ferent types during natural infection and (2) the vaccine does not afford cross-protection 
against types affected by this natural competition.61 Future epidemiologic studies are 
needed to show whether type replacement occurs.
Challenges to primary cervical cancer screening after vaccination
The potential impact of HPV vaccination needs to be taken into account when planning 
for future screening guidelines. It is estimated that there will be a 50-60% reduction in 
colposcopy referrals due to prevention of HPV 16 and 18 lesions. This will lower the 
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positive predictive value (PPV) of any screening test for cervical cancer.62 However, HPV 
testing is automated and therefore more objective and thus less likely to be influenced by 
this effect than cytology.63
Due to the high costs of vaccination it is important to restrict the costs of cervical 
screening programs and implement an approach based on the vaccine implementation.64 
Later and less frequent screening will probably only become an acceptable worldwide 
policy if vaccination uptake is high across social and economic strata.65
In the future, provided there is a high vaccination coverage with a polyvalent vaccine 
or a high level of cross-protection, a long duration of protection or a validated booster 
vaccination schedule, screening will likely be superfluous.
What should be monitored in the post-vaccine era?
The HPV dynamics described in this thesis represent a baseline for future research on the 
potential shift in HPV epidemiology due to HPV vaccination.
Future studies should monitor HPV DNA type-specific prevalence in sexually active 
young adults to analyze whether type-replacement takes place and to measure the level 
of protection against HPV type 16 and 18, and the level of cross-protection to related 
types. Furthermore, population coverage of HPV vaccination and duration of protection 
should be monitored in order to estimate the impact of vaccination on cervical screening 
results. This will eventually provide information on the need to screen in this vaccinated 
cohort, and if so, it will help to develop new guidelines for cervical cancer screening 
algorithms.
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Summary
Chapter 1
Genital human papillomavirus (HPV) infection is the causal factor in the cervical car-
cinogenesis. Genital HPV infections are sexually transmitted and the lifetime risk of an 
infection is estimated to be about 80%. Acquiring an HPV infection is the initial step, but 
a persistent HPV infection is necessary for the further development of precursor lesion 
and/or cervical carcinoma. Fortunately most women (80-85%) clear their HPV infection 
spontaneously. On the basis of epidemiological criteria 15 anogenital HPV types are 
classified as high risk.
It is still not clearly understood why HPV infections are transient in some women and 
persist in others. The main identified co-factors are; sexual behaviour, long-term oral con-
traceptive pill (OCP) use, smoking, parity, specific HPV type, co-infection with other HPV 
types or other sexually transmitted diseases and intrinsic host factors like endogenous 
hormones and genetics.
Detection of HPV may be influenced by demographics and occurrence of the above 
mentioned co-factors in the study population. As well as the HPV DNA test used that may 
also influence HPV detection.
Chapter 2
Based on the high sensitivity and objectivity of HPV detection, testing for HPV has re-
cently been advocated as a primary cancer screening tool. Currently, physician-collected 
cervical samples are considered the gold standard for HPV detection. However, self-
sampling is an inexpensive, well accepted, method for human papillomavirus detection 
that may increase participation of non responders in current screening programs.
We reviewed the studies comparing self-sampling with physician-sampling to determine 
if self-sampling could be implemented in cervical cancer screening as a tool for HPV 
detection, and which combination of sampling device and HPV test may be used.
Self-sampling showed a good overall agreement with physician-sampling when a swab 
or a brush was used in combination with a PCR-based test for HPV DNA detection. The 
agreement was only moderate when using other sampling devices or HC2 for HPV DNA 
detection. However, the clinical sensitivity of self-sampling with PCR based tests needs 
to be validated. Future studies should focus especially on general screening populations 
to determine if self-sampling combined with PCR based HPV testing is a valid tool for 
national screening.
In high-risk populations, although based on only a few studies, physician-sampling had 
a higher sensitivity for CIN2+ detection than self-sampling.
Today self-sampling for HPV detection has proven that its sensitivity is sufficient to screen 
women otherwise not screened, and may be implemented in national screening pro-
grams to reach non-responders. Further research is necessary before a wide implementa-
tion in an already successful national screening program is possible.
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Chapter 3
In this chapter the HPV type-specific incidence and clearance and its relation with age 
and sexual behaviour is analyzed. Incidence rates of any-type high-risk HPV and low-risk 
HPV were 17.0 per 1000-person months, and 14.3 per 1000-person months, respec-
tively. HPV types 16, 52, 51, and 31 had the highest type specific incidence rates. HPV 
incidence rates in this young Dutch study population are comparable to incidence rates 
in young women in other western countries and not related to age. Within this 12 month 
follow-up study, the overall clearance of the newly detected type-specific high-risk HPV 
infections and low-risk HPV infections was 61.2% and 69.0%, respectively. Independent 
factors significantly influencing incidence and clearance were all related to past or cur-
rent sexual behaviour, except for the clearance of HPV 16. Women with HPV 16 and 
co-infection with other high-risk HPV types had a lower proportion of clearance than 
women only infected with HPV 16.
The fact that incidence and clearance were not only related to current sexual behavior, 
but also to past sexual behavior indicates that accidental pick-up or re-activation of a 
latent HPV may be quite common. HPV clearance is also likely to be related to host im-
mune factors, as clearance did show a relation with multiple infections.
Chapter 4
The detection of a persistent hr-HPV infection represents an important marker of an in-
creased risk for CIN and cervical carcinoma. However, there is no consensus on the 
definition of persistence. Most investigators define a persistent HPV infection as detection 
of the same HPV type, or group of types, on two consecutive visits, but these visits could 
be from 2 months up to 72 months apart. Several risk factors have been identified that are 
associated with HPV persistence, especially viral load, type-specific HPV and smoking. 
This chapter describes the analysis of hr-HPV persistence and associated risk factors in a 
prospective cohort of young unscreened women. Additionally, the relation between hr-
HPV status and cytology/histology results is examined.
We showed that hr-HPV infections are more likely to persist the longer they have been 
present. HPV genotypes 16, 18, 31, and 45 were most likely to persist. Other co-factors 
influencing persistence were, multiple HPV infections, smoking and multiple lifetime 
sexual partners. Women with a persistent hr-HPV infection have a higher rate of HSIL/
CIN2+ detected in the following year. Thus, women with a persistent hr-HPV infection 
should be monitored for HSIL/CIN2+ development.
Chapter 5
There are several indications that hormonal factors might influence HPV dynamics. Long-
term oral contraceptive pill (OCP) use is identified as risk factor for cervical cancer and a 
woman’s’ last menstrual period (LMP) is found to be related to HPV detection. The muco-
sal immunity of the female genital tract, which is influenced by reproductive hormones, 
may explain the possible effect of OCP use and the menstrual cycle on HPV detection.
161
9
In this chapter the potential influence from OCP use and sample timing within the 
menstrual cycle on HPV detection is analysed. Furthermore we investigated the potential 
difference in the HPV prevalence, incidence, and persistence between OCP users and 
non users.
The baseline HPV prevalence, the annual HPV incidence, and annual persistence did 
not differ between OCP users and nonusers. High-risk HPV detection was significantly 
influenced by the timing of sampling within the menstrual cycle when OCP users and 
nonusers were analyzed separately. In the second half of the menstrual cycle high-risk 
HPV detection decreased in nonusers and increased in OCP users. When women used 
OCPs continuously, high-risk HPV detection returned to the level of the first half of the 
menstrual cycle. Further studies are needed to investigate whether this effect remains 
with a less sensitive HPV detection test to elucidate the clinical implications of HPV 
detection in primary cervical screening. Because OCP use does not significantly influence 
HPV prevalence, incidence, or persistence, its increased risk for cervical cancer may be 
explained by a direct hormonal effect on the carcinogenesis.
Chapter 6
Two other co-factors that have been associated with cervical carcinoma are high parity 
and younger age at first full-term pregnancy. The aim of the study described in this chapter 
is to study the prevalence, incidence and clearance of human papillomavirus (HPV) in 
a prospective case control study of pregnant and non-pregnant women using a highly 
sensitive HPV detection and genotyping method. The 51 pregnant women and 51 non-
pregnant women were matched 1:1 with a propensity score. The time-point prevalence of 
any-type HPV, high-risk-HPV, and low-risk-HPV did not significantly differ between the 
pregnant and matched-control women. Furthermore the number of women with a newly 
detected hr-HPV type during follow-up was also similar between both groups. Many of 
the infections were cleared in both groups, however due to small numbers statistical 
analysis to identify any potential difference could not be performed. This prospective 
case-control study shows that pregnancy does not influence HPV detection in a low-
parity population of young, unscreened women.
Chapter 7
Most studies on self-sampling used liquid based collection systems. The use of liquid 
based self-samples contains the risk of leakage. In case of alcohol-containing preservation 
fluids, this may cause problems like inflammability and harm to eyes and skin. These 
problems may be avoided when applying self-sampled specimens to a solid dry carrier 
like the Indicator FTA elute cartridge (FTA cartridge). Previously, the FTA cartridge was 
found to be highly reliable when using the ultrasensitive SPF10 LiPA25 assay. In this 
chapter the performance of the FTA cartridge was evaluated using the clinically validated 
Hybrid Capture 2 (HC2) and GP5+/6+-PCR tests for HPV DNA detection.
A good concordance between liquid based and FTA cartridge systems in high-risk HPV 
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detection was found, when using the GP5+/6+ PCR. However, this concordance was 
much lower using HC2. The sensitivity of high-risk HPV detection on the FTA cartridge 
for high-grade CIN lesions was 84.6% with GP5+/6+ PCR, but only 53.8% with HC2. 
Therefore the use of the FTA cartridge with GP5+/6+ PCR is promising. It is necessary to 
evaluated the performance of the FTA cartridge with a clinically validated HPV DNA test 
like GP5+/6+ PCR on cervicovaginal self-samples obtained in a screening population, 
before implementation in national cervical screening program is possible.
Chapter 8
The previous chapters provide insight into the short-term natural history of HPV infections. 
These results, however also raise new questions. In the general discussion of this thesis, 
we formulate and discuss these new questions on the HPV dynamics; (1) When does a 
woman have a productive (replicating) infection in case an HPV type is detected? (2) 
When is the detected HPV type infectious? (i.e., when is there a high risk of transmission 
to a sexual partner?) (3) When is a newly detected HPV type truly a new infection and 
when does it represent a re-infection or reactivation?
Furthermore the role of HPV DNA detection in cervical cancer screening and HPV 
vaccination are discussed.
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Samenvatting
Hoofdstuk 1
In de carcinogenese van het cervixcarcinoom is een genitale infectie met het humaan 
papillomavirus (HPV) een noodzakelijke factor. HPV is seksueel overdraagbaar en het 
risico om ooit in het leven deze infectie te krijgen wordt geschat op 80%. Het oplopen 
van een HPV infectie is de eerste stap in de carcinogenese, maar voor het ontwikkelen 
van een voorstadium en/of cervixcarcinoom is het noodzakelijk dat het virus persisteert. 
Gelukkig klaren de meeste vrouwen (80-85%) een HPV infectie spontaan. Op basis van 
epidemiologische criteria zijn 15 anogenitale HPV typen als hoog-risico typen voor het 
ontstaan van cervixcarcinoom gedefinieerd.
Het is nog steeds niet duidelijk waarom HPV infecties bij sommige vrouwen van 
voorbijgaande aard zijn en waarom HPV infecties bij andere vrouwen persisteren. De 
factoren die hierin een rol lijken te spelen zijn: seksueel gedrag, langdurig gebruik van 
orale anticonceptie, roken, multi-pariteit, specifieke HPV typen, co-infectie met andere 
HPV typen of andere seksueel overdraagbare ziektes. Daarnaast spelen ook intrinsieke 
factoren als endogene hormonen en genetische predispositie, een rol.
De mate van detectie van HPV binnen een populatie wordt bepaald door demografische 
kenmerken en bovenstaande risicofactoren binnen de populatie, maar zeker ook door 
het soort HPV DNA test dat gebruikt wordt.
Hoofdstuk 2
Vanwege de hoge sensitiviteit en de objectiviteit van HPV-testen heeft de gezondheidsraad 
recent het advies uitgebracht aan de Minister van Volksgezondheid, Welzijn en Sport 
(VWS) om, in plaats van cytologie, HPV detectie te gebruiken als primaire test voor 
het bevolkingsonderzoek baarmoederhalskanker. Tot op heden wordt een sample 
(uitstrijk) van de cervix afgenomen door een arts (“arts-sample”), als de gouden standaard 
beschouwd. Een sample door de vrouw zelf afgenomen (“zelf-sample”) is een door 
vrouwen zeer geaccepteerde methode, die de deelname aan het bevolkingsonderzoek 
zou kunnen vergroten.
In hoofdstuk 2 zijn literatuurstudies beschreven die zelf-samples en arts-samples 
vergelijken om te bepalen of een zelf-sample voor HPV detectie geïmplementeerd 
kan worden in het bevolkingsonderzoek baarmoederhalskanker. Daarnaast wordt 
geanalyseerd welke combinatie van materiaal voor afname en HPV DNA test, het beste 
resultaat geeft.
In laag-risico populaties, zoals screeningspopulaties, toonden zelf-samples en arts-
samples een goede overeenkomst over de aanwezigheid van HPV wanneer voor de 
afname een wattenstaafje of een borsteltje werd gebruikt, in combinatie met een HPV 
PCR test. Deze overeenkomst voor HPV detectie was middelmatig wanneer andere 
afnamematerialen werden gebruikt of in combinatie met de hybrid capture 2 (HC2). De 
klinische sensitiviteit van een zelf-sample gecombineerd met een HPV test, dient echter 
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nog gevalideerd te worden.
In hoog-risico populaties, alhoewel gebaseerd op slechts enkele studies, had een arts-
sample een hogere sensitiviteit dan een zelf-sample voor de detectie van CIN2+.
Concluderend heeft het zelf afnemen van een vaginaal sample door de vrouw een bewezen 
voldoende hoge sensitiviteit voor HPV detectie. Zelf-afname voor HPV detectie zou in 
het bevolkingsonderzoek baarmoederhalskanker gebruikt kunnen worden om vrouwen 
die niet reageren op de oproep toch te kunnen bereiken. Om zelf-samples voor HPV 
detectie breed te kunnen implementeren in een reeds succesvol bevolkingsonderzoek is 
meer onderzoek nodig.
Hoofdstuk 3
In hoofdstuk 3 werd de HPV type-specifieke incidentie en klaring in relatie met leeftijd en 
seksueel gedrag bestudeerd. De incidentie van alle typen hoog-risico HPV en laag-risico 
HPV was respectievelijk 17.0 per 1000-persoon maanden, en 14.3 per 1000-persoon 
maanden. De HPV typen 16, 52, 51, en 31 hadden de hoogste type-specifieke incidentie. 
De HPV incidentie in deze jonge Nederlandse studiepopulatie is vergelijkbaar met de 
incidentie in andere westerse landen. Binnen deze studiegroep was de klaring van nieuwe 
HPV infecties hoog- respectievelijk laag-risico HPV types 61.2% respectievelijk 69.0% 
gedurende de studieduur van 12 maanden. Factoren die de incidentie en klaring van 
HPV significant beïnvloedden, waren alle gerelateerd aan het huidige seksuele gedrag of 
het seksuele gedrag in het verleden. Dit gold niet voor de klaring van HPV 16. Vrouwen 
die een HPV 16 hadden en tegelijkertijd een infectie met een ander HPV type, hadden 
een lager klaringspercentage dan vrouwen die alleen met HPV 16 geïnfecteerd waren.
Het feit dat incidentie en klaring niet alleen gerelateerd waren aan het huidige seksuele 
gedrag, maar ook aan het seksuele gedrag in het verleden, kan er op wijzen dat ‘accidental 
pick-up’ of reactivatie van een latente HPV infectie regelmatig voorkomt. De klaring van 
HPV lijkt ook gerelateerd te zijn aan de werking van het immuunsysteem van de vrouw, 
omdat het hebben van meerdere infecties negatief gerelateerd was aan klaring.
Hoofdstuk 4
De aanwezigheid van een persisterende hoog-risico HPV infectie is een belangrijke 
risicofactor voor cervicale intraepitheliale neoplasie (CIN) of cervixcarcinoom. 
Desondanks is er geen consensus over de definitie van persistentie. De meeste 
onderzoekers definiëren HPV persistentie als de detectie van hetzelfde HPV type, of HPV 
groep, op twee opeenvolgende afname momenten. Het interval tussen deze afnamen 
kan echter 2 tot 72 maanden zijn. Verscheidene risicofactoren voor HPV persistentie zijn 
virale load, HPV genotype en roken.
Hoofdstuk 4 beschrijft de analyse van HPV persistentie en gerelateerde risicofactoren in 
een prospectief cohort van jonge ongescreende vrouwen. Daarnaast is de relatie tussen 
detectie van hoog-risico HPV en cytologie/histologie uitslagen onderzocht.
Uit deze studie bleek dat hoe langer hoog-risico HPV infecties reeds aanwezig waren, 
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hoe hoger de kans dat de HPV infectie persisteert. De HPV genotypen 16, 18, 31, en 45 
hadden de hoogste persistentie percentages. Andere risicofactoren voor HPV persistentie 
waren het hebben van meerdere HPV typen, roken en het hebben van meerdere seksuele 
partners gedurende het leven. In de groep vrouwen met een persisterende hoog-risico 
HPV infectie werd een verhoogd percentage hoog gradige squameuse intraepitheliale 
laesie (HSIL) /CIN2+ gevonden. Vanwege deze hoge kans op ontwikkeling van HSIL/
CIN2+ moeten vrouwen met een persisterende hoog-risico HPV infectie vervolgd 
worden.
Hoofdstuk 5
Er zijn verschillende aanwijzingen dat hormonale factoren de HPV dynamiek beïnvloeden. 
Langdurig gebruik van de orale anticonceptie (OAC) is geïdentificeerd als risicofactor 
voor cervixcarcinoom en de menstruele cyclus lijkt gerelateerd te zijn aan verschillen 
in HPV detectie. De mucosale immuniteit van het vrouwelijke geslachtsorgaan, welke 
beïnvloed wordt door hormonen, kan mogelijk het potentiële effect van OAC gebruik en 
de menstruele cyclus op de HPV detectie verklaren.
In hoofdstuk 5 werd de potentiële invloed van OAC gebruik en de timing van sample 
afname binnen de menstruele cyclus op de HPV detectie onderzocht. Tevens werd het 
potentiële verschil in HPV prevalentie, incidentie en persistentie tussen OAC gebruiksters 
en niet-gebruiksters geanalyseerd. De HPV prevalentie bij start van de studie, de jaarlijkse 
incidentie en persistentie, waren niet significant verschillend tussen beide groepen. De 
detectie van hoog-risico HPV werd significant beïnvloed door het afnamemoment binnen 
de menstruele cyclus wanneer de resultaten van OAC gebruiksters en niet-gebruiksters 
afzonderlijk werden geanalyseerd. In de tweede helft van de menstruele cyclus nam de 
detectie van hoog-risico HPV af bij vrouwen met een natuurlijke menstruele cyclus en toe 
bij OAC gebruiksters. Bij vrouwen die continu OAC gebruikten, dus zonder stopweek, 
zagen we dat deze toename van HPV detectie weer normaliseerde naar het niveau van 
de eerste twee weken van de cyclus. Om de klinische relevantie te bepalen van dit 
verschil in HPV detectie binnen de menstruele cyclus, dient verder onderzoek gedaan te 
worden met een klinisch gevalideerde (dus minder gevoelige) HPV test.
Hoofdstuk 6
Twee andere factoren die geassocieerd worden met een verhoogd risico op 
cervixcarcinoom zijn hoge pariteit en jonge leeftijd bij de eerste voldragen zwangerschap. 
In hoofdstuk 6, een prospectieve case-control studie, werd het verschil in prevalentie, 
incidentie en klaring van HPV tussen zwangere en niet-zwangere vrouwen getest. 51 
zwangere en 51 niet-zwangere vrouwen werden 1 op 1 aan elkaar gekoppeld middels 
een propensity score. De prevalentie van alle HPV typen, hoog-risico HPV, en laag-risico 
HPV was niet significant verschillend tussen zwangere en niet-zwangere vrouwen. Het 
aantal nieuw gedetecteerde HPV typen in beide groepen was eveneens vergelijkbaar. 
Het grootste deel van de HPV infecties werden gedurende de studieperiode geklaard, 
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maar de aantallen waren te klein om een mogelijk verschil statistisch te verklaren. Deze 
prospectieve case-control studie laat zien dat in deze populatie van jonge ongescreende 
vrouwen met een lage pariteit, zwangerschap geen invloed heeft op de HPV detectie.
Hoofdstuk 7
De meeste studies die zelf-samples voor HPV detectie bestuderen gebruiken collectie 
systemen met vloeistof. Het gebruik hiervan kan risico bevatten op lekkage en, in het geval 
van vloeistoffen die alcohol bevatten, risico op ontvlamming en op schade aan ogen en 
huid. Deze mogelijke problemen kan men vermijden door een droog collectiesysteem, 
zoals de Indicator FTA elute cartridge (FTA cartridge), te gebruiken. In eerder onderzoek 
bleek de FTA cartridge in combinatie met SPF10 LiPA25 assay zeer betrouwbaar voor 
HPV detectie. In hoofdstuk 7 werd in een hoog-risico populatie het gebruik van de FTA 
cartridge in combinatie met de  klinisch gevalideerde HC2 en GP5+/6+ PCR HPV test 
onderzocht.
Met de GP5+/6+ PCR werd, voor detectie van hoog-risico HPV DNA, een goede 
overeenkomst gevonden voor de detectie van HPV tussen het op vloeistof gebaseerde 
systeem en de FTA cartridge. De sensitiviteit van hoog-risico HPV detectie op de FTA 
cartridge voor detectie van hooggradige CIN laesies was echter 84.6% met GP5+/6+ 
PCR, en slechts 53.8% met HC2. Het gebruik van de FTA cartridge in combinatie 
met de GP5+/6+ PCR lijkt veelbelovend. Voor een mogelijke implementatie in het 
bevolkingsonderzoek naar baarmoederhalskanker dient het gebruik van de FTA cartridge 
met een klinisch gevalideerde test als GP5+/6+ PCR onderzocht te worden op zelf-
samples in een screeningspopulatie.
Hoofdstuk 8
De voorgaande hoofdstukken geven inzicht in het natuurlijke gedrag van HPV infecties 
in een periode van één tot twee jaar en deze resultaten leiden opnieuw tot vragen over 
de HPV dynamiek. In de algemene discussie van dit manuscript worden deze vragen 
uitgewerkt: (1) Wanneer is er sprake van een productieve (replicerende) infectie bij 
detectie van een HPV type?; (2) Wanneer is het gedetecteerde HPV type infectieus? 
(d.w.z. wanneer is transmissie van het virus naar de seksuele partner hoog?); (3) Wanneer 
is een nieuw gedetecteerd HPV type werkelijk een nieuwe infectie en wanneer is dit een 
re-infectie of reactivatie?
Tenslotte wordt in hoofdstuk 8 de rol van HPV detectie in het bevolkingsonderzoek 
baarmoederhalskanker en HPV vaccinatie bediscussieerd.
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Poster presentations
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Dankwoord
Het is zover, het proefschrift is af! Het schrijven van een proefschrift doe je nooit alleen. 
Op deze plek wil ik graag iedereen bedanken die hieraan heeft meegewerkt of mij 
daarbuiten heeft ondersteund.
Allereerst het promotieteam: een team met goede ideeën, enthousiasme en de 
noodzakelijke kritische kijk op de dingen. De volgende spreuk vond ik erg toepasselijk 
om te omschrijven hoe we samen tot de beste ideeën en resultaten kwamen: ”de touwtjes 
in handen nemen, de eindjes aan elkaar knopen, en de knopen doorhakken”. (Loesje)
Leon, vrolijk fluitend door de gangen, bewaker van het overzicht en de rode draad. 
Bedankt voor de uitdaging en kritische noot die mij vaak net dat extra stapje verder deed 
gaan, maar ook voor je hartelijkheid en lof wanneer het dan uiteindelijk gelukt was.
Ruud, de basis van mijn interesse in wetenschappelijk onderzoek en de basis van 
mijn promotie. Door jouw enthousiasme en talrijke ideeën wist je mij steeds weer te 
motiveren. Je deur stond altijd open om samen te brainstormen hoe we de volgende 
stappen konden zetten. Samen met Lotte zorgde je ook voor die persoonlijke noot die 
een fijn werkklimaat mogelijk maakt.
Willem, altijd helder en duidelijk. Alle artikelen en onderzoeksideeën werden door jou 
vlot van kritisch, maar altijd nuttig commentaar voorzien. Dit leidde tot goede discussies 
en heldere formuleringen, wat mij weer motiveerde om door te gaan. En ook met alle 
labuitslagen is het uiteindelijke goed gekomen.
Dennis, mijn eerste stappen in ‘onderzoeksland’ waren als jouw stagiaire, bedankt voor 
deze introductie en je blijvende interesse in mijn onderzoek en mij persoonlijk.
Charlotte, eerst als jouw student-assistent, later als collega-onderzoekers werkte we 
samen aan het grote project wat leidde tot onze beider proefschriften. Jij maakte me 
wegwijs in ‘de kantoortuin’ en in de ‘HPV wereld’. Bedankt voor de samenwerking, alle 
klets-, spui- en brainstormmomenten en de gezellige congressen.
Wim Quint, mede-auteur en samen met je medewerkers zorgde je voor een deel van de 
HPV bepalingen, bedankt.
Jan Hendriks, aan jou de taak om mijn onderzoeksvragen te vertalen in statistische 
mogelijkheden en mij te leren hoe ik dit moest doen, in het bijzonder bedankt voor je 
bijdrage voor hoofdstuk 6.
172
Chapter 9
Summary, Samenvatting, Bibliography, Dankwoord, Curriculum Vitae
Hans Berkhof, als biostatisticus expert op het gebied van HPV-modellering, de ideale 
persoon om de longitudinale data van incidentie en klaring te analyseren. Ik moest je wel 
eerst overtuigen, maar ben dankbaar dat je hebt toegezegd. Deze samenwerking heeft 
het onderzoek naar een hoger niveau gebracht.
Birgit Witte, als nieuw lid van het team van Hans werd je meteen ondergedompeld in 
HPV. Bedankt voor je inzet en goede, snelle samenwerking.
Bert Siebers, jij hielp mij met de analyses van de cytologische resultaten en het omzetten 
van de PALGA bestanden. Enthousiast ging je met mijn vragen aan de slag en bleef je 
nauw betrokken bij het schrijven van hoofdstuk 4, bedankt.
Roosmarie, in de kantoortuin groeiden we naast elkaar op in het (HPV) onderzoek doen. 
Bedankt voor de samenwerking aan hoofdstuk 7.
Wim Abma, een goed onderzoek heeft ook een goede database en databasebeheerder 
nodig. Bedankt voor je geduld bij de uitleg en wanneer er weer een functie moest worden 
toegevoegd of gewijzigd.
MMB lab: Judith en Annelies, bedankt voor jullie inzet en geduld voor alle HPV 
bepalingen.
Alle deelneemsters aan het onderzoek: ‘Het vóórkomen van het Humaan papillomavirus 
bij jonge mensen’, bedankt voor het invullen van alle vragenlijsten en het afnemen van 
alle sampels.
Onderzoek HPV vaccinatie: Moniek van den Tooren, Nataschja Albrecht, Yvonne Derks, 
Nicole Diependaal, Silvie Kok, Carla Blom, Lotte Nuyten, Jenny Anderson, Annouc 
Smit-den Baars, Klara van der Vaart, Ron Berends, en alle meisjes en hun ouders die 
hebben deelgenomen. Dankzij jullie inzet bleef ook dit onderzoek doorgaan naast mijn 
promotieonderzoek, wat uiteindelijk tot een mooi publicatie heeft geleid.
Stage-studenten: Marlies, Iris en Karien. Door jullie te begeleiden in het doen van 
onderzoek heb ik zelf ook veel geleerd. Karien, leuk dat we samen een publicatie 
hebben. Succes met jullie carrière als arts/onderzoeker.
De kantoortuin: eigenlijk te veel om op te noemen, sommigen veel mee gewerkt, anderen 
weinig. Sommigen vanaf het begin aanwezig en anderen maar heel kort. Ondanks dat 
ieder zijn eigen onderzoek had, vormden we een groep en hing er een goede sfeer. 
Die goede sfeer kwam met name door de gezellige lunches, weekendjes weg, de taart- 
momenten bij verjaardagen en publicaties of wanneer iemand gewoon zin had om iets 
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te vieren. Bedankt leuke collega’s!
Rijnstate collega’s: gynaecologen, AIOS/ANIOS, verloskundigen, verpleegkundigen 
en poli-medewerksters. Ik voelde me meteen welkom toen ik bij jullie kwam werken. 
Bedankt voor de goede tijd en alle leerzame momenten tot nu toe. Gelukkig blijf ik nu 
ook tijdens de opleiding, zodat er nog vele mooie, leerzame jaren mogen volgen.
Marian, hardwerkend als altijd, maar ook altijd gezellig en vriendelijk. Een voorbeeld 
hoe je van werk en privé een succes kan maken. Bedankt dat ik altijd even bij je terecht 
kon en kan. Een hele eer dat je mijn paranimf wilt zijn!
Annemijn, gezellig, creatief en vrolijk. Maatje in de kantoortuin, maar gelukkig ook nu in 
de tijd daarna. Wat fijn en een eer dat ook jij mijn paranimf wilt zijn!
Lieve vrienden en vriendinnetjes, niet voor iedereen even duidelijk waar ik nu zo 
druk mee was, maar er was wel altijd oprechte interesse. Ik hoop dat dit boekje wat 
inzicht geeft. Vrienden geven kleur aan het leven, samen praten, lachen, eten, borrelen, 
weekendjes weg, of gewoon samen zijn. Bedankt voor jullie vriendschap!
Lieve mama en Johan, een warme thuisbasis waar ik altijd op terug kan vallen. Met deze 
fijne basis kon ik zelfstandig worden. Mama, je hebt me geleerd dat een mens alles kan 
zolang je het maar wilt en voor je heerlijke kookkunsten blijven wij natuurlijk graag 
thuiskomen. 
Lieve papa, ik bewonder hoe positief en optimistisch jij in het leven staat, je hebt me 
geleerd hoe door te gaan en de toekomst positief tegemoet te gaan, te ‘ontmoeten’ en te 
genieten van het nu. Fijn dat ik ‘anytime’ bij je terecht kan.
Wat een geluk dat ik jullie als ouders heb!
Lieve Micha, grote broer, wat een doorzettingsvermogen heb jij. Het voorbeeld dat je 
je hele leven kunt blijven leren. Blij dat je weer dichterbij woont en we elkaar weer 
vaker zien. Lieve Kiki, zusje, we lijken zoveel op elkaar, maar zijn toch net anders. Fijn 
dat wel zoveel lol hebben samen en bij elkaar altijd een luisterend oor kunnen vinden, 
bemoedigend, maar ook altijd eerlijk en relativerend.
Lieve Ary en Lia, jullie deur staat ook altijd voor mij open. Bedankt voor jullie, 
enthousiasme, steun en interesse.
Sander, lieverd, ze zeggen altijd, de beste prestaties worden geleverd wanneer er iemand 
is die je steunt en volledig achter je staat, dat klopt ook. Wanneer het nodig was zette je 
me achter de computer om de laatste dingen af te ronden, maar je haalde me er ook weer 
op tijd vandaan om samen gezellige dingen te doen. Wat een geluk dat wij elkaar hebben 
gevonden! De wereld is zoveel mooier met jou!
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Curriculum Vitae
Channa Schmeink werd geboren op 28 april 1983, te Huissen. Haar basisschooltijd 
bracht zij door in Wageningen en Huissen. In 2001 behaalde zij haar Gymnasium-
diploma aan het Olympuscollege te Arnhem.
Door een gunstige loting kon Channa direct starten met haar studie Geneeskunde in 
Nijmegen. Tijdens haar studententijd was ze niet alleen druk met studeren, vrienden, 
hardlopen, dans, reizen, en verschillende bijbaantjes, maar was ze ook actief binnen 
enkele commissies van de Medische Faculteit Vereniging Nijmegen (MFVN). De 
combinatie van reizen en reeds bestaande interesse in de gynaecologie zorgden ervoor 
dat ze voor haar co-schappen twee maanden naar Malawi ging voor een IFMSA-stage: 
Mother and Child health care.
Tijdens haar wetenschappelijke stage deed Channa onderzoek naar ‘Kennis omtrent 
cervixcarcinoom, uitstrijkjes en HPV onder jonge mannen en vrouwen’ bij dr. Dennis van 
Hamont. In het laatste jaar van haar co-schappen werkte ze mee met dr. Charlotte Lenselink 
aan de opzet van het onderzoek ‘Het vóórkomen van het Humaan papillomavirus bij 
jonge mensen’. Beide onder leiding van dr. Ruud Bekkers. Hiermee werd de basis van het 
promotieonderzoek van Channa gelegd. Haar co-schappen sloot ze af met een tropen 
co-schap en een rondreis in Tanzania. Daarnaast deed ze bij terugkomst nog een extra 
keuze co-schap gynaecologie om haar liefde voor dit vak te bevestigen.
Vanaf maart 2008 werkte zij onder begeleiding van haar promotor prof. dr. Leon Massuger, 
en de co-promotoren dr. Ruud Bekkers en dr. Willem Melchers, als arts-onderzoeker 
fulltime aan het onderzoek, hetgeen resulteerde in dit proefschrift.
In april 2011 is Channa gestart als ANIOS Gynaecologie in het Rijnstate Ziekenhuis 
te Arnhem. Sinds 1 januari 2012 is zij als AIOS Gynaecologie in ditzelfde 
ziekenhuis werkzaam (opleiders Dr. F.P.H.L.J. Dijkhuizen, dr. R.L.M. Bekkers en 
prof. dr. D.D.M. Braat).
Channa woont sinds 2006 samen met Sander Beikes in Arnhem.

